BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Giantonio BJ, Catalano PJ, Meropol NJ, O'Dwyer PJ, Mitchell EP, Alberts SR, Schwartz MA, Benson AB 3rd;  Eastern Cooperative Oncology Group Study E3200. Bevacizumab in combination with oxaliplatin, fluorouracil, and leucovorin (FOLFOX4) for previously treated metastatic colorectal cancer: results from the Eastern Cooperative Oncology Group Study E3200. J Clin Oncol. 2007;25:1539-1544. [PMID: 17442997 DOI: 10.1200/jco.2006.09.6305] [Cited by in Crossref: 1633] [Cited by in F6Publishing: 676] [Article Influence: 108.9] [Reference Citation Analysis]
Number Citing Articles
1 Whyte S, Pandor A, Stevenson M. Bevacizumab for metastatic colorectal cancer: a NICE single technology appraisal. Pharmacoeconomics 2012;30:1119-32. [PMID: 23058097 DOI: 10.2165/11597210-000000000-00000] [Cited by in Crossref: 29] [Cited by in F6Publishing: 29] [Article Influence: 3.2] [Reference Citation Analysis]
2 Heijmen L, Punt CJ, Ter Voert EG, de Geus-Oei LF, Heerschap A, Bussink J, Sweep CG, Zerbi V, Oyen WJ, Span PN, Boerman O, van Laarhoven HW. Monitoring the effects of bevacizumab beyond progression in a murine colorectal cancer model: a functional imaging approach. Invest New Drugs 2013;31:881-90. [PMID: 23325291 DOI: 10.1007/s10637-012-9920-9] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
3 Rosen LS, Jacobs IA, Burkes RL. Bevacizumab in Colorectal Cancer: Current Role in Treatment and the Potential of Biosimilars. Target Oncol. 2017;12:599-610. [PMID: 28801849 DOI: 10.1007/s11523-017-0518-1] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 11.5] [Reference Citation Analysis]
4 Tong F, Ying Y, Pan H, Zhao W, Li H, Zhan X. MicroRNA-466 (miR-466) functions as a tumor suppressor and prognostic factor in colorectal cancer (CRC). Bosn J Basic Med Sci 2018;18:252-9. [PMID: 29338680 DOI: 10.17305/bjbms.2018.2376] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
5 Agostara B, Carruba G, Usset A. The management of cancer in the elderly: targeted therapies in oncology. Immun Ageing 2008;5:16. [PMID: 19116012 DOI: 10.1186/1742-4933-5-16] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
6 Ramjiawan RR, Griffioen AW, Duda DG. Anti-angiogenesis for cancer revisited: Is there a role for combinations with immunotherapy? Angiogenesis. 2017;20:185-204. [PMID: 28361267 DOI: 10.1007/s10456-017-9552-y] [Cited by in Crossref: 215] [Cited by in F6Publishing: 220] [Article Influence: 43.0] [Reference Citation Analysis]
7 Weng MT, Tsao PN, Lin HL, Tung CC, Change MC, Chang YT, Wong JM, Wei SC. Hes1 Increases the Invasion Ability of Colorectal Cancer Cells via the STAT3-MMP14 Pathway. PLoS One 2015;10:e0144322. [PMID: 26650241 DOI: 10.1371/journal.pone.0144322] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 2.9] [Reference Citation Analysis]
8 Angerilli V, Galuppini F, Businello G, Dal Santo L, Savarino E, Realdon S, Guzzardo V, Nicolè L, Lazzarin V, Lonardi S, Loupakis F, Fassan M. MicroRNAs as Predictive Biomarkers of Resistance to Targeted Therapies in Gastrointestinal Tumors. Biomedicines 2021;9:318. [PMID: 33801049 DOI: 10.3390/biomedicines9030318] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
9 Dewdney A, Cunningham D, Barbachano Y, Chau I. Correlation of bevacizumab-induced hypertension and outcome in the BOXER study, a phase II study of capecitabine, oxaliplatin (CAPOX) plus bevacizumab as peri-operative treatment in 45 patients with poor-risk colorectal liver-only metastases unsuitable for upfront resection. Br J Cancer. 2012;106:1718-1721. [PMID: 22531628 DOI: 10.1038/bjc.2012.152] [Cited by in Crossref: 22] [Cited by in F6Publishing: 24] [Article Influence: 2.2] [Reference Citation Analysis]
10 Malik PS, Raina V, André N. Metronomics as maintenance treatment in oncology: time for chemo-switch. Front Oncol 2014;4:76. [PMID: 24782987 DOI: 10.3389/fonc.2014.00076] [Cited by in Crossref: 15] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
11 Meadows KL, Hurwitz HI. Anti-VEGF therapies in the clinic. Cold Spring Harb Perspect Med 2012;2:a006577. [PMID: 23028128 DOI: 10.1101/cshperspect.a006577] [Cited by in Crossref: 132] [Cited by in F6Publishing: 124] [Article Influence: 13.2] [Reference Citation Analysis]
12 Hayashi H, Arao T, Matsumoto K, Kimura H, Togashi Y, Hirashima Y, Horita Y, Iwasa S, Okita NT, Honma Y, Takashima A, Kato K, Hamaguchi T, Shimada Y, Nakagawa K, Nishio K, Yamada Y. Biomarkers of reactive resistance and early disease progression during chemotherapy plus bevacizumab treatment for colorectal carcinoma. Oncotarget 2014;5:2588-95. [PMID: 24809949 DOI: 10.18632/oncotarget.1811] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 3.4] [Reference Citation Analysis]
13 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford). 2013;15:106-115. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Moriarity A, O'Sullivan J, Kennedy J, Mehigan B, McCormick P. Current targeted therapies in the treatment of advanced colorectal cancer: a review. Ther Adv Med Oncol. 2016;8:276-293. [PMID: 27482287 DOI: 10.1177/1758834016646734] [Cited by in Crossref: 54] [Cited by in F6Publishing: 54] [Article Influence: 9.0] [Reference Citation Analysis]
15 Mortimer J, Zonder HB, Pal SK. Lessons learned from the bevacizumab experience. Cancer Control 2012;19:309-16. [PMID: 23037498 DOI: 10.1177/107327481201900407] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
16 Kurkjian C, Kummar S. Advances in the treatment of metastatic colorectal cancer. Am J Ther 2009;16:412-20. [PMID: 19955859 DOI: 10.1097/MJT.0b013e3181907ed9] [Cited by in Crossref: 25] [Cited by in F6Publishing: 14] [Article Influence: 2.1] [Reference Citation Analysis]
17 Lin CY, Lin TH, Chen CC, Chen MC, Chen CP. Combination chemotherapy with Regorafenib in metastatic colorectal cancer treatment: A single center, retrospective study. PLoS One 2018;13:e0190497. [PMID: 29304109 DOI: 10.1371/journal.pone.0190497] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
18 Wong R, Cunningham D. What is the impact of biologicals in colorectal cancer? Targ Oncol 2008;3:59-69. [DOI: 10.1007/s11523-008-0074-9] [Reference Citation Analysis]
19 Bonadio RC, Amor Divino PH, Obando JSM, Lima KCA, Recchimuzzi DZ, Kruger JAP, Saragiotto DF, Capareli FC, Hoff PM. Conversion Chemotherapy With a Modified FLOX Regimen for Borderline or Unresectable Liver Metastases From Colorectal Cancer: An Alternative for Limited-Resources Settings. J Glob Oncol. 2019;5:1-6. [PMID: 31479339 DOI: 10.1200/jgo.19.00180] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Derangère V, Fumet JD, Boidot R, Bengrine L, Limagne E, Chevriaux A, Vincent J, Ladoire S, Apetoh L, Rébé C, Ghiringhelli F. Does bevacizumab impact anti-EGFR therapy efficacy in metastatic colorectal cancer? Oncotarget 2016;7:9309-21. [PMID: 26824184 DOI: 10.18632/oncotarget.7008] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
21 Duda DG, Willett CG, Ancukiewicz M, di Tomaso E, Shah M, Czito BG, Bentley R, Poleski M, Lauwers GY, Carroll M. Plasma soluble VEGFR-1 is a potential dual biomarker of response and toxicity for bevacizumab with chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:577-583. [PMID: 20484123 DOI: 10.1634/theoncologist.2010-0029] [Cited by in Crossref: 70] [Cited by in F6Publishing: 59] [Article Influence: 5.8] [Reference Citation Analysis]
22 Yamaguchi K, Taniguchi H, Komori A, Narita Y, Nitta S, Nomura M, Kadowaki S, Takahari D, Ura T, Andoh M, Muro K, Mori K, Igarashi Y. A single-arm phase II trial of combined chemotherapy with S-1, oral leucovorin, and bevacizumab in heavily pre-treated patients with metastatic colorectal cancer. BMC Cancer 2015;15:601. [PMID: 26311588 DOI: 10.1186/s12885-015-1606-1] [Cited by in Crossref: 11] [Cited by in F6Publishing: 7] [Article Influence: 1.6] [Reference Citation Analysis]
23 Hochster HS. HORIZON I: Is there a future for oral anti-angiogenics on the horizon of colorectal cancer therapy? Br J Cancer 2013;108:477-8. [PMID: 23422787 DOI: 10.1038/bjc.2013.20] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
24 Li L, Zhuang Q, Cao Z, Yin R, Zhu Y, Zhu L, Xie X, Zhang Y, Li L, Wu Q, Zheng J, Zhou Q, Li X, Wu L, Feng Y, Wang C. Paclitaxel plus nedaplatin vs. paclitaxel plus carboplatin in women with epithelial ovarian cancer: A multi-center, randomized, open-label, phase III trial. Oncol Lett 2018;15:3646-52. [PMID: 29467885 DOI: 10.3892/ol.2018.7761] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
25 Yokoyama S, Takifuji K, Hotta T, Matsuda K, Watanabe T, Mitani Y, Ieda J, Yamaue H. Survival benefit of lateral lymph node dissection according to the region of involvement and the number of lateral lymph nodes involved. Surg Today 2014;44:1097-103. [PMID: 24370948 DOI: 10.1007/s00595-013-0815-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
26 Song X, Zhao Z, Barber B, Gregory C, Schutt D, Gao S. Characterizing medical care by disease phase in metastatic colorectal cancer. J Oncol Pract 2011;7:25s-30s. [PMID: 21886516 DOI: 10.1200/JOP.2011.000304] [Cited by in Crossref: 14] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
27 Schellhaas E, Loddenkemper C, Schmittel A, Buhr HJ, Pohlen U. Bowel perforation in non-small cell lung cancer after bevacizumab therapy. Invest New Drugs. 2009;27:184-187. [PMID: 18665327 DOI: 10.1007/s10637-008-9162-z] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 1.5] [Reference Citation Analysis]
28 Dobsch P, Michels B, Müller-Schilling M, Kandulski A. [Therapeutic regimens using monoclonal antibodies in gastroenterology]. Internist (Berl) 2019;60:1043-58. [PMID: 31501913 DOI: 10.1007/s00108-019-00682-2] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
29 Su Y, Yang WB, Li S, Ye ZJ, Shi HZ, Zhou Q. Effect of angiogenesis inhibitor bevacizumab on survival in patients with cancer: a meta-analysis of the published literature. PLoS One 2012;7:e35629. [PMID: 22539986 DOI: 10.1371/journal.pone.0035629] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
30 Hurwitz HI, Tebbutt NC, Kabbinavar F, Giantonio BJ, Guan ZZ, Mitchell L, Waterkamp D, Tabernero J. Efficacy and safety of bevacizumab in metastatic colorectal cancer: pooled analysis from seven randomized controlled trials. Oncologist. 2013;18:1004-1012. [PMID: 23881988 DOI: 10.1634/theoncologist.2013-0107] [Cited by in Crossref: 155] [Cited by in F6Publishing: 142] [Article Influence: 17.2] [Reference Citation Analysis]
31 Spurrell EL, Lockley M. Adaptive immunity in cancer immunology and therapeutics. Ecancermedicalscience 2014;8:441. [PMID: 25075215 DOI: 10.3332/ecancer.2014.441] [Cited by in F6Publishing: 19] [Reference Citation Analysis]
32 Liu G, Jeraj R, Vanderhoek M, Perlman S, Kolesar J, Harrison M, Simoncic U, Eickhoff J, Carmichael L, Chao B, Marnocha R, Ivy P, Wilding G. Pharmacodynamic study using FLT PET/CT in patients with renal cell cancer and other solid malignancies treated with sunitinib malate. Clin Cancer Res 2011;17:7634-44. [PMID: 22038997 DOI: 10.1158/1078-0432.CCR-11-1677] [Cited by in Crossref: 48] [Cited by in F6Publishing: 17] [Article Influence: 4.4] [Reference Citation Analysis]
33 Abajo A, Bitarte N, Zarate R, Boni V, Lopez I, Gonzalez-Huarriz M, Rodriguez J, Bandres E, Garcia-Foncillas J. Identification of colorectal cancer metastasis markers by an angiogenesis-related cytokine-antibody array. World J Gastroenterol 2012; 18(7): 637-645 [PMID: 22363134 DOI: 10.3748/wjg.v18.i7.637] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
34 Mitani S, Muro K. No benefit from ramucirumab in first-line chemotherapy? Transl Gastroenterol Hepatol 2017;2:30. [PMID: 28529984 DOI: 10.21037/tgh.2017.03.18] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
35 Ochiai T, Nishimura K, Watanabe T, Kitajima M, Nakatani A, Marusasa T, Hashiguchi T, Uchida T, Sakuyama N, Sato T, Kishine K, Futagawa S, Nagaoka I. Identification of responders/non-responders to 5-fluorouracil based on individual 50% inhibitory area under the concentration curve of 5-fluorouracil obtained with collagen gel droplet-embedded culture-drug sensitivity test in colorectal cancer. Oncol Lett 2011;2:309-13. [PMID: 22866082 DOI: 10.3892/ol.2011.251] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
36 Itatani Y, Kawada K, Yamamoto T, Sakai Y. Resistance to Anti-Angiogenic Therapy in Cancer-Alterations to Anti-VEGF Pathway. Int J Mol Sci 2018;19:E1232. [PMID: 29670046 DOI: 10.3390/ijms19041232] [Cited by in Crossref: 64] [Cited by in F6Publishing: 66] [Article Influence: 16.0] [Reference Citation Analysis]
37 Samalin E, Bouché O, Thézenas S, Francois E, Adenis A, Bennouna J, Taieb J, Desseigne F, Seitz JF, Conroy T. Sorafenib and irinotecan (NEXIRI) as second- or later-line treatment for patients with metastatic colorectal cancer and KRAS-mutated tumours: a multicentre Phase I/II trial. Br J Cancer. 2014;110:1148-1154. [PMID: 24407191 DOI: 10.1038/bjc.2013.813] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 5.0] [Reference Citation Analysis]
38 Hong YS, Lee J, Kim KP, Lee JL, Park YS, Park JO, Park SH, Kim SY, Baek JY, Kim JH. Multicenter phase II study of second-line bevacizumab plus doublet combination chemotherapy in patients with metastatic colorectal cancer progressed after upfront bevacizumab plus doublet combination chemotherapy. Invest New Drugs. 2013;31:183-191. [PMID: 22782485 DOI: 10.1007/s10637-012-9853-3] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
39 de Gramont A, Hubbard J, Shi Q, O'Connell MJ, Buyse M, Benedetti J, Bot B, O'Callaghan C, Yothers G, Goldberg RM, Blanke CD, Benson A, Deng Q, Alberts SR, Andre T, Wolmark N, Grothey A, Sargent D. Association between disease-free survival and overall survival when survival is prolonged after recurrence in patients receiving cytotoxic adjuvant therapy for colon cancer: simulations based on the 20,800 patient ACCENT data set. J Clin Oncol. 2010;28:460-465. [PMID: 20008641 DOI: 10.1200/jco.2009.23.1407] [Cited by in Crossref: 50] [Cited by in F6Publishing: 23] [Article Influence: 3.8] [Reference Citation Analysis]
40 Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, Hasegawa K, Hotta K, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kinugasa Y, Murofushi K, Nakajima TE, Oka S, Tanaka T, Taniguchi H, Tsuji A, Uehara K, Ueno H, Yamanaka T, Yamazaki K, Yoshida M, Yoshino T, Itabashi M, Sakamaki K, Sano K, Shimada Y, Tanaka S, Uetake H, Yamaguchi S, Yamaguchi N, Kobayashi H, Matsuda K, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1-42. [PMID: 31203527 DOI: 10.1007/s10147-019-01485-z] [Cited by in Crossref: 282] [Cited by in F6Publishing: 260] [Article Influence: 94.0] [Reference Citation Analysis]
41 Chang HM, Moudgil R, Scarabelli T, Okwuosa TM, Yeh ETH. Cardiovascular Complications of Cancer Therapy: Best Practices in Diagnosis, Prevention, and Management: Part 1. J Am Coll Cardiol 2017;70:2536-51. [PMID: 29145954 DOI: 10.1016/j.jacc.2017.09.1096] [Cited by in Crossref: 145] [Cited by in F6Publishing: 123] [Article Influence: 29.0] [Reference Citation Analysis]
42 Vacchelli E, Aranda F, Eggermont A, Galon J, Sautès-Fridman C, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Tumor-targeting monoclonal antibodies in cancer therapy. Oncoimmunology 2014;3:e27048. [PMID: 24605265 DOI: 10.4161/onci.27048] [Cited by in Crossref: 59] [Cited by in F6Publishing: 58] [Article Influence: 59.0] [Reference Citation Analysis]
43 Aranda E, Abad A, Carrato A, Cervantes A, García-Foncillas J, García Alfonso P, García Carbonero R, Gómez España A, Tabernero JM, Díaz-Rubio E. Treatment recommendations for metastatic colorectal cancer. Clin Transl Oncol 2011;13:162-78. [PMID: 21421461 DOI: 10.1007/s12094-011-0636-7] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
44 Vadakara J, Borghaei H. Personalized medicine and treatment approaches in non-small-cell lung carcinoma. Pharmgenomics Pers Med 2012;5:113-23. [PMID: 23226067 DOI: 10.2147/PGPM.S24258] [Cited by in Crossref: 1] [Cited by in F6Publishing: 14] [Article Influence: 0.1] [Reference Citation Analysis]
45 Gibbs P, Gebski V, Van Buskirk M, Thurston K, Cade DN, Van Hazel GA. Selective Internal Radiation Therapy (SIRT) with yttrium-90 resin microspheres plus standard systemic chemotherapy regimen of FOLFOX versus FOLFOX alone as first-line treatment of non-resectable liver metastases from colorectal cancer: the SIRFLOX study. BMC Cancer. 2014;14:897. [PMID: 25487708 DOI: 10.1186/1471-2407-14-897] [Cited by in Crossref: 37] [Cited by in F6Publishing: 34] [Article Influence: 4.6] [Reference Citation Analysis]
46 Marshall JL. Vascular Endothelial Growth Factor plus Epidermal Growth Factor Receptor Dual Targeted Therapy in Metastatic Colorectal Cancer: Synergy or Antagonism? J Oncol 2009;2009:937305. [PMID: 20016807 DOI: 10.1155/2009/937305] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.6] [Reference Citation Analysis]
47 Yin C, Ma G, Rong Y, Kong P, Yang Q, Jiang C, Liao F, Zhang B, He W, Xia L. The Efficacy of Bevacizumab in Different Line Chemotherapy for Chinese Patients with Metastatic Colorectal Cancer. J Cancer 2016;7:1901-6. [PMID: 27698931 DOI: 10.7150/jca.15802] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
48 Song X, Long SR, Barber B, Kassed CA, Healey M, Jones C, Zhao Z. Systematic review on infusion reactions associated with chemotherapies and monoclonal antibodies for metastatic colorectal cancer. Curr Clin Pharmacol 2012;7:56-65. [PMID: 22299770 DOI: 10.2174/157488412799218806] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
49 Ab Mutalib NS, Md Yusof NF, Abdul SN, Jamal R. Pharmacogenomics DNA Biomarkers in Colorectal Cancer: Current Update. Front Pharmacol 2017;8:736. [PMID: 29075194 DOI: 10.3389/fphar.2017.00736] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 2.4] [Reference Citation Analysis]
50 Mulcahy M. Bevacizumab with 5-fluorouracil and leucovorin following hypersensitivity to oxaliplatin: . Anti-Cancer Drugs 2009;20:S30-2. [DOI: 10.1097/01.cad.0000359485.30669.29] [Reference Citation Analysis]
51 Wang X, Wei Q, Gao J, Li J, Li J, Gong J, Li Y, Shen L. Clinicopathologic features and treatment efficacy of Chinese patients with BRAF-mutated metastatic colorectal cancer: a retrospective observational study. Chin J Cancer 2017;36:81. [PMID: 29037218 DOI: 10.1186/s40880-017-0247-y] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
52 Kounis I, Lewin M, Laurent-Bellue A, Poli E, Coilly A, Duclos-Vallée JC, Guettier C, Adam R, Lerut J, Samuel D, Rosmorduc O. Advanced epithelioid hemangioendothelioma of the liver: could lenvatinib offer a bridge treatment to liver transplantation? Ther Adv Med Oncol 2022;14:17588359221086909. [PMID: 35340695 DOI: 10.1177/17588359221086909] [Reference Citation Analysis]
53 Bennouna J, Deslandres M, Senellart H, de Labareyre C, Ruiz-Soto R, Wixon C, Botbyl J, Suttle AB, Delord JP. A phase I open-label study of the safety, tolerability, and pharmacokinetics of pazopanib in combination with irinotecan and cetuximab for relapsed or refractory metastatic colorectal cancer. Invest New Drugs 2015;33:138-47. [PMID: 25248752 DOI: 10.1007/s10637-014-0142-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
54 Moustakas A, Kreisl TN. New treatment options in the management of glioblastoma multiforme: a focus on bevacizumab. Onco Targets Ther 2010;3:27-38. [PMID: 20616955 DOI: 10.2147/ott.s5307] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
55 Abe Y, Sakuyama N, Sato T, Kishine K, Nagayasu K, Nakatani A, Kitajima M, Watanabe T, Nishimura K, Ochiai T, Nagaoka I. Evaluation of the 5-fluorouracil plasma level in patients with colorectal cancer undergoing continuous infusion chemotherapy. Mol Clin Oncol 2019;11:289-95. [PMID: 31396387 DOI: 10.3892/mco.2019.1893] [Reference Citation Analysis]
56 Melichar B, Hrůzová K, Krčmová LK, Javorská L, Pešková E, Solichová D, Hyšpler R, Malířová E, Vošmik M, Bartoušková M, Klos D, Študentová H. Association of peripheral blood cell count-derived ratios, biomarkers of inflammatory response and tumor growth with outcome in previously treated metastatic colorectal carcinoma patients receiving cetuximab. Pteridines 2017;28:221-32. [DOI: 10.1515/pterid-2017-0016] [Reference Citation Analysis]
57 Cremolini C, Antoniotti C, Pietrantonio F, Berenato R, Tampellini M, Baratelli C, Salvatore L, Marmorino F, Borelli B, Nichetti F, Bironzo P, Sonetto C, Bartolomeo MD, Braud F, Loupakis F, Falcone A, Di Maio M. Surrogate Endpoints in Second-Line Trials of Targeted Agents in Metastatic Colorectal Cancer: A Literature-Based Systematic Review and Meta-Analysis. Cancer Res Treat 2017;49:834-45. [PMID: 27857020 DOI: 10.4143/crt.2016.249] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.2] [Reference Citation Analysis]
58 Chino H, Amano Y, Yamauchi Y, Matsuda J, Takeda N, Tanaka G, Takai D, Nagase T. Cardiogenic syncope possibly related to bevacizumab-containing combination chemotherapy for advanced non-small cell lung cancer. J Thorac Dis 2016;8:2646-50. [PMID: 27747019 DOI: 10.21037/jtd.2016.08.96] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
59 Comunanza V, Bussolino F. Therapy for Cancer: Strategy of Combining Anti-Angiogenic and Target Therapies. Front Cell Dev Biol 2017;5:101. [PMID: 29270405 DOI: 10.3389/fcell.2017.00101] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 5.4] [Reference Citation Analysis]
60 Reinacher-Schick A. [Systemic treatment of advanced colorectal cancer]. Pathologe 2008;29 Suppl 2:191-5. [PMID: 18791719 DOI: 10.1007/s00292-008-1071-6] [Reference Citation Analysis]
61 Bailey CH, Jameson G, Sima C, Fleck S, White E, Von Hoff DD, Weiss GJ. Progression-free Survival Decreases with Each Subsequent Therapy in Patients Presenting for Phase I Clinical Trials. J Cancer 2012;3:7-13. [PMID: 22211140 DOI: 10.7150/jca.3.7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
62 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.CD007047.pub2] [Cited by in Crossref: 20] [Cited by in F6Publishing: 26] [Article Influence: 4.0] [Reference Citation Analysis]
63 Shin SJ, Jeung HC, Ahn JB, Rha SY, Roh JK, Park KS, Kim DH, Kim C, Chung HC. A phase I pharmacokinetic and pharmacodynamic study of CKD-732, an antiangiogenic agent, in patients with refractory solid cancer. Invest New Drugs 2010;28:650-8. [PMID: 19585083 DOI: 10.1007/s10637-009-9287-8] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.1] [Reference Citation Analysis]
64 Guan ZZ, Xu JM, Luo RC, Feng FY, Wang LW, Shen L, Yu SY, Ba Y, Liang J, Wang D, Qin SK, Wang JJ, He J, Qi C, Xu RH. Efficacy and safety of bevacizumab plus chemotherapy in Chinese patients with metastatic colorectal cancer: a randomized phase III ARTIST trial. Chin J Cancer 2011;30:682-9. [PMID: 21959045 DOI: 10.5732/cjc.011.10188] [Cited by in Crossref: 69] [Cited by in F6Publishing: 69] [Article Influence: 7.7] [Reference Citation Analysis]
65 Abu-Hejleh T, Mezhir JJ, Goodheart MJ, Halfdanarson TR. Incidence and management of gastrointestinal perforation from bevacizumab in advanced cancers. Curr Oncol Rep. 2012;14:277-284. [PMID: 22532266 DOI: 10.1007/s11912-012-0238-8] [Cited by in Crossref: 33] [Cited by in F6Publishing: 25] [Article Influence: 3.3] [Reference Citation Analysis]
66 Sponholz S, Schirren M, Baldes N, Oguzhan S, Schirren J. Repeat resection for recurrent pulmonary metastasis of colorectal cancer. Langenbecks Arch Surg 2017;402:77-85. [PMID: 28058514 DOI: 10.1007/s00423-016-1547-4] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
67 Poultsides GA, Servais EL, Saltz LB, Patil S, Kemeny NE, Guillem JG, Weiser M, Temple LK, Wong WD, Paty PB. Outcome of primary tumor in patients with synchronous stage IV colorectal cancer receiving combination chemotherapy without surgery as initial treatment. J Clin Oncol 2009;27:3379-84. [PMID: 19487380 DOI: 10.1200/JCO.2008.20.9817] [Cited by in Crossref: 260] [Cited by in F6Publishing: 100] [Article Influence: 20.0] [Reference Citation Analysis]
68 Eisenbeis AM, Grau SJ. Monoclonal antibodies and Fc fragments for treating solid tumors. Biologics 2012;6:13-20. [PMID: 22291463 DOI: 10.2147/BTT.S19955] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
69 Bouchahda M, Saffroy R, Karaboué A, Hamelin J, Innominato P, Saliba F, Lévi F, Bosselut N, Lemoine A. Undetectable RAS-Mutant Clones in Plasma: Possible Implication for Anti-EGFR Therapy and Prognosis in Patients With RAS-Mutant Metastatic Colorectal Cancer. JCO Precis Oncol 2020;4:PO. [PMID: 33015528 DOI: 10.1200/PO.19.00400] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 2.5] [Reference Citation Analysis]
70 Galvano A, Incorvaia L, Badalamenti G, Rizzo S, Guarini A, Cusenza S, Castellana L, Barraco N, Calò V, Cutaia S, Currò G, Silvestris N, Beretta GD, Bazan V, Russo A. How to Deal with Second Line Dilemma in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis. Cancers (Basel) 2019;11:E1189. [PMID: 31443300 DOI: 10.3390/cancers11081189] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
71 Lee SJ, Lee I, Lee J, Park C, Kang WK. Statins, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors, potentiate the anti-angiogenic effects of bevacizumab by suppressing angiopoietin2, BiP, and Hsp90α in human colorectal cancer. Br J Cancer. 2014;111:497-505. [PMID: 24945998 DOI: 10.1038/bjc.2014.283] [Cited by in Crossref: 26] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
72 Qu CY, Zheng Y, Zhou M, Zhang Y, Shen F, Cao J, Xu LM. Value of bevacizumab in treatment of colorectal cancer: A meta-analysis. World J Gastroenterol 2015; 21(16): 5072-5080 [PMID: 25945023 DOI: 10.3748/wjg.v21.i16.5072] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 37] [Article Influence: 5.9] [Reference Citation Analysis]
73 Ryanne Wu R, Lindenberg PA, Slack R, Noone AM, Marshall JL, He AR. Evaluation of hypertension as a marker of bevacizumab efficacy. J Gastrointest Cancer. 2009;40:101-108. [PMID: 19921473 DOI: 10.1007/s12029-009-9104-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 1.7] [Reference Citation Analysis]
74 Mocellin S, Baretta Z, Roqué I Figuls M, Solà I, Martin-Richard M, Hallum S, Bonfill Cosp X. Second-line systemic therapy for metastatic colorectal cancer. Cochrane Database Syst Rev 2017;1:CD006875. [PMID: 28128439 DOI: 10.1002/14651858.CD006875.pub3] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 2.2] [Reference Citation Analysis]
75 Rapisarda A, Melillo G. Overcoming disappointing results with antiangiogenic therapy by targeting hypoxia. Nat Rev Clin Oncol 2012;9:378-90. [PMID: 22525710 DOI: 10.1038/nrclinonc.2012.64] [Cited by in Crossref: 115] [Cited by in F6Publishing: 102] [Article Influence: 11.5] [Reference Citation Analysis]
76 Rosa B, de Jesus JP, de Mello EL, Cesar D, Correia MM. Effectiveness and safety of monoclonal antibodies for metastatic colorectal cancer treatment: systematic review and meta-analysis. Ecancermedicalscience 2015;9:582. [PMID: 26557880 DOI: 10.3332/ecancer.2015.582] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
77 Volz NB, Stintzing S, Zhang W, Yang D, Ning Y, Wakatsuki T, El-Khoueiry RE, Li JE, Kardosh A, Loupakis F, Cremolini C, Falcone A, Scherer SJ, Lenz HJ. Genes involved in pericyte-driven tumor maturation predict treatment benefit of first-line FOLFIRI plus bevacizumab in patients with metastatic colorectal cancer. Pharmacogenomics J 2015;15:69-76. [PMID: 25069475 DOI: 10.1038/tpj.2014.40] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
78 Lai E, Cascinu S, Scartozzi M. Are All Anti-Angiogenic Drugs the Same in the Treatment of Second-Line Metastatic Colorectal Cancer? Expert Opinion on Clinical Practice. Front Oncol 2021;11:637823. [PMID: 34041019 DOI: 10.3389/fonc.2021.637823] [Reference Citation Analysis]
79 Hsu HC, Liu YC, Wang CW, Chou WC, Hsu YJ, Chiang JM, Lin YC, Yang TS. Sequential cetuximab/bevacizumab therapy is associated with improved outcomes in patients with wild-type KRAS exon 2 metastatic colorectal cancer. Cancer Med 2019;8:3437-46. [PMID: 31090176 DOI: 10.1002/cam4.2235] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
80 Ronnekleiv-Kelly SM, Kennedy GD. Management of stage IV rectal cancer: Palliative options. World J Gastroenterol 2011; 17(7): 835-847 [PMID: 21412493 DOI: 10.3748/wjg.v17.i7.835] [Cited by in CrossRef: 31] [Cited by in F6Publishing: 17] [Article Influence: 2.8] [Reference Citation Analysis]
81 Yu HK, Lee HJ, Yun SJ, Lee SJ, Langley RR, Yoon Y, Yi LS, Bae DS, Kim JS, Kim SJ. Antiangiogenic Therapy with Human Apolipoprotein(a) Kringle V and Paclitaxel in a Human Ovarian Cancer Mouse Model. Transl Oncol 2014;7:368-76. [PMID: 25180060 DOI: 10.1016/j.tranon.2014.04.005] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
82 Wade R, Duarte A, Simmonds M, Rodriguez-Lopez R, Duffy S, Woolacott N, Spackman E. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence. Pharmacoeconomics 2015;33:457-66. [PMID: 25616671 DOI: 10.1007/s40273-015-0257-z] [Cited by in Crossref: 13] [Cited by in F6Publishing: 17] [Article Influence: 2.2] [Reference Citation Analysis]
83 Belizon A, Balik E, Horst P, Feingold D, Arnell T, Azarani T, Cekic V, Skitt R, Kumara S, Whelan RL. Persistent elevation of plasma vascular endothelial growth factor levels during the first month after minimally invasive colorectal resection. Surg Endosc. 2008;22:287-297. [PMID: 18204877 DOI: 10.1007/s00464-007-9725-7] [Cited by in Crossref: 36] [Cited by in F6Publishing: 31] [Article Influence: 2.6] [Reference Citation Analysis]
84 Pai SG, Fuloria J. Novel therapeutic agents in the treatment of metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(1): 99-104 [PMID: 26798440 DOI: 10.4251/wjgo.v8.i1.99] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
85 Park DY, Choi C, Shin E, Lee JH, Kwon CH, Jo HJ, Kim HR, Kim HS, Oh N, Lee JS, Park OK, Park E, Park J, Shin JY, Kim JI, Seo JS, Park HD, Park J. NTRK1 fusions for the therapeutic intervention of Korean patients with colon cancer. Oncotarget 2016;7:8399-412. [PMID: 26716414 DOI: 10.18632/oncotarget.6724] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 2.3] [Reference Citation Analysis]
86 Pitule P, Čedíková M, Třeška V, Králíčková M, Liška V. Assessing colorectal cancer heterogeneity: one step closer to tailored medicine. J Appl Biomed 2013;11:115-29. [DOI: 10.2478/v10136-012-0035-6] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
87 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/theoncologist.2010-0387] [Cited by in Crossref: 38] [Cited by in F6Publishing: 37] [Article Influence: 3.5] [Reference Citation Analysis]
88 Cheng YD, Yang H, Chen GQ, Zhang ZC. Molecularly targeted drugs for metastatic colorectal cancer. Drug Des Devel Ther 2013;7:1315-22. [PMID: 24204124 DOI: 10.2147/DDDT.S52485] [Cited by in Crossref: 4] [Cited by in F6Publishing: 20] [Article Influence: 0.4] [Reference Citation Analysis]
89 Boven E, Massard C, Armand JP, Tillier C, Hartog V, Brega NM, Countouriotis AM, Ruiz-Garcia A, Soria JC. A phase I, dose-finding study of sunitinib in combination with irinotecan in patients with advanced solid tumours. Br J Cancer 2010;103:993-1000. [PMID: 20717111 DOI: 10.1038/sj.bjc.6605852] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
90 Butler CT, Kennedy SA, Buckley A, Doyle R, Conroy E, Gallagher WM, O'Sullivan J, Kennedy BN. 1,4-dihydroxy quininib attenuates growth of colorectal cancer cells and xenografts and regulates the TIE-2 signaling pathway in patient tumours. Oncotarget 2019;10:3725-44. [PMID: 31217905 DOI: 10.18632/oncotarget.26966] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
91 Nakayama G, Ishigure K, Yokoyama H, Uehara K, Kojima H, Ishiyama A, Hayashi N, Takano N, Hattori N, Kobayashi D, Tanaka C, Hayashi M, Kanda M, Yamada S, Sugimoto H, Koike M, Fujiwara M, Fujii T, Murotani K, Ando Y, Kodera Y. The efficacy and safety of CapeOX plus bevacizumab therapy followed by capecitabine plus bevacizumab maintenance therapy in patients with metastatic colorectal cancer: a multi-center, single-arm, phase II study (CCOG-0902). BMC Cancer 2017;17:243. [PMID: 28376737 DOI: 10.1186/s12885-017-3245-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
92 Pol J, Vacchelli E, Aranda F, Castoldi F, Eggermont A, Cremer I, Sautès-Fridman C, Fucikova J, Galon J, Spisek R, Tartour E, Zitvogel L, Kroemer G, Galluzzi L. Trial Watch: Immunogenic cell death inducers for anticancer chemotherapy. Oncoimmunology 2015;4:e1008866. [PMID: 26137404 DOI: 10.1080/2162402X.2015.1008866] [Cited by in Crossref: 144] [Cited by in F6Publishing: 108] [Article Influence: 20.6] [Reference Citation Analysis]
93 Okita NT, Esaki T, Baba E, Sakai D, Tokunaga S, Takiuchi H, Mizunuma N, Nagashima K, Kato K. A multicenter phase II study of the stop-and-go modified FOLFOX6 with bevacizumab for first-line treatment of patients with metastatic colorectal cancer. Invest New Drugs 2012;30:2026-31. [PMID: 22160802 DOI: 10.1007/s10637-011-9779-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
94 Parseghian CM, Parikh NU, Wu JY, Jiang ZQ, Henderson L, Tian F, Pastor B, Ychou M, Raghav K, Dasari A, Fogelman DR, Katsiampoura AD, Menter DG, Wolff RA, Eng C, Overman MJ, Thierry AR, Gallick GE, Kopetz S. Dual Inhibition of EGFR and c-Src by Cetuximab and Dasatinib Combined with FOLFOX Chemotherapy in Patients with Metastatic Colorectal Cancer. Clin Cancer Res 2017;23:4146-54. [PMID: 28280091 DOI: 10.1158/1078-0432.CCR-16-3138] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 5.4] [Reference Citation Analysis]
95 Qi WX, Shen Z, Tang LN, Yao Y. Bevacizumab increases the risk of gastrointestinal perforation in cancer patients: a meta-analysis with a focus on different subgroups. Eur J Clin Pharmacol. 2014;70:893-906. [PMID: 24858820 DOI: 10.1007/s00228-014-1687-9] [Cited by in Crossref: 28] [Cited by in F6Publishing: 25] [Article Influence: 3.5] [Reference Citation Analysis]
96 Melichar B, Casado E, Bridgewater J, Bennouna J, Campone M, Vitek P, Delord JP, Cerman J Jr, Salazar R, Dvorak J, Sguotti C, Urban P, Viraswami-Appanna K, Tan E, Tabernero J. Clinical activity of patupilone in patients with pretreated advanced/metastatic colon cancer: results of a phase I dose escalation trial. Br J Cancer 2011;105:1646-53. [PMID: 22027708 DOI: 10.1038/bjc.2011.438] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
97 Shinozaki E, Makiyama A, Kagawa Y, Satake H, Tanizawa Y, Cai Z, Piao Y. Treatment sequences of patients with advanced colorectal cancer and use of second-line FOLFIRI with antiangiogenic drugs in Japan: A retrospective observational study using an administrative database. PLoS One 2021;16:e0246160. [PMID: 33556095 DOI: 10.1371/journal.pone.0246160] [Reference Citation Analysis]
98 Wang YH, Liu YL, Zhao XH, Jiang SX, Sun XW, Wang XS. Prognosis analysis and treatment strategy for patients with Dukes D stage rectal cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(34): 3844-3848 [DOI: 10.11569/wcjd.v16.i34.3844] [Reference Citation Analysis]
99 Aguilar G, Albiol S, Alcaide J, Alonso M, Alonso V, Andreu M, Aparicio J, de la Vega FA, Arrivi A, Ayuso JR, Bohn U, Bouzas R, Cano JM, Castañón C, Castells A, Cerdà P, Cerezo L, Conill C, Cuatrecasas M, Pozo MND, Delgado JI, Enriquez-navascues JM, Escudero P, Espín E, l RE, Falcó E, Farré J, Feliu J, Fernández-martos C, Ferrer AI, Gallego R, Galvez E, de Albéniz XG, Olmo DG, García-carbonero R, Dorronsoro MG, Martín CG, Moreno SG, Hernández A, Iraola A, Jímenez E, Jiménez MC, Jurado I, Leno R, León A, Martín E, Martín M, Maurel J, Méndez JC, Méndez R, Palma P, Pardo F, Pereira F, Pérez-altozano J, Pérez E, Rodríguez J, Ruiz-casado AI, Sabater L, Sarría L, Segura A, Sevilla I, Tobeña M, Torres E, Viudez A, Zanui M, Zorrilla M. Guidelines for diagnosis, staging and treatment of metastatic colorectal cancer by Grupo Español Multidisciplinar en Cancer Digestivo (GEMCAD). Colorectal Cancer 2015;4:97-112. [DOI: 10.2217/crc.15.9] [Reference Citation Analysis]
100 Prasetyanti PR, Capone E, Barcaroli D, D'Agostino D, Volpe S, Benfante A, van Hooff S, Iacobelli V, Rossi C, Iacobelli S, Medema JP, De Laurenzi V, Sala G. ErbB-3 activation by NRG-1β sustains growth and promotes vemurafenib resistance in BRAF-V600E colon cancer stem cells (CSCs). Oncotarget 2015;6:16902-11. [PMID: 26160848 DOI: 10.18632/oncotarget.4642] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 4.0] [Reference Citation Analysis]
101 Dattatreya S. Metastatic colorectal cancer-prolonging overall survival with targeted therapies. South Asian J Cancer 2013;2:179-85. [PMID: 24455615 DOI: 10.4103/2278-330X.114152] [Cited by in Crossref: 18] [Cited by in F6Publishing: 9] [Article Influence: 2.3] [Reference Citation Analysis]
102 Brown JC, Rosenthal MH, Ma C, Zhang S, Nimeiri HS, McCleary NJ, Abrams TA, Yurgelun MB, Cleary JM, Rubinson DA, Schrag D, Bullock AJ, Allen J, Zuckerman D, Chan E, Chan JA, Wolpin B, Constantine M, Weckstein DJ, Faggen MA, Thomas CA, Kournioti C, Yuan C, Zheng H, Hollis BW, Fuchs CS, Ng K, Meyerhardt JA. Effect of High-Dose vs Standard-Dose Vitamin D3 Supplementation on Body Composition among Patients with Advanced or Metastatic Colorectal Cancer: A Randomized Trial. Cancers (Basel) 2020;12:E3451. [PMID: 33233566 DOI: 10.3390/cancers12113451] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
103 Terme M, Colussi O, Marcheteau E, Tanchot C, Tartour E, Taieb J. Modulation of immunity by antiangiogenic molecules in cancer. Clin Dev Immunol. 2012;2012:492920. [PMID: 23320019 DOI: 10.1155/2012/492920] [Cited by in Crossref: 74] [Cited by in F6Publishing: 65] [Article Influence: 7.4] [Reference Citation Analysis]
104 Moscetti L, Nelli F, Fabbri MA, Sperduti I, Alesini D, Cortesi E, Gemma D, Gamucci T, Grande R, Pavese I. Maintenance single-agent bevacizumab or observation after first-line chemotherapy in patients with metastatic colorectal cancer: a multicenter retrospective study. Invest New Drugs. 2013;31:1035-1043. [PMID: 23417697 DOI: 10.1007/s10637-013-9936-9] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
105 Gong J, Cho M, Fakih M. RAS and BRAF in metastatic colorectal cancer management. J Gastrointest Oncol 2016;7:687-704. [PMID: 27747083 DOI: 10.21037/jgo.2016.06.12] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 5.8] [Reference Citation Analysis]
106 Pan Q, Wang M. [Predictive biomarkers for bevacizumab in anti-tumor therapy]. Zhongguo Fei Ai Za Zhi 2011;14:606-12. [PMID: 21762631 DOI: 10.3779/j.issn.1009-3419.2011.07.08] [Reference Citation Analysis]
107 Bangi E, Ang C, Smibert P, Uzilov AV, Teague AG, Antipin Y, Chen R, Hecht C, Gruszczynski N, Yon WJ, Malyshev D, Laspina D, Selkridge I, Rainey H, Moe AS, Lau CY, Taik P, Wilck E, Bhardwaj A, Sung M, Kim S, Yum K, Sebra R, Donovan M, Misiukiewicz K, Schadt EE, Posner MR, Cagan RL. A personalized platform identifies trametinib plus zoledronate for a patient with KRAS-mutant metastatic colorectal cancer. Sci Adv. 2019;5:eaav6528. [PMID: 31131321 DOI: 10.1126/sciadv.aav6528] [Cited by in Crossref: 36] [Cited by in F6Publishing: 29] [Article Influence: 12.0] [Reference Citation Analysis]
108 Nakajima J. Pulmonary metastasis: rationale for local treatments and techniques. Gen Thorac Cardiovasc Surg 2010;58:445-51. [PMID: 20859722 DOI: 10.1007/s11748-010-0609-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
109 Reddy SK, Kesmodel SB, Alexander HR. Isolated hepatic perfusion for patients with liver metastases. Ther Adv Med Oncol. 2014;6:180-194. [PMID: 25057304 DOI: 10.1177/1758834014529175] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
110 Prat A, Casado E, Cortés J. New approaches in angiogenic targeting for colorectal cancer. World J Gastroenterol 2007; 13(44): 5857-5866 [PMID: 17990351 DOI: 10.3748/wjg.v13.i44.5857] [Cited by in CrossRef: 39] [Cited by in F6Publishing: 34] [Article Influence: 2.6] [Reference Citation Analysis]
111 Bouganim N, Mamo A, Wasserman DW, Batist G, Metrakos P, Chaudhury P, Hassanain M, Kavan P. Bevacizumab-based therapy for colorectal cancer: experience from a large Canadian cohort at the Jewish General Hospital between 2004 and 2009. Curr Oncol 2013;20:247-51. [PMID: 24155628 DOI: 10.3747/co.20.1370] [Reference Citation Analysis]
112 Hadden WJ, de Reuver PR, Brown K, Mittal A, Samra JS, Hugh TJ. Resection of colorectal liver metastases and extra-hepatic disease: a systematic review and proportional meta-analysis of survival outcomes. HPB (Oxford). 2016;18:209-220. [PMID: 27017160 DOI: 10.1016/j.hpb.2015.12.004] [Cited by in Crossref: 35] [Cited by in F6Publishing: 27] [Article Influence: 5.8] [Reference Citation Analysis]
113 Chen XL, Lei YH, Liu CF, Yang QF, Zuo PY, Liu CY, Chen CZ, Liu YW. Angiogenesis inhibitor bevacizumab increases the risk of ischemic heart disease associated with chemotherapy: a meta-analysis. PLoS One 2013;8:e66721. [PMID: 23818962 DOI: 10.1371/journal.pone.0066721] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 3.3] [Reference Citation Analysis]
114 Puia-Negulescu S, Lebossé F, Mabrut JY, Muller X, Rossignol G, Antonini T, Erard D, Radenne S, Guillet M, Souquet JC, Mohkam K, Lesurtel M. Liver Transplantation for Colorectal Liver Metastases: Current Management and Future Perspectives. Int J Mol Sci 2021;22:3093. [PMID: 33803503 DOI: 10.3390/ijms22063093] [Reference Citation Analysis]
115 Lewandowski RJ, Memon K, Mulcahy MF, Hickey R, Marshall K, Williams M, Salzig K, Gates VL, Atassi B, Vouche M. Twelve-year experience of radioembolization for colorectal hepatic metastases in 214 patients: survival by era and chemotherapy. Eur J Nucl Med Mol Imaging. 2014;41:1861-1869. [PMID: 24906565 DOI: 10.1007/s00259-014-2799-2] [Cited by in Crossref: 51] [Cited by in F6Publishing: 47] [Article Influence: 6.4] [Reference Citation Analysis]
116 Li J, Xu R, Xu J, Denda T, Ikejiri K, Shen L, Toh Y, Shimada K, Kato T, Sakai K, Yamamoto M, Mishima H, Wang J, Baba H. Phase II study of S-1 plus leucovorin in patients with metastatic colorectal cancer: Regimen of 1 week on, 1 week off. Cancer Sci 2017;108:2045-51. [PMID: 28763145 DOI: 10.1111/cas.13335] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
117 Di Benedetto F, Berretta M, D'Amico G, Montalti R, De Ruvo N, Cautero N, Guerrini GP, Ballarin R, Spaggiari M, Tarantino G, Di Sandro S, Pecchi A, Luppi G, Gerunda GE. Liver resection for colorectal metastases in older adults: a paired matched analysis. J Am Geriatr Soc 2011;59:2282-90. [PMID: 22188075 DOI: 10.1111/j.1532-5415.2011.03734.x] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 2.6] [Reference Citation Analysis]
118 Molhoek KR, Griesemann H, Shu J, Gershenwald JE, Brautigan DL, Slingluff CL Jr. Human melanoma cytolysis by combined inhibition of mammalian target of rapamycin and vascular endothelial growth factor/vascular endothelial growth factor receptor-2. Cancer Res 2008;68:4392-7. [PMID: 18519701 DOI: 10.1158/0008-5472.CAN-07-5844] [Cited by in Crossref: 27] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
119 Nicolay NH, Berry DP, Sharma RA. Liver metastases from colorectal cancer: radioembolization with systemic therapy. Nat Rev Clin Oncol. 2009;6:687-697. [PMID: 19884901 DOI: 10.1038/nrclinonc.2009.165] [Cited by in Crossref: 71] [Cited by in F6Publishing: 57] [Article Influence: 5.5] [Reference Citation Analysis]
120 Song J, Yoo J, Kwon A, Kim D, Nguyen HK, Lee BY, Suh W, Min KH. Structure-Activity Relationship of Indole-Tethered Pyrimidine Derivatives that Concurrently Inhibit Epidermal Growth Factor Receptor and Other Angiokinases. PLoS One 2015;10:e0138823. [PMID: 26401847 DOI: 10.1371/journal.pone.0138823] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
121 Freidlin B, Korn EL, Gray R. A general inefficacy interim monitoring rule for randomized clinical trials. Clinical Trials 2010;7:197-208. [DOI: 10.1177/1740774510369019] [Cited by in Crossref: 41] [Article Influence: 3.4] [Reference Citation Analysis]
122 Li Q, Wang D, Li J, Chen P. Clinicopathological and prognostic significance of HER-2/neu and VEGF expression in colon carcinomas. BMC Cancer. 2011;11:277. [PMID: 21708009 DOI: 10.1186/1471-2407-11-277] [Cited by in Crossref: 35] [Cited by in F6Publishing: 34] [Article Influence: 3.2] [Reference Citation Analysis]
123 Lau DK, Mencel J, Chau I. Safety and efficacy review of aflibercept for the treatment of metastatic colorectal cancer. Expert Opin Drug Saf 2022;:1-9. [PMID: 34986714 DOI: 10.1080/14740338.2022.2008905] [Reference Citation Analysis]
124 Orazem M, Draulans C, Spaas M, Van Cutsem E, Debecker M, De Meerleer G, Tejpar S, Dekervel J, Haustermans K. A fatal wound complication following sequential anti-angiogenesis, immune checkpoint inhibition and ultra-hypofractionated radiotherapy. Clin J Gastroenterol 2021;14:1121-5. [PMID: 33844128 DOI: 10.1007/s12328-021-01399-2] [Reference Citation Analysis]
125 Fathy M, Nikaido T. In vivo modulation of iNOS pathway in hepatocellular carcinoma by Nigella sativa. Environ Health Prev Med 2013;18:377-85. [PMID: 23609474 DOI: 10.1007/s12199-013-0336-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.1] [Reference Citation Analysis]
126 Chau I, Cunningham D. Treatment in advanced colorectal cancer: what, when and how? Br J Cancer. 2009;100:1704-1719. [PMID: 19436303 DOI: 10.1038/sj.bjc.6605061] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 5.8] [Reference Citation Analysis]
127 Ko JH, Kwon HS, Kim B, Min G, Shin C, Yang SW, Lee SW, Lee Y, Hong D, Kim YS. Preclinical Efficacy and Safety of an Anti-Human VEGFA and Anti-Human NRP1 Dual-Targeting Bispecific Antibody (IDB0076). Biomolecules 2020;10:E919. [PMID: 32560565 DOI: 10.3390/biom10060919] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 2.0] [Reference Citation Analysis]
128 Schoffelen R, Boerman OC, Goldenberg DM, Sharkey RM, van Herpen CM, Franssen GM, McBride WJ, Chang CH, Rossi EA, van der Graaf WT, Oyen WJ. Development of an imaging-guided CEA-pretargeted radionuclide treatment of advanced colorectal cancer: first clinical results. Br J Cancer 2013;109:934-42. [PMID: 23860529 DOI: 10.1038/bjc.2013.376] [Cited by in Crossref: 55] [Cited by in F6Publishing: 49] [Article Influence: 6.1] [Reference Citation Analysis]
129 Kuderer NM, Culakova E, Lyman GH, Francis C, Falanga A, Khorana AA. A Validated Risk Score for Venous Thromboembolism Is Predictive of Cancer Progression and Mortality. Oncologist 2016;21:861-7. [PMID: 27125754 DOI: 10.1634/theoncologist.2015-0361] [Cited by in Crossref: 36] [Cited by in F6Publishing: 36] [Article Influence: 6.0] [Reference Citation Analysis]
130 Carola C, Ghiringhelli F, Kim S, André T, Barlet J, Bengrine-Lefevre L, Marijon H, Garcia-Larnicol ML, Borg C, Dainese L, Steuer N, Richa H, Benetkiewicz M, Larsen AK, Gramont A, Chibaudel B. FOLFIRI3-aflibercept in previously treated patients with metastatic colorectal cancer. World J Clin Oncol 2018; 9(5): 110-118 [PMID: 30254966 DOI: 10.5306/wjco.v9.i5.110] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
131 Rossi L, Zullo A, Zoratto F, Papa A, Strudel M, Colonna M, Tomao S. Chemotherapy and target therapy as neo-adjuvant approach for initially unresectable colorectal liver metastases. Oncol Rev 2012;6:e6. [PMID: 25992208 DOI: 10.4081/oncol.2012.e6] [Reference Citation Analysis]
132 Boisen MK, Dehlendorff C, Linnemann D, Nielsen BS, Larsen JS, Osterlind K, Nielsen SE, Tarpgaard LS, Qvortrup C, Pfeiffer P. Tissue microRNAs as predictors of outcome in patients with metastatic colorectal cancer treated with first line Capecitabine and Oxaliplatin with or without Bevacizumab. PLoS One. 2014;9:e109430. [PMID: 25329796 DOI: 10.1371/journal.pone.0109430] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 4.1] [Reference Citation Analysis]
133 Maneikyte J, Bausys A, Leber B, Horvath A, Feldbacher N, Hoefler G, Strupas K, Stiegler P, Schemmer P. Dietary glycine decreases both tumor volume and vascularization in a combined colorectal liver metastasis and chemotherapy model. Int J Biol Sci 2019;15:1582-90. [PMID: 31360101 DOI: 10.7150/ijbs.35513] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
134 Saridaki Z, Asimakopoulou N, Boukovinas I, Souglakos J. How to Identify the Right Patients for the Right Treatment in Metastatic Colorectal Cancer (mCRC). Curr Colorectal Cancer Rep 2015;11:151-9. [DOI: 10.1007/s11888-015-0270-9] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
135 Dotan E, Meropol NJ, Burtness B, Denlinger CS, Lee J, Mintzer D, Zhu F, Ruth K, Tuttle H, Sylvester J, Cohen SJ. A phase II study of capecitabine, oxaliplatin, and cetuximab with or without bevacizumab as frontline therapy for metastatic colorectal cancer. A Fox Chase extramural research study. J Gastrointest Cancer 2012;43:562-9. [PMID: 22294255 DOI: 10.1007/s12029-012-9368-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
136 Arimoto A, Uehara K, Tsuzuki T, Aiba T, Ebata T, Nagino M. Role of bevacizumab in neoadjuvant chemotherapy and its influence on microvessel density in rectal cancer. Int J Clin Oncol 2015;20:935-42. [PMID: 25788218 DOI: 10.1007/s10147-015-0818-3] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.7] [Reference Citation Analysis]
137 Strickler JH, Hurwitz HI. Maintenance therapy for first-line metastatic colorectal cancer: activity and sustainability. Oncologist 2012;17:9-10. [PMID: 22234629 DOI: 10.1634/theoncologist.2011-0358] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
138 Komori S, Osada S, Tomita H, Nishio K, Kumazawa I, Tachibana S, Tsuchiya J, Yoshida K. Predictive value of orotate phosphoribosyltransferase in colorectal cancer patients receiving 5-FU-based chemotherapy. Mol Clin Oncol 2013;1:453-60. [PMID: 24649191 DOI: 10.3892/mco.2013.71] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
139 Sakai K, Tsurutani J, Yamanaka T, Yoneshige A, Ito A, Togashi Y, De Velasco MA, Terashima M, Fujita Y, Tomida S, Tamura T, Nakagawa K, Nishio K. Extended RAS and BRAF Mutation Analysis Using Next-Generation Sequencing. PLoS One 2015;10:e0121891. [PMID: 25954997 DOI: 10.1371/journal.pone.0121891] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 3.1] [Reference Citation Analysis]
140 Doi A, Takeda H, Umemoto K, Oumi R, Wada S, Hamaguchi S, Mimura H, Arai H, Horie Y, Mizukami T, Izawa N, Ogura T, Nakajima TE, Sunakawa Y. Inferior mesenteric arteriovenous fistula during treatment with bevacizumab in colorectal cancer patient: A case report. World J Gastrointest Oncol 2020; 12(11): 1364-1371 [PMID: 33250967 DOI: 10.4251/wjgo.v12.i11.1364] [Cited by in CrossRef: 2] [Article Influence: 1.0] [Reference Citation Analysis]
141 Korn EL, Freidlin B, Mooney M. Stopping or reporting early for positive results in randomized clinical trials: the National Cancer Institute Cooperative Group experience from 1990 to 2005. J Clin Oncol 2009;27:1712-21. [PMID: 19237631 DOI: 10.1200/JCO.2008.19.5339] [Cited by in Crossref: 26] [Cited by in F6Publishing: 9] [Article Influence: 2.0] [Reference Citation Analysis]
142 Comella P, Casaretti R, Sandomenico C, Avallone A, Franco L. Role of oxaliplatin in the treatment of colorectal cancer. Ther Clin Risk Manag 2009;5:229-38. [PMID: 19436599 DOI: 10.2147/tcrm.s3583] [Cited by in Crossref: 29] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
143 Zhang HY, Guo JH, Gao S, Chen H, Wang XD, Zhang PJ, Liu P, Cao G, Xu HF, Zhu LZ, Yang RJ, Li J, Zhu X. Effect of primary tumor side on survival outcomes in metastatic colorectal cancer patients after hepatic arterial infusion chemotherapy. World J Gastrointest Oncol 2018; 10(11): 431-438 [PMID: 30487954 DOI: 10.4251/wjgo.v10.i11.431] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
144 Hochster HS, Grothey A, Hart L, Rowland K, Ansari R, Alberts S, Chowhan N, Ramanathan RK, Keaton M, Hainsworth JD, Childs BH. Improved time to treatment failure with an intermittent oxaliplatin strategy: results of CONcePT. Ann Oncol 2014;25:1172-8. [PMID: 24608198 DOI: 10.1093/annonc/mdu107] [Cited by in Crossref: 42] [Cited by in F6Publishing: 33] [Article Influence: 5.3] [Reference Citation Analysis]
145 Totzeck M, Mincu RI, Rassaf T. Cardiovascular Adverse Events in Patients With Cancer Treated With Bevacizumab: A Meta-Analysis of More Than 20 000 Patients. J Am Heart Assoc 2017;6:e006278. [PMID: 28862931 DOI: 10.1161/JAHA.117.006278] [Cited by in Crossref: 50] [Cited by in F6Publishing: 28] [Article Influence: 10.0] [Reference Citation Analysis]
146 Finkelmeier F, You SJ, Waidmann O, Wolff R, Zeuzem S, Bähr O, Trojan J. Bevacizumab in Combination with Chemotherapy for Colorectal Brain Metastasis. J Gastrointest Cancer 2016;47:82-8. [PMID: 26714801 DOI: 10.1007/s12029-015-9795-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
147 García-Carbonero R, van Cutsem E, Rivera F, Jassem J, Gore I Jr, Tebbutt N, Braiteh F, Argiles G, Wainberg ZA, Funke R, Anderson M, McCall B, Stroh M, Wakshull E, Hegde P, Ye W, Chen D, Chang I, Rhee I, Hurwitz H. Randomized Phase II Trial of Parsatuzumab (Anti-EGFL7) or Placebo in Combination with FOLFOX and Bevacizumab for First-Line Metastatic Colorectal Cancer. Oncologist 2017;22:375-e30. [PMID: 28275117 DOI: 10.1634/theoncologist.2016-0133] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 2.6] [Reference Citation Analysis]
148 Awasthi N, Schwarz RE. Profile of nintedanib in the treatment of solid tumors: the evidence to date. Onco Targets Ther. 2015;8:3691-3701. [PMID: 26677336 DOI: 10.2147/OTT.S78805] [Cited by in Crossref: 39] [Cited by in F6Publishing: 21] [Article Influence: 5.6] [Reference Citation Analysis]
149 Sun W. Angiogenesis in metastatic colorectal cancer and the benefits of targeted therapy. J Hematol Oncol. 2012;5:63. [PMID: 23057939 DOI: 10.1186/1756-8722-5-63] [Cited by in Crossref: 56] [Cited by in F6Publishing: 52] [Article Influence: 5.6] [Reference Citation Analysis]
150 Stefano AD, Moretto R, Cella CA, Romano FJ, Raimondo L, Fiore G, Pietro FD, Pepe S, Placido SD, Carlomagno C. Bevacizumab maintenance in metastatic colorectal cancer: How long? World J Clin Cases 2014; 2(11): 717-723 [PMID: 25405197 DOI: 10.12998/wjcc.v2.i11.717] [Reference Citation Analysis]
151 Kuo YH, Lin CH, Shau WY, Chen TJ, Yang SH, Huang SM, Hsu C, Lu YS, Cheng AL. Dynamics of circulating endothelial cells and endothelial progenitor cells in breast cancer patients receiving cytotoxic chemotherapy. BMC Cancer 2012;12:620. [PMID: 23268621 DOI: 10.1186/1471-2407-12-620] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 1.0] [Reference Citation Analysis]
152 Palethorpe HM, Tomita Y, Smith E, Pei JV, Townsend AR, Price TJ, Young JP, Yool AJ, Hardingham JE. The Aquaporin 1 Inhibitor Bacopaside II Reduces Endothelial Cell Migration and Tubulogenesis and Induces Apoptosis. Int J Mol Sci 2018;19:E653. [PMID: 29495367 DOI: 10.3390/ijms19030653] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 4.5] [Reference Citation Analysis]
153 Aprile G, Zanon E, Tuniz F, Iaiza E, De Pauli F, Pella N, Pizzolitto S, Buffoli A, Piga A, Skrap M. Neurosurgical management and postoperative whole-brain radiotherapy for colorectal cancer patients with symptomatic brain metastases. J Cancer Res Clin Oncol. 2009;135:451-457. [PMID: 18779977 DOI: 10.1007/s00432-008-0468-1] [Cited by in Crossref: 30] [Cited by in F6Publishing: 28] [Article Influence: 2.1] [Reference Citation Analysis]
154 Katayose Y, Unno M. Management of liver metastases from colorectal cancer. Clin J Gastroenterol 2010;3:128-35. [PMID: 26190118 DOI: 10.1007/s12328-010-0155-z] [Cited by in Crossref: 2] [Article Influence: 0.2] [Reference Citation Analysis]
155 Hall M, Gourley C, McNeish I, Ledermann J, Gore M, Jayson G, Perren T, Rustin G, Kaye S. Targeted anti-vascular therapies for ovarian cancer: current evidence. Br J Cancer 2013;108:250-8. [PMID: 23385789 DOI: 10.1038/bjc.2012.541] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 5.7] [Reference Citation Analysis]
156 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Chin K, Yamaguchi T. A phase I/II study of biweekly capecitabine and irinotecan plus bevacizumab as second-line chemotherapy in patients with metastatic colorectal cancer. Drug Des Devel Ther 2015;9:1653-62. [PMID: 25834402 DOI: 10.2147/DDDT.S80449] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
157 Li N, Deng W, Zhang G, Du Y, Guo Y, Ma Y, Wei C, Bie L, Zhang C, Song T, Luo S, Fang B. Low-Dose Apatinib Combined With S-1 in Refractory Metastatic Colorectal Cancer: A Phase 2, Multicenter, Single-Arm, Prospective Study. Front Oncol 2021;11:728854. [PMID: 34540697 DOI: 10.3389/fonc.2021.728854] [Reference Citation Analysis]
158 Tejpar S, Prenen H, Mazzone M. Overcoming resistance to antiangiogenic therapies. Oncologist. 2012;17:1039-1050. [PMID: 22773560 DOI: 10.1634/theoncologist.2012-0068] [Cited by in Crossref: 42] [Cited by in F6Publishing: 36] [Article Influence: 4.2] [Reference Citation Analysis]
159 Wang Y, Yao X, Ge J, Hu F, Zhao Y. Can vascular endothelial growth factor and microvessel density be used as prognostic biomarkers for colorectal cancer? A systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:102736. [PMID: 25143961 DOI: 10.1155/2014/102736] [Cited by in Crossref: 8] [Cited by in F6Publishing: 18] [Article Influence: 1.0] [Reference Citation Analysis]
160 Chandra S, Sheth J, Anantharaman G, Gopalakrishnan M. Ranibizumab-induced retinal reperfusion and regression of neovascularization in diabetic retinopathy: An angiographic illustration. Am J Ophthalmol Case Rep 2018;9:41-4. [PMID: 29468217 DOI: 10.1016/j.ajoc.2018.01.006] [Cited by in Crossref: 15] [Cited by in F6Publishing: 10] [Article Influence: 3.8] [Reference Citation Analysis]
161 Boerner T, Zambirinis C, Gagnière J, Chou JF, Gonen M, Kemeny NE, Cercek A, Connell LC, Kingham TP, Allen PJ, Balachandran VP, Drebin J, Jarnagin WR, D'Angelica MI. Early liver metastases after "failure" of adjuvant chemotherapy for stage III colorectal cancer: is there a role for additional adjuvant therapy? HPB (Oxford) 2021;23:601-8. [PMID: 32943326 DOI: 10.1016/j.hpb.2020.08.018] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
162 Qu YL, Saifuding•Keyoumu, Tang Y. Efficacy and safety of bevacizumab combined with chemotherapy in treatment of metastatic colorectal cancer. Shijie Huaren Xiaohua Zazhi 2016; 24(17): 2748-2754 [DOI: 10.11569/wcjd.v24.i17.2748] [Reference Citation Analysis]
163 Maeda Y, Shinohara T, Minagawa N, Kobayashi T, Koyama R, Shimada S, Tsunetoshi Y, Murayama K, Hasegawa H. A retrospective analysis of emergency surgery for cases of acute abdomen during cancer chemotherapy. Case series. Ann Med Surg (Lond) 2020;57:143-7. [PMID: 32760583 DOI: 10.1016/j.amsu.2020.07.038] [Reference Citation Analysis]
164 Martinetti A, Miceli R, Sottotetti E, Di Bartolomeo M, de Braud F, Gevorgyan A, Dotti KF, Bajetta E, Campiglio M, Bianchi F, Bregni G, Pietrantonio F. Circulating biomarkers in advanced colorectal cancer patients randomly assigned to three bevacizumab-based regimens. Cancers (Basel) 2014;6:1753-68. [PMID: 25256831 DOI: 10.3390/cancers6031753] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 1.5] [Reference Citation Analysis]
165 Dahl O, Borkamo ED, Fluge O. Current status of antivascular therapy and targeted treatment in the clinic. Int J Hyperthermia 2008;24:97-110. [PMID: 18214773 DOI: 10.1080/02656730701824406] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
166 Giordano G, Febbraro A, Venditti M, Campidoglio S, Olivieri N, Raieta K, Parcesepe P, Imbriani GC, Remo A, Pancione M. Targeting angiogenesis and tumor microenvironment in metastatic colorectal cancer: role of aflibercept. Gastroenterol Res Pract. 2014;2014:526178. [PMID: 25136356 DOI: 10.1155/2014/526178] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
167 Duda DG. Molecular Biomarkers of Response to Antiangiogenic Therapy for Cancer. ISRN Cell Biol 2012;2012:587259. [PMID: 24340224 DOI: 10.5402/2012/587259] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
168 Hsu CW, King TM, Wang HT, Wang JH. Factors that influence survival in unresectable metastatic or locally advanced colorectal cancer. Int J Colorectal Dis 2011;26:1559-66. [PMID: 21573902 DOI: 10.1007/s00384-011-1231-7] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
169 Wu S, Kim C, Baer L, Zhu X. Bevacizumab increases risk for severe proteinuria in cancer patients. J Am Soc Nephrol. 2010;21:1381-1389. [PMID: 20538785 DOI: 10.1681/asn.2010020167] [Cited by in Crossref: 141] [Cited by in F6Publishing: 59] [Article Influence: 11.8] [Reference Citation Analysis]
170 Brown AP, Citrin DE, Camphausen KA. Clinical biomarkers of angiogenesis inhibition. Cancer Metastasis Rev 2008;27:415-34. [PMID: 18414993 DOI: 10.1007/s10555-008-9143-x] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 2.4] [Reference Citation Analysis]
171 Moudgil R, Yeh ET. Mechanisms of Cardiotoxicity of Cancer Chemotherapeutic Agents: Cardiomyopathy and Beyond. Can J Cardiol 2016;32:863-870.e5. [PMID: 27117975 DOI: 10.1016/j.cjca.2016.01.027] [Cited by in Crossref: 33] [Cited by in F6Publishing: 28] [Article Influence: 5.5] [Reference Citation Analysis]
172 Yoshida T, Takahashi K, Shibuya K, Muto O, Yoshida Y, Taguchi D, Shimazu K, Fukuda K, Ono F, Nomura K, Shibata H. Clinical efficacy and safety of second line and salvage aflibercept for advanced colorectal cancer in Akita prefecture. World J Gastrointest Oncol 2021; 13(4): 295-304 [PMID: 33889280 DOI: 10.4251/wjgo.v13.i4.295] [Cited by in CrossRef: 1] [Article Influence: 1.0] [Reference Citation Analysis]
173 Ye H, Lu CD, Zheng SM. Drug selection in isolated hepatic perfusion for nonresectable liver tumors: recent trends and perspectives. Shijie Huaren Xiaohua Zazhi 2008; 16(23): 2621-2625 [DOI: 10.11569/wcjd.v16.i23.2621] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]
174 Chong G, Tebbutt NC. Using bevacizumab with different chemotherapeutic regimens in metastatic colorectal cancer: balancing utility with low toxicity. Ther Adv Med Oncol 2010;2:309-17. [PMID: 21789143 DOI: 10.1177/1758834010375096] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
175 Jayson GC, Zhou C, Backen A, Horsley L, Marti-Marti K, Shaw D, Mescallado N, Clamp A, Saunders MP, Valle JW, Mullamitha S, Braun M, Hasan J, McEntee D, Simpson K, Little RA, Watson Y, Cheung S, Roberts C, Ashcroft L, Manoharan P, Scherer SJ, Del Puerto O, Jackson A, O'Connor JPB, Parker GJM, Dive C. Plasma Tie2 is a tumor vascular response biomarker for VEGF inhibitors in metastatic colorectal cancer. Nat Commun 2018;9:4672. [PMID: 30405103 DOI: 10.1038/s41467-018-07174-1] [Cited by in Crossref: 25] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
176 Lakatos G, Tulassay Z. [Antiangiogenic therapy for gastrointestinal tumors]. Orv Hetil 2008;149:2317-24. [PMID: 19042183 DOI: 10.1556/OH.2008.28496] [Reference Citation Analysis]
177 Itatani Y, Yamamoto T, Zhong C, Molinolo AA, Ruppel J, Hegde P, Taketo MM, Ferrara N. Suppressing neutrophil-dependent angiogenesis abrogates resistance to anti-VEGF antibody in a genetic model of colorectal cancer. Proc Natl Acad Sci U S A 2020;117:21598-608. [PMID: 32817421 DOI: 10.1073/pnas.2008112117] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
178 Bhattacharya A. Methylselenocysteine: a promising antiangiogenic agent for overcoming drug delivery barriers in solid malignancies for therapeutic synergy with anticancer drugs. Expert Opin Drug Deliv 2011;8:749-63. [PMID: 21473705 DOI: 10.1517/17425247.2011.571672] [Cited by in Crossref: 32] [Cited by in F6Publishing: 25] [Article Influence: 2.9] [Reference Citation Analysis]
179 Hofheinz R, Petersen V, Kindler M, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Stein A. Bevacizumab in first-line treatment of elderly patients with metastatic colorectal cancer: German community-based observational cohort study results. BMC Cancer. 2014;14:761. [PMID: 25311943 DOI: 10.1186/1471-2407-14-761] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
180 Suenaga M, Mizunuma N, Matsusaka S, Shinozaki E, Ozaka M, Ogura M, Yamaguchi T. Phase II study of reintroduction of oxaliplatin for advanced colorectal cancer in patients previously treated with oxaliplatin and irinotecan: RE-OPEN study. Drug Des Devel Ther 2015;9:3099-108. [PMID: 26124634 DOI: 10.2147/DDDT.S85567] [Cited by in Crossref: 24] [Cited by in F6Publishing: 13] [Article Influence: 3.4] [Reference Citation Analysis]
181 Chibaudel B, Tournigand C, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:75-89. [PMID: 22423266 DOI: 10.1177/1758834011431592] [Cited by in Crossref: 48] [Cited by in F6Publishing: 48] [Article Influence: 4.8] [Reference Citation Analysis]
182 Bencsikova B, Bortlicek Z, Halamkova J, Ostrizkova L, Kiss I, Melichar B, Pavlik T, Dusek L, Valik D, Vyzula R. Efficacy of bevacizumab and chemotherapy in the first-line treatment of metastatic colorectal cancer: broadening KRAS-focused clinical view. BMC Gastroenterol. 2015;15:37. [PMID: 25888291 DOI: 10.1186/s12876-015-0266-6] [Cited by in Crossref: 12] [Cited by in F6Publishing: 13] [Article Influence: 1.7] [Reference Citation Analysis]
183 An MM, Zou Z, Shen H, Liu P, Chen ML, Cao YB, Jiang YY. Incidence and risk of significantly raised blood pressure in cancer patients treated with bevacizumab: an updated meta-analysis. Eur J Clin Pharmacol 2010;66:813-21. [PMID: 20401474 DOI: 10.1007/s00228-010-0815-4] [Cited by in Crossref: 51] [Cited by in F6Publishing: 46] [Article Influence: 4.3] [Reference Citation Analysis]
184 Rashad N, Abdulla M, Farouk M, Elkerm Y, Eid Salem S, Yehia M, Saad AS, Abdel Aziz AH, Refaat G, Awad I, Elnaggar M, Kamal K, Refky B, Abdelkhalek M, Touny A, Kassem L, Shash E, Abdelhay AA, Mahmoud BE, Oualla K, Chraiet N, Awadelkarim H Maki H, Kader YA. Resource Oriented Decision Making for Treatment of Metastatic Colorectal Cancer (mCRC) in a Lower-Middle Income Country: Egyptian Foundation of Medical Sciences (EFMS) Consensus Recommendations 2020. CMAR 2022;Volume 14:821-42. [DOI: 10.2147/cmar.s340030] [Reference Citation Analysis]
185 Bloch O, Safaee M, Sun MZ, Butowski NA, McDermott MW, Berger MS, Aghi MK, Parsa AT. Disseminated progression of glioblastoma after treatment with bevacizumab. Clin Neurol Neurosurg 2013;115:1795-801. [PMID: 23706614 DOI: 10.1016/j.clineuro.2013.04.017] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.6] [Reference Citation Analysis]
186 Wang J, Zhu C. Anticoagulation in combination with antiangiogenesis and chemotherapy for cancer patients: evidence and hypothesis. Onco Targets Ther 2016;9:4737-46. [PMID: 27536135 DOI: 10.2147/OTT.S103184] [Cited by in Crossref: 9] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
187 Desautels D, Harlos C, Czaykowski P. The advent of precision therapy in gastrointestinal malignancies: Targeting the human epidermal growth factor receptor family in colorectal and esophagogastric cancer. J Carcinog 2014;13:13. [PMID: 25525412 DOI: 10.4103/1477-3163.145609] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
188 Bertaut A, Touchefeu Y, Blanc J, Bouché O, François E, Conroy T, Artru P, Adenis A, Gobbo J, Borg C, Ghiringhelli F, Bennouna J. Health-Related Quality of Life Analysis in Metastatic Colorectal Cancer Patients Treated by Second-Line Chemotherapy, Associated With Either Cetuximab or Bevacizumab: The PRODIGE 18 Randomized Phase II Study. Clin Colorectal Cancer 2021:S1533-0028(21)00087-6. [PMID: 34838460 DOI: 10.1016/j.clcc.2021.09.001] [Reference Citation Analysis]
189 Morimoto H, Hida Y, Maishi N, Nishihara H, Hatanaka Y, Li C, Matsuno Y, Nakamura T, Hirano S, Hida K. Biglycan, tumor endothelial cell secreting proteoglycan, as possible biomarker for lung cancer. Thorac Cancer 2021;12:1347-57. [PMID: 33709550 DOI: 10.1111/1759-7714.13907] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
190 Zeng J, Yuan D, Liu H, Song Y. [Vascular normalization and cancer immunotherapy]. Zhongguo Fei Ai Za Zhi 2014;17:273-6. [PMID: 24667268 DOI: 10.3779/j.issn.1009-3419.2014.03.16] [Reference Citation Analysis]
191 Yang L, Jiang YQ, Mei Q, Chen Y. Bevacizumab-induced hypertension in patients with metastatic colorectal cancer: Its incidence and clinical significance. Shijie Huaren Xiaohua Zazhi 2012; 20(26): 2525-2528 [DOI: 10.11569/wcjd.v20.i26.2525] [Reference Citation Analysis]
192 Meng X, Zhao R, Wu S, Shen G, Ding L, Sun B, Wang J. Efficacy of repeated low-dose bevacizumab treatment with long-dosing interval for radiation-induced brain necrosis: A case report. Cancer Biol Ther 2017;18:63-6. [PMID: 28152324 DOI: 10.1080/15384047.2016.1276127] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
193 Braghiroli MI, Riechelmann RP, Sabbaga J, Hoff PM. Do We Need another Antiangiogenesis Agent for Colorectal Cancer: are Bevacizumab and Aflibercept the Same? Curr Colorectal Cancer Rep 2013;9:317-25. [DOI: 10.1007/s11888-013-0187-0] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
194 Suenaga M, Nishina T, Mizunuma N, Yasui H, Ura T, Denda T, Ikeda J, Esaki T, Nishisaki H, Takano Y, Sugiyama Y, Muro K. Multicenter phase II study of FOLFIRI plus bevacizumab after discontinuation of oxaliplatin-based regimen for advanced or recurrent colorectal cancer (CR0802). BMC Cancer 2015;15:176. [PMID: 25884814 DOI: 10.1186/s12885-015-1175-3] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
195 Raj N, Saltz L. Biologic agents in the treatment of colorectal cancer: an update. Colorectal Cancer 2014;3:363-74. [DOI: 10.2217/crc.14.26] [Reference Citation Analysis]
196 Peng Y, Chen Y, Zhang X, Yang Y, Cao D, Bi F, Li Z, Gou H. Tumoral cavitation in colorectal cancer patients with unresectable lung metastasis treated with bevacizumab and chemotherapy. J Cancer Res Clin Oncol 2018;144:1339-46. [PMID: 29774414 DOI: 10.1007/s00432-018-2656-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
197 Chin VT, Nagrial AM, Chou A, Biankin AV, Gill AJ, Timpson P, Pajic M. Rho-associated kinase signalling and the cancer microenvironment: novel biological implications and therapeutic opportunities. Expert Rev Mol Med 2015;17:e17. [PMID: 26507949 DOI: 10.1017/erm.2015.17] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 4.1] [Reference Citation Analysis]
198 Escalante CP, Chang YC, Liao K, Rouleau T, Halm J, Bossi P, Bhadriraju S, Brito-Dellan N, Sahai S, Yusuf SW, Zalpour A, Elting LS;  Epidemiology Section of the Mucositis Study Group of the Multinational Association of Supportive Care in Cancer; 2013. Meta-analysis of cardiovascular toxicity risks in cancer patients on selected targeted agents. Support Care Cancer. 2016;24:4057-4074. [PMID: 27344327 DOI: 10.1007/s00520-016-3310-3] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
199 Grothey A, Galanis E. Targeting angiogenesis: progress with anti-VEGF treatment with large molecules. Nat Rev Clin Oncol 2009;6:507-18. [DOI: 10.1038/nrclinonc.2009.110] [Cited by in Crossref: 257] [Cited by in F6Publishing: 224] [Article Influence: 19.8] [Reference Citation Analysis]
200 Jitawatanarat P, Wee W. Update on antiangiogenic therapy in colorectal cancer: aflibercept and regorafenib. J Gastrointest Oncol 2013;4:231-8. [PMID: 23730520 DOI: 10.3978/j.issn.2078-6891.2013.008] [Cited by in F6Publishing: 6] [Reference Citation Analysis]
201 Marsala A, Lee EW, Padia SA. Yttrium-90 Radioembolization for Metastatic Colorectal Cancer: Outcomes by Number of Lines of Therapy. Semin Intervent Radiol 2017;34:116-20. [PMID: 28579679 DOI: 10.1055/s-0037-1602711] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.6] [Reference Citation Analysis]
202 Hopirtean C, Nagy V. Optimizing the use of anti VEGF targeted therapies in patients with metastatic colorectal cancer: review of literature. Clujul Med 2018;91:12-7. [PMID: 29440946 DOI: 10.15386/cjmed-881] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.8] [Reference Citation Analysis]
203 Watanabe T, Muro K, Ajioka Y, Hashiguchi Y, Ito Y, Saito Y, Hamaguchi T, Ishida H, Ishiguro M, Ishihara S, Kanemitsu Y, Kawano H, Kinugasa Y, Kokudo N, Murofushi K, Nakajima T, Oka S, Sakai Y, Tsuji A, Uehara K, Ueno H, Yamazaki K, Yoshida M, Yoshino T, Boku N, Fujimori T, Itabashi M, Koinuma N, Morita T, Nishimura G, Sakata Y, Shimada Y, Takahashi K, Tanaka S, Tsuruta O, Yamaguchi T, Yamaguchi N, Tanaka T, Kotake K, Sugihara K;  Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2016 for the treatment of colorectal cancer. Int J Clin Oncol. 2018;23:1-34. [PMID: 28349281 DOI: 10.1007/s10147-017-1101-6] [Cited by in Crossref: 400] [Cited by in F6Publishing: 364] [Article Influence: 80.0] [Reference Citation Analysis]
204 Ghiringhelli F, Bichard D, Limat S, Lorgis V, Vincent J, Borg C, Berthou J, Orry D, Ortega-Deballon P, Lakkis Z, Facy O, Heyd B, Rat P, Nerich V, Ladoire S. Bevacizumab efficacy in metastatic colorectal cancer is dependent on primary tumor resection. Ann Surg Oncol 2014;21:1632-40. [PMID: 24419756 DOI: 10.1245/s10434-013-3463-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 2.0] [Reference Citation Analysis]
205 Sadahiro S, Suzuki T, Tanaka A, Okada K, Kamata H, Koisumi J. Clinical significance of and future perspectives for hepatic arterial infusion chemotherapy in patients with liver metastases from colorectal cancer. Surg Today 2013;43:1088-94. [PMID: 23143145 DOI: 10.1007/s00595-012-0416-1] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
206 Li Y, Zhao J, Wu X, Zhang Y, Jin Y, Cai W. Clinical and genomic characteristics of metabolic syndrome in colorectal cancer. Aging (Albany NY) 2021;13:5442-60. [PMID: 33582655 DOI: 10.18632/aging.202474] [Reference Citation Analysis]
207 Stintzing S. Management of colorectal cancer. F1000Prime Rep 2014;6:108. [PMID: 25580262 DOI: 10.12703/P6-108] [Cited by in Crossref: 51] [Cited by in F6Publishing: 31] [Article Influence: 6.4] [Reference Citation Analysis]
208 Li S, Xu HX, Wu CT, Wang WQ, Jin W, Gao HL, Li H, Zhang SR, Xu JZ, Qi ZH, Ni QX, Yu XJ, Liu L. Angiogenesis in pancreatic cancer: current research status and clinical implications. Angiogenesis 2019;22:15-36. [PMID: 30168025 DOI: 10.1007/s10456-018-9645-2] [Cited by in Crossref: 50] [Cited by in F6Publishing: 55] [Article Influence: 12.5] [Reference Citation Analysis]
209 Shitara K, Yuki S, Yamazaki K, Naito Y, Fukushima H, Komatsu Y, Yasui H, Takano T, Muro K. Validation study of a prognostic classification in patients with metastatic colorectal cancer who received irinotecan-based second-line chemotherapy. J Cancer Res Clin Oncol 2013;139:595-603. [PMID: 23250506 DOI: 10.1007/s00432-012-1349-1] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
210 Chibaudel B, Bonnetain F, Tournigand C, de Larauze MH, de Gramont A, Laurent-Puig P, Paget J, Hadengue A, Notelet D, Benetkiewicz M. STRATEGIC-1: A multiple-lines, randomized, open-label GERCOR phase III study in patients with unresectable wild-type RAS metastatic colorectal cancer. BMC Cancer. 2015;15:496. [PMID: 26141683 DOI: 10.1186/s12885-015-1503-7] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
211 Kim SH, Choi MK, Park NY, Hyun JW, Lee MY, Kim HJ, Jung SK, Cha Y. Serum neurofilament light chain levels as a biomarker of neuroaxonal injury and severity of oxaliplatin-induced peripheral neuropathy. Sci Rep 2020;10:7995. [PMID: 32409710 DOI: 10.1038/s41598-020-64511-5] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
212 Economopoulou P, Kotsakis A, Kapiris I, Kentepozidis N. Cancer therapy and cardiovascular risk: focus on bevacizumab. Cancer Manag Res 2015;7:133-43. [PMID: 26082660 DOI: 10.2147/CMAR.S77400] [Cited by in Crossref: 43] [Cited by in F6Publishing: 20] [Article Influence: 6.1] [Reference Citation Analysis]
213 Conley BA, Staudt L, Takebe N, Wheeler DA, Wang L, Cardenas MF, Korchina V, Zenklusen JC, McShane LM, Tricoli JV, Williams PM, Lubensky I, O'Sullivan-Coyne G, Kohn E, Little RF, White J, Malik S, Harris LN, Mann B, Weil C, Tarnuzzer R, Karlovich C, Rodgers B, Shankar L, Jacobs PM, Nolan T, Berryman SM, Gastier-Foster J, Bowen J, Leraas K, Shen H, Laird PW, Esteller M, Miller V, Johnson A, Edmondson EF, Giordano TJ, Kim B, Ivy SP. The Exceptional Responders Initiative: Feasibility of a National Cancer Institute Pilot Study. J Natl Cancer Inst 2021;113:27-37. [PMID: 32339229 DOI: 10.1093/jnci/djaa061] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 5.0] [Reference Citation Analysis]
214 Dossa F, Acuna SA, Rickles AS, Berho M, Wexner SD, Quereshy FA, Baxter NN, Chadi SA. Association Between Adjuvant Chemotherapy and Overall Survival in Patients With Rectal Cancer and Pathological Complete Response After Neoadjuvant Chemotherapy and Resection. JAMA Oncol 2018;4:930-7. [PMID: 29710274 DOI: 10.1001/jamaoncol.2017.5597] [Cited by in Crossref: 47] [Cited by in F6Publishing: 44] [Article Influence: 15.7] [Reference Citation Analysis]
215 Tanaka N, Sakamoto K, Okabe H, Fujioka A, Yamamura K, Nakagawa F, Nagase H, Yokogawa T, Oguchi K, Ishida K, Osada A, Kazuno H, Yamada Y, Matsuo K. Repeated oral dosing of TAS-102 confers high trifluridine incorporation into DNA and sustained antitumor activity in mouse models. Oncol Rep 2014;32:2319-26. [PMID: 25230742 DOI: 10.3892/or.2014.3487] [Cited by in Crossref: 75] [Cited by in F6Publishing: 64] [Article Influence: 9.4] [Reference Citation Analysis]
216 Kirstein MM, Lange A, Prenzler A, Manns MP, Kubicka S, Vogel A. Targeted therapies in metastatic colorectal cancer: a systematic review and assessment of currently available data. Oncologist. 2014;19:1156-1168. [PMID: 25326159 DOI: 10.1634/theoncologist.2014-0032] [Cited by in Crossref: 69] [Cited by in F6Publishing: 65] [Article Influence: 8.6] [Reference Citation Analysis]
217 Jeong JH, Ojha U, Lee YM. Pathological angiogenesis and inflammation in tissues. Arch Pharm Res 2021;44:1-15. [PMID: 33230600 DOI: 10.1007/s12272-020-01287-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
218 Mulcahy M. Addition of bevacizumab for control of malignant ascites from colon cancer: . Anti-Cancer Drugs 2009;20:S33-6. [DOI: 10.1097/01.cad.0000359486.68787.f7] [Reference Citation Analysis]
219 Basu B, Eisen T. Perspectives in drug development for metastatic renal cell cancer. Target Oncol 2010;5:139-56. [PMID: 20689997 DOI: 10.1007/s11523-010-0149-2] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
220 Quan Q, Huang Y, Chen Q, Qiu H, Hu Q, Rong Y, Li T, Xia L, Zhang B. Impact of Serum Apolipoprotein A-I on Prognosis and Bevacizumab Efficacy in Patients with Metastatic Colorectal Cancer: a Propensity Score-Matched Analysis. Transl Oncol 2017;10:288-94. [PMID: 28292509 DOI: 10.1016/j.tranon.2017.01.006] [Cited by in Crossref: 6] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
221 Li Y, Huang P, Peng H, Yue H, Wu M, Liu S, Qin R, Fan J, Han Y. Antitumor effects of Endostar(rh-endostatin) combined with gemcitabine in different administration sequences to treat Lewis lung carcinoma. Cancer Manag Res 2019;11:3469-79. [PMID: 31114380 DOI: 10.2147/CMAR.S192868] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
222 Van Cutsem E, Joulain F, Hoff PM, Mitchell E, Ruff P, Lakomý R, Prausová J, Moiseyenko VM, van Hazel G, Cunningham D, Arnold D, Schmoll HJ, Ten Tije AJ, McKendrick J, Kröning H, Humblet Y, Grávalos C, Le-Guennec S, Andria M, Dochy E, Vishwanath RL, Macarulla T, Tabernero J. Aflibercept Plus FOLFIRI vs. Placebo Plus FOLFIRI in Second-Line Metastatic Colorectal Cancer: a Post Hoc Analysis of Survival from the Phase III VELOUR Study Subsequent to Exclusion of Patients who had Recurrence During or Within 6 Months of Completing Adjuvant Oxaliplatin-Based Therapy. Target Oncol 2016;11:383-400. [PMID: 26706237 DOI: 10.1007/s11523-015-0402-9] [Cited by in Crossref: 27] [Cited by in F6Publishing: 23] [Article Influence: 5.4] [Reference Citation Analysis]
223 Haraldsdottir S, Wu C, Bloomston M, Goldberg RM. What is the optimal neo-adjuvant treatment for liver metastasis? Ther Adv Med Oncol. 2013;5:221-234. [PMID: 23858331 DOI: 10.1177/1758834013485111] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
224 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Takiuchi H, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2010 for the treatment of colorectal cancer. Int J Clin Oncol 2012;17:1-29. [PMID: 22002491 DOI: 10.1007/s10147-011-0315-2] [Cited by in Crossref: 491] [Cited by in F6Publishing: 477] [Article Influence: 44.6] [Reference Citation Analysis]
225 George TJ, Ivey AM, Ali A, Lee JH, Wang Y, Daily KC, Ramnaraign BH, Tan SA, Terracina KP, Read TE, Dang LH, Iqbal A. Activity of Sorafenib Plus Capecitabine in Previously Treated Metastatic Colorectal Cancer. Oncologist 2021;26:362-e724. [PMID: 33512054 DOI: 10.1002/onco.13689] [Reference Citation Analysis]
226 Okita Y, Nonaka M, Umehara T, Kanemura Y, Kodama Y, Mano M, Nakajima S. Efficacy of temozolomide and bevacizumab for the treatment of leptomeningeal dissemination of recurrent glioblastoma: A case report. Oncol Lett 2015;9:1885-8. [PMID: 25789061 DOI: 10.3892/ol.2015.2940] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
227 Goldstein DA, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. First- and second-line bevacizumab in addition to chemotherapy for metastatic colorectal cancer: a United States-based cost-effectiveness analysis. J Clin Oncol 2015;33:1112-8. [PMID: 25691669 DOI: 10.1200/JCO.2014.58.4904] [Cited by in Crossref: 97] [Cited by in F6Publishing: 49] [Article Influence: 13.9] [Reference Citation Analysis]
228 Ma WH, An YH, Zhang YQ, Guo Y, Li N. Bevacizumab maintenance treatment for colorectal cancer: A meta-analysis. Shijie Huaren Xiaohua Zazhi 2017; 25(4): 340-350 [DOI: 10.11569/wcjd.v25.i4.340] [Reference Citation Analysis]
229 Schmoll H, Van Cutsem E, Stein A, Valentini V, Glimelius B, Haustermans K, Nordlinger B, van de Velde C, Balmana J, Regula J, Nagtegaal I, Beets-tan R, Arnold D, Ciardiello F, Hoff P, Kerr D, Köhne C, Labianca R, Price T, Scheithauer W, Sobrero A, Tabernero J, Aderka D, Barroso S, Bodoky G, Douillard J, El Ghazaly H, Gallardo J, Garin A, Glynne-jones R, Jordan K, Meshcheryakov A, Papamichail D, Pfeiffer P, Souglakos I, Turhal S, Cervantes A. ESMO Consensus Guidelines for management of patients with colon and rectal cancer. A personalized approach to clinical decision making. Annals of Oncology 2012;23:2479-516. [DOI: 10.1093/annonc/mds236] [78495111110.1093/annonc/mds236','', '1007-9327')">Reference Citation Analysis]
230 Li Y, Hou H, Zhang P, Zhang Z. Co-delivery of doxorubicin and paclitaxel by reduction/pH dual responsive nanocarriers for osteosarcoma therapy. Drug Deliv 2020;27:1044-53. [PMID: 32633576 DOI: 10.1080/10717544.2020.1785049] [Cited by in Crossref: 10] [Cited by in F6Publishing: 6] [Article Influence: 10.0] [Reference Citation Analysis]
231 Zuurbier L, Rahman A, Cordes M, Scheick J, Wong TJ, Rustenburg F, Joseph JC, Dynoodt P, Casey R, Drillenburg P, Gerhards M, Barat A, Klinger R, Fender B, O'Connor DP, Betge J, Ebert MP, Gaiser T, Prehn JHM, Griffioen AW, van Grieken NCT, Ylstra B, Byrne AT, van der Flier LG, Gallagher WM, Postel R. Apelin: A putative novel predictive biomarker for bevacizumab response in colorectal cancer. Oncotarget 2017;8:42949-61. [PMID: 28487489 DOI: 10.18632/oncotarget.17306] [Cited by in Crossref: 29] [Cited by in F6Publishing: 27] [Article Influence: 7.3] [Reference Citation Analysis]
232 Montagnani F, Di Leonardo G, Pino M, Perboni S, Ribecco A, Fioretto L. Protracted Inhibition of Vascular Endothelial Growth Factor Signaling Improves Survival in Metastatic Colorectal Cancer: A Systematic Review. J Transl Int Med. 2017;5:18-26. [PMID: 28680835 DOI: 10.1515/jtim-2017-0005] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
233 Feng M, Jin JQ, Xia L, Xiao T, Mei S, Wang X, Huang X, Chen J, Liu M, Chen C, Rafi S, Zhu AX, Feng YX, Zhu D. Pharmacological inhibition of β-catenin/BCL9 interaction overcomes resistance to immune checkpoint blockades by modulating Treg cells. Sci Adv 2019;5:eaau5240. [PMID: 31086813 DOI: 10.1126/sciadv.aau5240] [Cited by in Crossref: 35] [Cited by in F6Publishing: 42] [Article Influence: 11.7] [Reference Citation Analysis]
234 Messersmith WA, Jimeno A, Jacene H, Zhao M, Kulesza P, Laheru DA, Kahn Y, Spira A, Dancey J, Iacobuzio-Donahue C, Donehower RC, Carducci M, Rudek MA, Hidalgo M. Phase I trial of oxaliplatin, infusional 5-fluorouracil, and leucovorin (FOLFOX4) with erlotinib and bevacizumab in colorectal cancer. Clin Colorectal Cancer 2010;9:297-304. [PMID: 21208844 DOI: 10.3816/CCC.2010.n.043] [Cited by in Crossref: 17] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
235 Strickler JH, Rushing CN, Niedzwiecki D, McLeod A, Altomare I, Uronis HE, Hsu SD, Zafar SY, Morse MA, Chang DZ, Wells JL, Blackwell KL, Marcom PK, Arrowood C, Bolch E, Haley S, Rangwala FA, Hatch AJ, Nixon AB, Hurwitz HI. A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancer. BMC Cancer 2019;19:1032. [PMID: 31675952 DOI: 10.1186/s12885-019-6234-8] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
236 Wurz GT, Kao CJ, DeGregorio MW. Novel cancer antigens for personalized immunotherapies: latest evidence and clinical potential. Ther Adv Med Oncol 2016;8:4-31. [PMID: 26753003 DOI: 10.1177/1758834015615514] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
237 Kline CL, El-Deiry WS. Personalizing colon cancer therapeutics: targeting old and new mechanisms of action. Pharmaceuticals (Basel) 2013;6:988-1038. [PMID: 24276379 DOI: 10.3390/ph6080988] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 0.9] [Reference Citation Analysis]
238 Barni S, Cabiddu M, Guarneri P, Lonati V, Petrelli F. The risk for anemia with targeted therapies for solid tumors. Oncologist 2012;17:715-24. [PMID: 22531357 DOI: 10.1634/theoncologist.2012-0024] [Cited by in Crossref: 24] [Cited by in F6Publishing: 21] [Article Influence: 2.4] [Reference Citation Analysis]
239 Thomann S, Longerich T, Bazhin AV, Mier W, Schemmer P, Ryschich E. Selective targeting of liver cancer with the endothelial marker CD146. Oncotarget 2014;5:8614-24. [PMID: 25238265 DOI: 10.18632/oncotarget.2345] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 1.6] [Reference Citation Analysis]
240 Kotaka M, Xu R, Muro K, Park YS, Morita S, Iwasa S, Uetake H, Nishina T, Nozawa H, Matsumoto H. Study protocol of the Asian XELIRI ProjecT (AXEPT): a multinational, randomized, non-inferiority, phase III trial of second-line chemotherapy for metastatic colorectal cancer, comparing the efficacy and safety of XELIRI with or without bevacizumab versus FOLFIRI with or without bevacizumab. Chin J Cancer. 2016;35:102. [PMID: 28007025 DOI: 10.1186/s40880-016-0166-3] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
241 Pachón V, Trujillo-Santos J, Domènech P, Gallardo E, Font C, González-Porras JR, Pérez-Segura P, Maestre A, Mateo J, Muñoz A, Peris ML, Lecumberri R. Cancer-Associated Thrombosis: Beyond Clinical Practice Guidelines-A Multidisciplinary (SEMI-SEOM-SETH) Expert Consensus. TH Open 2018;2:e373-86. [PMID: 31249964 DOI: 10.1055/s-0038-1675577] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 2.3] [Reference Citation Analysis]
242 Bender RJ, Mac Gabhann F. Dysregulation of the vascular endothelial growth factor and semaphorin ligand-receptor families in prostate cancer metastasis. BMC Syst Biol 2015;9:55. [PMID: 26341082 DOI: 10.1186/s12918-015-0201-z] [Cited by in Crossref: 11] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
243 Li T, Wang B, Wang Z, Ragaz J, Zhang J, Sun S, Cao J, Lv F, Wang L, Zhang S, Ni C, Wu Z, Xie J, Hu X. Bevacizumab in Combination with Modified FOLFOX6 in Heavily Pretreated Patients with HER2/Neu-Negative Metastatic Breast Cancer: A Phase II Clinical Trial. PLoS One 2015;10:e0133133. [PMID: 26186012 DOI: 10.1371/journal.pone.0133133] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
244 Biondo S, Frago R, Kreisler E, Espin-Basany E; Spanish CR4 Group. Impact of resection versus no resection of the primary tumor on survival in patients with colorectal cancer and synchronous unresectable metastases: protocol for a randomized multicenter study (CR4). Int J Colorectal Dis 2017;32:1085-90. [PMID: 28497402 DOI: 10.1007/s00384-017-2827-3] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 2.4] [Reference Citation Analysis]
245 Shimura T, Kataoka H, Hirata Y, Mizushima T, Murakami K, Mabuchi M, Mizoshita T, Kubota E, Tanida S, Kamiya T, Joh T. Metastatic colorectal cancer with severe liver dysfunction successfully treated using FOLFOX therapy. J Gastrointest Cancer 2011;42:68-72. [PMID: 20563895 DOI: 10.1007/s12029-010-9176-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 0.3] [Reference Citation Analysis]
246 Tsai HT, Marshall JL, Weiss SR, Huang CY, Warren JL, Freedman AN, Fu AZ, Sansbury LB, Potosky AL. Bevacizumab use and risk of cardiovascular adverse events among elderly patients with colorectal cancer receiving chemotherapy: a population-based study. Ann Oncol 2013;24:1574-9. [PMID: 23429865 DOI: 10.1093/annonc/mdt019] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 3.0] [Reference Citation Analysis]
247 Loupakis F, Cremolini C, Yang D, Salvatore L, Zhang W, Wakatsuki T, Bohanes P, Schirripa M, Benhaim L, Lonardi S, Antoniotti C, Aprile G, Graziano F, Ruzzo A, Lucchesi S, Ronzoni M, De Vita F, Tonini G, Falcone A, Lenz HJ. Prospective validation of candidate SNPs of VEGF/VEGFR pathway in metastatic colorectal cancer patients treated with first-line FOLFIRI plus bevacizumab. PLoS One 2013;8:e66774. [PMID: 23861747 DOI: 10.1371/journal.pone.0066774] [Cited by in Crossref: 49] [Cited by in F6Publishing: 44] [Article Influence: 5.4] [Reference Citation Analysis]
248 Lim C, Doussot A, Osseis M, Esposito F, Salloum C, Calderaro J, Tournigand C, Azoulay D. Bevacizumab improves survival in patients with synchronous colorectal liver metastases provided the primary tumor is resected first. Clin Transl Oncol. 2018;20:1274-1279. [PMID: 29594943 DOI: 10.1007/s12094-018-1858-8] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
249 Price TJ, Lipton L, McGreivy J, McCoy S, Sun YN, Rosenthal MA. Safety and pharmacokinetics of motesanib in combination with gemcitabine for the treatment of patients with solid tumours. Br J Cancer 2008;99:1387-94. [PMID: 18971935 DOI: 10.1038/sj.bjc.6604723] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
250 Kim ST, Kim TW, Kim KP, Kim TY, Han SW, Lee JY, Lim SH, Lee MY, Kim H, Park YS. Regorafenib as Salvage Treatment in Korean Patients with Refractory Metastatic Colorectal Cancer. Cancer Res Treat 2015;47:790-5. [PMID: 25672574 DOI: 10.4143/crt.2014.126] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.9] [Reference Citation Analysis]
251 Ilic I, Jankovic S, Ilic M. Bevacizumab Combined with Chemotherapy Improves Survival for Patients with Metastatic Colorectal Cancer: Evidence from Meta Analysis. PLoS One 2016;11:e0161912. [PMID: 27579775 DOI: 10.1371/journal.pone.0161912] [Cited by in Crossref: 24] [Cited by in F6Publishing: 16] [Article Influence: 4.0] [Reference Citation Analysis]
252 Turner DC, Navid F, Daw NC, Mao S, Wu J, Santana VM, Neel M, Rao B, Willert JR, Loeb DM, Harstead KE, Throm SL, Freeman BB 3rd, Stewart CF. Population pharmacokinetics of bevacizumab in children with osteosarcoma: implications for dosing. Clin Cancer Res 2014;20:2783-92. [PMID: 24637635 DOI: 10.1158/1078-0432.CCR-13-2364] [Cited by in Crossref: 27] [Cited by in F6Publishing: 15] [Article Influence: 3.4] [Reference Citation Analysis]
253 Alvarez RH, Guarneri V, Icli F, Johnston S, Khayat D, Loibl S, Martin M, Zielinski C, Conte P, Hortobagyi GN. Bevacizumab treatment for advanced breast cancer. Oncologist 2011;16:1684-97. [PMID: 21976315 DOI: 10.1634/theoncologist.2011-0113] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
254 Castro MG, Candolfi M, Kroeger K, King GD, Curtin JF, Yagiz K, Mineharu Y, Assi H, Wibowo M, Ghulam Muhammad AK, Foulad D, Puntel M, Lowenstein PR. Gene therapy and targeted toxins for glioma. Curr Gene Ther 2011;11:155-80. [PMID: 21453286 DOI: 10.2174/156652311795684722] [Cited by in Crossref: 43] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
255 Liang HL, Hu AP, Li SL, Liu JY. Combining bevacizumab and panitumumab with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) as second-line treatment in patients with metastatic colorectal cancer. Med Oncol 2014;31:976. [PMID: 24793617 DOI: 10.1007/s12032-014-0976-6] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
256 Hubbard JM, Grothey A, Sargent DJ. Systemic therapy for elderly patients with gastrointestinal cancer. Clin Med Insights Oncol 2011;5:89-99. [PMID: 21603244 DOI: 10.4137/CMO.S6983] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
257 Jang HJ, Kim BJ, Kim JH, Kim HS. The addition of bevacizumab in the first-line treatment for metastatic colorectal cancer: an updated meta-analysis of randomized trials. Oncotarget. 2017;8:73009-73016. [PMID: 29069844 DOI: 10.18632/oncotarget.20314] [Cited by in Crossref: 17] [Cited by in F6Publishing: 14] [Article Influence: 3.4] [Reference Citation Analysis]
258 Hubbard JM, Kim G, Borad MJ, Johnson E, Qin R, Lensing J, Puttabasavaiah S, Wright J, Erlichman C, Grothey A. Phase I trial of FOLFIRI in combination with sorafenib and bevacizumab in patients with advanced gastrointestinal malignancies. Invest New Drugs 2016;34:96-103. [PMID: 26581401 DOI: 10.1007/s10637-015-0308-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
259 Tamiya A, Yamazaki K, Boku N, Machida N, Kojima T, Taku K, Yasui H, Fukutomi A, Hironaka S, Onozawa Y. Safety of bevacizumab treatment in combination with standard chemotherapy for metastatic colorectal cancer: a retrospective review of 65 Japanese patients. Int J Clin Oncol. 2009;14:513-517. [PMID: 19967487 DOI: 10.1007/s10147-009-0911-6] [Cited by in Crossref: 13] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
260 Modest DP, Hiddemann W, Heinemann V. [Chemotherapy of metastatic colorectal cancer]. Internist (Berl) 2014;55:37-42. [PMID: 24399471 DOI: 10.1007/s00108-013-3314-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
261 Emmanouilides C, Sfakiotaki G, Androulakis N, Kalbakis K, Christophylakis C, Kalykaki A, Vamvakas L, Kotsakis A, Agelaki S, Diamandidou E. Front-line bevacizumab in combination with oxaliplatin, leucovorin and 5-fluorouracil (FOLFOX) in patients with metastatic colorectal cancer: a multicenter phase II study. BMC Cancer. 2007;7:91. [PMID: 17537235 DOI: 10.1186/1471-2407-7-91] [Cited by in Crossref: 69] [Cited by in F6Publishing: 58] [Article Influence: 4.6] [Reference Citation Analysis]
262 Altomare I, Bendell JC, Bullock KE, Uronis HE, Morse MA, Hsu SD, Zafar SY, Blobe GC, Pang H, Honeycutt W. A phase II trial of bevacizumab plus everolimus for patients with refractory metastatic colorectal cancer. Oncologist. 2011;16:1131-1137. [PMID: 21795432 DOI: 10.1634/theoncologist.2011-0078] [Cited by in Crossref: 42] [Cited by in F6Publishing: 47] [Article Influence: 3.8] [Reference Citation Analysis]
263 Macy ME, Sawczyn KK, Garrington TP, Graham DK, Gore L. Pediatric developmental therapies: interesting new drugs now in early-stage clinical trials. Curr Oncol Rep 2008;10:477-90. [PMID: 18928662 DOI: 10.1007/s11912-008-0073-0] [Cited by in Crossref: 13] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
264 Ramjeesingh R, Meyer RM, Brouwers M, Chen BE, Booth CM. Alignment of practice guidelines with targeted-therapy drug funding policies in Ontario. Curr Oncol 2013;20:e21-33. [PMID: 23444033 DOI: 10.3747/co.20.1166] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
265 Leong S, Eckhardt SG, Chan E, Messersmith WA, Spratlin J, Camidge DR, Diab S, Khosravan R, Lin X, Chow Maneval E, Lockhart AC. A phase I study of sunitinib combined with modified FOLFOX6 in patients with advanced solid tumors. Cancer Chemother Pharmacol 2012;70:65-74. [PMID: 22623210 DOI: 10.1007/s00280-012-1880-4] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
266 Dufraing K, Keppens C, Tack V, Siebers AG, Kafatos G, Dube S, Demonty G, Lowe K, Kroeze LI, Ligtenberg M, Normanno N, Tembuyser L, Sara VB, van Krieken JH, C Dequeker EM. Evolution of RAS testing over time: factors influencing mutation rates in metastatic colorectal cancer patients. Colorectal Cancer 2020;9:CRC14. [DOI: 10.2217/crc-2019-0013] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
267 Oka S, Shinohara S, Kuwata T, Takenaka M, Chikaishi Y, Hirai A, Ichiki Y, Shimajiri S, Aoki T, Tanaka F. The major thoracic vascular invasion of lung cancer. Ann Med Surg (Lond) 2017;20:13-8. [PMID: 28702181 DOI: 10.1016/j.amsu.2017.06.025] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.6] [Reference Citation Analysis]
268 Botrel TEA, Clark LGO, Paladini L, Clark OAC. Efficacy and safety of bevacizumab plus chemotherapy compared to chemotherapy alone in previously untreated advanced or metastatic colorectal cancer: a systematic review and meta-analysis. BMC Cancer. 2016;16:677. [PMID: 27558497 DOI: 10.1186/s12885-016-2734-y] [Cited by in Crossref: 42] [Cited by in F6Publishing: 43] [Article Influence: 7.0] [Reference Citation Analysis]
269 Luo H, Zhang Y, Deng Y, Li L, Sheng Z, Yu Y, Lin Y, Chen X, Feng P. Nxhl Controls Angiogenesis by Targeting VE-PTP Through Interaction With Nucleolin. Front Cell Dev Biol 2021;9:728821. [PMID: 34733844 DOI: 10.3389/fcell.2021.728821] [Reference Citation Analysis]
270 Grande R, Gemma D, Sperduti I, Gelibter A, Giampaolo MA, Trombetta G, Nelli F, Gamucci T. Changing monoclonal antibody keeping unaltered the chemotherapy regimen in metastatic colorectal cancer patients: is efficacy maintained? Springerplus 2013;2:185. [PMID: 23667824 DOI: 10.1186/2193-1801-2-185] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
271 Toyama Y, Ushigome T, Watanabe K, Kitamura H, Onda S, Saito R, Yoshida S, Kawahara H, Yanagisawa S, Yanaga K. Possibility of sandwiched liver surgery with molecular targeting drugs, cetuximab and bevacizumab on colon cancer liver metastases: a case report. World J Surg Oncol 2012;10:129. [PMID: 22747970 DOI: 10.1186/1477-7819-10-129] [Reference Citation Analysis]
272 Broglio KR, Stivers DN, Berry DA. Predicting clinical trial results based on announcements of interim analyses. Trials 2014;15:73. [PMID: 24607270 DOI: 10.1186/1745-6215-15-73] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
273 Dai F, Shu L, Bian Y, Wang Z, Yang Z, Chu W, Gao S. Safety of bevacizumab in treating metastatic colorectal cancer: a systematic review and meta-analysis of all randomized clinical trials. Clin Drug Investig. 2013;33:779-788. [PMID: 23979925 DOI: 10.1007/s40261-013-0125-6] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 2.8] [Reference Citation Analysis]
274 Huang H, Zheng Y, Zhu J, Zhang J, Chen H, Chen X. An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients. PLoS One 2014;9:e89960. [PMID: 24599121 DOI: 10.1371/journal.pone.0089960] [Cited by in Crossref: 24] [Cited by in F6Publishing: 20] [Article Influence: 3.0] [Reference Citation Analysis]
275 Torres OJ, Marques MC, Santos FN, Farias IC, Coutinho AK, Oliveira CV, Kalil AN, Mello CA, Kruger JA, Fernandes GD, Quireze C Jr, Murad AM, Silva MJ, Zurstrassen CE, Freitas HC, Cruz MR, Weschenfelder R, Linhares MM, Castro LD, Vollmer C, Dixon E, Ribeiro HS, Coimbra FJ. BRAZILIAN CONSENSUS FOR MULTIMODAL TREATMENT OF COLORECTAL LIVER METASTASES. MODULE 3: CONTROVERSIES AND UNRESECTABLE METASTASES. Arq Bras Cir Dig 2016;29:173-9. [PMID: 27759781 DOI: 10.1590/0102-6720201600030011] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
276 Folprecht G. [Current medicinal treatment of metastasized colorectal carcinoma]. Chirurg. 2010;81:507-515. [PMID: 20574792 DOI: 10.1007/s00104-010-1892-8] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
277 Kawasaki A, Mimatsu K, Oida T, Kanou H, Kuboi Y, Fukino N, Kida K, Amano S. A case of long partial response to combination therapy of bevacizumab and capecitabine for liver metastases of rectal cancer. Case Rep Gastroenterol 2011;5:28-32. [PMID: 21326855 DOI: 10.1159/000323138] [Reference Citation Analysis]
278 Okines A, Puerto OD, Cunningham D, Chau I, Van Cutsem E, Saltz L, Cassidy J. Surgery with curative-intent in patients treated with first-line chemotherapy plus bevacizumab for metastatic colorectal cancer First BEAT and the randomised phase-III NO16966 trial. Br J Cancer 2009;101:1033-8. [PMID: 19789532 DOI: 10.1038/sj.bjc.6605259] [Cited by in Crossref: 128] [Cited by in F6Publishing: 106] [Article Influence: 9.8] [Reference Citation Analysis]
279 Zhao T, Wang X, Xu T, Xu X, Liu Z. Bevacizumab significantly increases the risks of hypertension and proteinuria in cancer patients: A systematic review and comprehensive meta-analysis. Oncotarget. 2017;8:51492-51506. [PMID: 28881662 DOI: 10.18632/oncotarget.18190] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 3.8] [Reference Citation Analysis]
280 Patel A, Sun W. Ziv-aflibercept in metastatic colorectal cancer. Biologics 2014;8:13-25. [PMID: 24368879 DOI: 10.2147/BTT.S39360] [Cited by in Crossref: 3] [Cited by in F6Publishing: 8] [Article Influence: 0.3] [Reference Citation Analysis]
281 Mumenthaler SM, Foo J, Choi NC, Heise N, Leder K, Agus DB, Pao W, Michor F, Mallick P. The Impact of Microenvironmental Heterogeneity on the Evolution of Drug Resistance in Cancer Cells. Cancer Inform 2015;14:19-31. [PMID: 26244007 DOI: 10.4137/CIN.S19338] [Cited by in Crossref: 16] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
282 Verdaguer H, Tabernero J, Macarulla T. Ramucirumab in metastatic colorectal cancer: evidence to date and place in therapy. Ther Adv Med Oncol. 2016;8:230-242. [PMID: 27239240 DOI: 10.1177/1758834016635888] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 5.0] [Reference Citation Analysis]
283 Battaglin F, Puccini A, Intini R, Schirripa M, Ferro A, Bergamo F, Lonardi S, Zagonel V, Lenz HJ, Loupakis F. The role of tumor angiogenesis as a therapeutic target in colorectal cancer. Expert Rev Anticancer Ther 2018;18:251-66. [PMID: 29338550 DOI: 10.1080/14737140.2018.1428092] [Cited by in Crossref: 20] [Cited by in F6Publishing: 23] [Article Influence: 5.0] [Reference Citation Analysis]
284 Chung CH, Pohlmann PR, Rothenberg ML, Burkey BB, Parker J, Palka K, Aulino J, Puzanov I, Murphy B. Insulin-like growth factor-1 receptor inhibitor, AMG-479, in cetuximab-refractory head and neck squamous cell carcinoma. Head Neck 2011;33:1804-8. [PMID: 20652976 DOI: 10.1002/hed.21478] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
285 Ciombor KK, Berlin J. Targeting metastatic colorectal cancer - present and emerging treatment options. Pharmgenomics Pers Med 2014;7:137-44. [PMID: 25045279 DOI: 10.2147/PGPM.S47582] [Cited by in Crossref: 2] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
286 Suzuki S, Tanigawara Y. Forced expression of S100A10 reduces sensitivity to oxaliplatin in colorectal cancer cells. Proteome Sci 2014;12:26. [PMID: 24851084 DOI: 10.1186/1477-5956-12-26] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.8] [Reference Citation Analysis]
287 Rahma OE, Hamilton JM, Wojtowicz M, Dakheel O, Bernstein S, Liewehr DJ, Steinberg SM, Khleif SN. The immunological and clinical effects of mutated ras peptide vaccine in combination with IL-2, GM-CSF, or both in patients with solid tumors. J Transl Med. 2014;12:55. [PMID: 24565030 DOI: 10.1186/1479-5876-12-55] [Cited by in Crossref: 42] [Cited by in F6Publishing: 38] [Article Influence: 5.3] [Reference Citation Analysis]
288 Patel SR, Karnad AB, Ketchum NS, Pollock BH, Sarantopoulos J, Weitman S, Mahalingam D. Should we move beyond VEGF inhibition in metastatic colorectal cancer? Lessons from early phase clinical trials. J Gastrointest Oncol 2014;5:99-103. [PMID: 24772337 DOI: 10.3978/j.issn.2078-6891.2014.002] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
289 Kaiser LD, Melemed AS, Preston AJ, Chaudri Ross HA, Niedzwiecki D, Fyfe GA, Gough JM, Bushnell WD, Stephens CL, Mace MK, Abrams JS, Schilsky RL. Optimizing collection of adverse event data in cancer clinical trials supporting supplemental indications. J Clin Oncol 2010;28:5046-53. [PMID: 20921453 DOI: 10.1200/JCO.2010.29.6608] [Cited by in Crossref: 13] [Cited by in F6Publishing: 5] [Article Influence: 1.1] [Reference Citation Analysis]
290 Roy S, Kumaravel S, Sharma A, Duran CL, Bayless KJ, Chakraborty S. Hypoxic tumor microenvironment: Implications for cancer therapy. Exp Biol Med (Maywood) 2020;245:1073-86. [PMID: 32594767 DOI: 10.1177/1535370220934038] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
291 Kummar S, Chen HX, Wright J, Holbeck S, Millin MD, Tomaszewski J, Zweibel J, Collins J, Doroshow JH. Utilizing targeted cancer therapeutic agents in combination: novel approaches and urgent requirements. Nat Rev Drug Discov 2010;9:843-56. [PMID: 21031001 DOI: 10.1038/nrd3216] [Cited by in Crossref: 168] [Cited by in F6Publishing: 152] [Article Influence: 14.0] [Reference Citation Analysis]
292 Han K, Peyret T, Quartino A, Gosselin NH, Gururangan S, Casanova M, Merks JH, Massimino M, Grill J, Daw NC, Navid F, Jin J, Allison DE. Bevacizumab dosing strategy in paediatric cancer patients based on population pharmacokinetic analysis with external validation. Br J Clin Pharmacol 2016;81:148-60. [PMID: 26345283 DOI: 10.1111/bcp.12778] [Cited by in Crossref: 26] [Cited by in F6Publishing: 18] [Article Influence: 3.7] [Reference Citation Analysis]
293 Pranchevicius MC, Vieira TR. Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering. Bioengineered 2013;4:305-12. [PMID: 23644447 DOI: 10.4161/bioe.24666] [Cited by in Crossref: 14] [Cited by in F6Publishing: 11] [Article Influence: 1.6] [Reference Citation Analysis]
294 Bayoglu İV, Yildiz I, Varol U, Cokmert S, Alacacıoğlu A, Kucukzeybek Y, Akyol M, Demir L, Dirican A, Tarhan O. Uracil/tegafur as a possible salvage therapy in chemo-refractory colorectal cancer patients: a single institutional retrospective study. Contemp Oncol (Pozn) 2015;19:385-90. [PMID: 26793023 DOI: 10.5114/wo.2015.53374] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
295 Bécouarn Y, Cany L, Pulido M, Beyssac R, Texereau P, Le Morvan V, Béchade D, Brunet R, Aitouferoukh S, Lalet C, Mathoulin-Pélissier S, Fonck M, Robert J. FOLFIRI® and bevacizumab in first-line treatment for colorectal cancer patients: safety, efficacy and genetic polymorphisms. BMC Res Notes 2014;7:260. [PMID: 24758527 DOI: 10.1186/1756-0500-7-260] [Cited by in Crossref: 10] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
296 Marín-Pozo JF, Duarte-Pérez JM, Sánchez-Rovira P. Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience. Medicine (Baltimore) 2016;95:e3623. [PMID: 27175672 DOI: 10.1097/MD.0000000000003623] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
297 Jakobs TF, Saleem S, Atassi B, Reda E, Lewandowski RJ, Yaghmai V, Miller F, Ryu RK, Ibrahim S, Sato KT. Fibrosis, portal hypertension, and hepatic volume changes induced by intra-arterial radiotherapy with 90yttrium microspheres. Dig Dis Sci. 2008;53:2556-2563. [PMID: 18231857 DOI: 10.1007/s10620-007-0148-z] [Cited by in Crossref: 89] [Cited by in F6Publishing: 82] [Article Influence: 6.4] [Reference Citation Analysis]
298 Ebos JM, Kerbel RS. Antiangiogenic therapy: impact on invasion, disease progression, and metastasis. Nat Rev Clin Oncol 2011;8:210-21. [PMID: 21364524 DOI: 10.1038/nrclinonc.2011.21] [Cited by in Crossref: 474] [Cited by in F6Publishing: 447] [Article Influence: 43.1] [Reference Citation Analysis]
299 Mestier L, Manceau G, Neuzillet C, Bachet JB, Spano JP, Kianmanesh R, Vaillant JC, Bouché O, Hannoun L, Karoui M. Primary tumor resection in colorectal cancer with unresectable synchronous metastases: A review. World J Gastrointest Oncol 2014; 6(6): 156-169 [PMID: 24936226 DOI: 10.4251/wjgo.v6.i6.156] [Cited by in CrossRef: 24] [Cited by in F6Publishing: 21] [Article Influence: 3.0] [Reference Citation Analysis]
300 Pantaleo MA, Astolfi A, Nannini M, Paterini P, Piazzi G, Ercolani G, Brandi G, Martinelli G, Pession A, Pinna AD, Biasco G. Gene expression profiling of liver metastases from colorectal cancer as potential basis for treatment choice. Br J Cancer 2008;99:1729-34. [PMID: 18827815 DOI: 10.1038/sj.bjc.6604681] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 2.1] [Reference Citation Analysis]
301 Xiang Z, Deng X, He W, Yang Q, Ni L, Dehghan Shasaltaneh M, Maghsoudloo M, Yang G, Wu J, Imani S, Wen Q. Treatment of malignant pleural effusion in non-small cell lung cancer with VEGF-directed therapy. Ann Med 2022;54:1357-71. [PMID: 35543207 DOI: 10.1080/07853890.2022.2071977] [Reference Citation Analysis]
302 Lee SJ, Lee SY, Lee WS, Yoo JS, Sun JM, Lee J, Park SH, Park JO, Ahn MJ, Lim HY, Kang WK, Park YS. Phase I trial and pharmacokinetic study of tanibirumab, a fully human monoclonal antibody to vascular endothelial growth factor receptor 2, in patients with refractory solid tumors. Invest New Drugs 2017;35:782-90. [PMID: 28391576 DOI: 10.1007/s10637-017-0463-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.2] [Reference Citation Analysis]
303 Akeel N, Toonsi WA. Gastrointestinal Perforation With an Intraluminal Stent and Bevacizumab use in Advanced Metastatic Colorectal Cancer. Cureus 2021;13:e12831. [PMID: 33628692 DOI: 10.7759/cureus.12831] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
304 Han K, Peyret T, Marchand M, Quartino A, Gosselin NH, Girish S, Allison DE, Jin J. Population pharmacokinetics of bevacizumab in cancer patients with external validation. Cancer Chemother Pharmacol 2016;78:341-51. [PMID: 27329360 DOI: 10.1007/s00280-016-3079-6] [Cited by in Crossref: 28] [Cited by in F6Publishing: 26] [Article Influence: 4.7] [Reference Citation Analysis]
305 Temraz S, Mukherji D, Shamseddine A. Sequencing of treatment in metastatic colorectal cancer: Where to fit the target? World J Gastroenterol 2014; 20(8): 1993-2004 [PMID: 24616571 DOI: 10.3748/wjg.v20.i8.1993] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 15] [Article Influence: 2.1] [Reference Citation Analysis]
306 Jackson MW, Rusthoven CG, Fisher CM, Schefter TE. Clinical potential of bevacizumab in the treatment of metastatic and locally advanced cervical cancer: current evidence. Onco Targets Ther 2014;7:751-9. [PMID: 24876784 DOI: 10.2147/OTT.S49429] [Cited by in Crossref: 4] [Cited by in F6Publishing: 8] [Article Influence: 0.5] [Reference Citation Analysis]
307 Izzedine H. Anti-VEGF Cancer Therapy in Nephrology Practice. Int J Nephrol 2014;2014:143426. [PMID: 25210627 DOI: 10.1155/2014/143426] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.4] [Reference Citation Analysis]
308 Kazazi-Hyseni F, Beijnen JH, Schellens JH. Bevacizumab. Oncologist 2010;15:819-25. [PMID: 20688807 DOI: 10.1634/theoncologist.2009-0317] [Cited by in Crossref: 75] [Cited by in F6Publishing: 63] [Article Influence: 6.3] [Reference Citation Analysis]
309 Clarke JM, Hurwitz HI. Ziv-aflibercept: binding to more than VEGF-A--does more matter? Nat Rev Clin Oncol 2013;10:10-1. [PMID: 23149898 DOI: 10.1038/nrclinonc.2012.197] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
310 Gyanchandani R, Ortega Alves MV, Myers JN, Kim S. A proangiogenic signature is revealed in FGF-mediated bevacizumab-resistant head and neck squamous cell carcinoma. Mol Cancer Res 2013;11:1585-96. [PMID: 24092775 DOI: 10.1158/1541-7786.MCR-13-0358] [Cited by in Crossref: 37] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
311 Kumar J, Bhargava M, Aggarwal S. Bevacizumab-induced reversible thrombocytopenia in a patient with adenocarcinoma of colon: rare adverse effect of bevacizumab. Case Rep Oncol Med 2012;2012:695430. [PMID: 23094167 DOI: 10.1155/2012/695430] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
312 Schwarz RE, Berlin JD, Lenz HJ, Nordlinger B, Rubbia-Brandt L, Choti MA. Systemic cytotoxic and biological therapies of colorectal liver metastases: expert consensus statement. HPB (Oxford) 2013;15:106-15. [PMID: 23297721 DOI: 10.1111/j.1477-2574.2012.00558.x] [Cited by in Crossref: 33] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
313 Hachimaru A, Maeda R, Suda T, Takagi Y. Repeat pulmonary resection for recurrent lung metastases from colorectal cancer: an analysis of prognostic factors. Interact Cardiovasc Thorac Surg 2016;22:826-30. [PMID: 26920721 DOI: 10.1093/icvts/ivv382] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
314 Amit L, Ben-Aharon I, Vidal L, Leibovici L, Stemmer S. The impact of Bevacizumab (Avastin) on survival in metastatic solid tumors--a meta-analysis and systematic review. PLoS One 2013;8:e51780. [PMID: 23349675 DOI: 10.1371/journal.pone.0051780] [Cited by in Crossref: 50] [Cited by in F6Publishing: 45] [Article Influence: 5.6] [Reference Citation Analysis]
315 Dietvorst MH, Eskens FA. Current and Novel Treatment Options for Metastatic Colorectal Cancer: Emphasis on Aflibercept. Biol Ther 2013;3:25-33. [PMID: 24392302 DOI: 10.1007/s13554-013-0009-6] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
316 Stathopoulos J, Armakolas A, Stathopoulos GP, Gomatos IP. Plasma VEGF levels in breast cancer patients with and without metastases. Oncol Lett 2010;1:739-41. [PMID: 22966372 DOI: 10.3892/ol_00000129] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
317 Kang BW, Kim TW, Lee JL, Ryu MH, Chang HM, Yu CS, Kim JC, Kim JH, Kang YK, Lee JS. Bevacizumab plus FOLFIRI or FOLFOX as third-line or later treatment in patients with metastatic colorectal cancer after failure of 5-fluorouracil, irinotecan, and oxaliplatin: a retrospective analysis. Med Oncol. 2009;26:32-37. [PMID: 18498064 DOI: 10.1007/s12032-008-9077-8] [Cited by in Crossref: 30] [Cited by in F6Publishing: 32] [Article Influence: 2.1] [Reference Citation Analysis]
318 Lièvre A, Samalin E, Mitry E, Assenat E, Boyer-Gestin C, Lepère C, Bachet JB, Portales F, Vaillant JN, Ychou M, Rougier P. Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study. BMC Cancer 2009;9:347. [PMID: 19785749 DOI: 10.1186/1471-2407-9-347] [Cited by in Crossref: 32] [Cited by in F6Publishing: 36] [Article Influence: 2.5] [Reference Citation Analysis]
319 Wong WWL, Zargar M, Berry SR, Ko YJ, Riesco-Martínez M, Chan KKW. Cost-effectiveness analysis of selective first-line use of biologics for unresectable RAS wild-type left-sided metastatic colorectal cancer. Curr Oncol 2019;26:e597-609. [PMID: 31708653 DOI: 10.3747/co.26.4843] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
320 Snoeren N, Voest EE, Bergman AM, Dalesio O, Verheul HM, Tollenaar RA, van der Sijp JR, Schouten SB, Rinkes IH, van Hillegersberg R. A randomized two arm phase III study in patients post radical resection of liver metastases of colorectal cancer to investigate bevacizumab in combination with capecitabine plus oxaliplatin (CAPOX) vs CAPOX alone as adjuvant treatment. BMC Cancer. 2010;10:545. [PMID: 20937118 DOI: 10.1186/1471-2407-10-545] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.5] [Reference Citation Analysis]
321 Argyriou AA, Kalofonos HP. Recent advances relating to the clinical application of naked monoclonal antibodies in solid tumors. Mol Med 2009;15:183-91. [PMID: 19305491 DOI: 10.2119/molmed.2009.00007] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
322 Kim Y, Kim TW, Han SW, Ahn JB, Kim ST, Lee J, Park JO, Park YS, Lim HY, Kang WK. A Single Arm, Phase II Study of Simvastatin Plus XELOX and Bevacizumab as First-Line Chemotherapy in Metastatic Colorectal Cancer Patients. Cancer Res Treat 2019;51:1128-34. [PMID: 30477287 DOI: 10.4143/crt.2018.379] [Cited by in Crossref: 4] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
323 Sullivan LA, Brekken RA. The VEGF family in cancer and antibody-based strategies for their inhibition. MAbs 2010;2:165-75. [PMID: 20190566 DOI: 10.4161/mabs.2.2.11360] [Cited by in Crossref: 110] [Cited by in F6Publishing: 95] [Article Influence: 10.0] [Reference Citation Analysis]
324 Ocana A, Ethier JL, Díez-González L, Corrales-Sánchez V, Srikanthan A, Gascón-Escribano MJ, Templeton AJ, Vera-Badillo F, Seruga B, Niraula S, Pandiella A, Amir E. Influence of companion diagnostics on efficacy and safety of targeted anti-cancer drugs: systematic review and meta-analyses. Oncotarget 2015;6:39538-49. [PMID: 26446908 DOI: 10.18632/oncotarget.5946] [Cited by in Crossref: 21] [Cited by in F6Publishing: 17] [Article Influence: 3.5] [Reference Citation Analysis]
325 Lisby AN, Flickinger JC Jr, Bashir B, Weindorfer M, Shelukar S, Crutcher M, Snook AE, Waldman SA. GUCY2C as a biomarker to target precision therapies for patients with colorectal cancer. Expert Rev Precis Med Drug Dev 2021;6:117-29. [PMID: 34027103 DOI: 10.1080/23808993.2021.1876518] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
326 Fakih M. SIR-Spheres ® radioembolization in the management of metastatic colorectal cancer: a medical oncology perspective. Colorectal Cancer 2014;3:331-43. [DOI: 10.2217/crc.14.29] [Reference Citation Analysis]
327 Grothey A, Allegra C. Antiangiogenesis therapy in the treatment of metastatic colorectal cancer. Ther Adv Med Oncol. 2012;4:301-319. [PMID: 23118806 DOI: 10.1177/1758834012454464] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 1.9] [Reference Citation Analysis]
328 Alcindor T, Beauger N. Oxaliplatin: a review in the era of molecularly targeted therapy. Curr Oncol 2011;18:18-25. [PMID: 21331278 DOI: 10.3747/co.v18i1.708] [Cited by in Crossref: 188] [Cited by in F6Publishing: 183] [Article Influence: 17.1] [Reference Citation Analysis]
329 Kiesewetter B, Raderer M, Steger GG, Bartsch R, Pirker R, Zöchbauer-Müller S, Prager G, Krainer M, Preusser M, Schmidinger M, Zielinski CC. The European Society for Medical Oncology Magnitude of Clinical Benefit Scale in daily practice: a single institution, real-life experience at the Medical University of Vienna. ESMO Open 2016;1:e000066. [PMID: 27843624 DOI: 10.1136/esmoopen-2016-000066] [Cited by in Crossref: 15] [Cited by in F6Publishing: 11] [Article Influence: 2.5] [Reference Citation Analysis]
330 Sarkisyan G, Gay LJ, Nguyen N, Felding BH, Rosen H. Host endothelial S1PR1 regulation of vascular permeability modulates tumor growth. Am J Physiol Cell Physiol 2014;307:C14-24. [PMID: 24740542 DOI: 10.1152/ajpcell.00043.2014] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
331 Murukesh N, Dive C, Jayson GC. Biomarkers of angiogenesis and their role in the development of VEGF inhibitors. Br J Cancer 2010;102:8-18. [PMID: 20010945 DOI: 10.1038/sj.bjc.6605483] [Cited by in Crossref: 162] [Cited by in F6Publishing: 148] [Article Influence: 12.5] [Reference Citation Analysis]
332 Fu AZ, Zhao Z, Gao S, Barber B, Liu GG. Comorbid Conditions in Patients With Metastatic Colorectal Cancer. World J Oncol 2011;2:225-31. [PMID: 29147252 DOI: 10.4021/wjon370e] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
333 Karaca-Mandic P, McCullough JS, Siddiqui MA, Van Houten H, Shah ND. Impact of new drugs and biologics on colorectal cancer treatment and costs. J Oncol Pract 2011;7:e30s-7s. [PMID: 21886509 DOI: 10.1200/JOP.2011.000302] [Cited by in Crossref: 11] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
334 Kyutoku M, Nakagami H, Koriyama H, Tomioka H, Nakagami F, Shimamura M, Kurinami H, Zhengda P, Jo DH, Kim JH, Takakura N, Morishita R. Development of novel DNA vaccine for VEGF in murine cancer model. Sci Rep 2013;3:3380. [PMID: 24287585 DOI: 10.1038/srep03380] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
335 Yamaue H, Tsunoda T, Tani M, Miyazawa M, Yamao K, Mizuno N, Okusaka T, Ueno H, Boku N, Fukutomi A, Ishii H, Ohkawa S, Furukawa M, Maguchi H, Ikeda M, Togashi Y, Nishio K, Ohashi Y. Randomized phase II/III clinical trial of elpamotide for patients with advanced pancreatic cancer: PEGASUS-PC Study. Cancer Sci 2015;106:883-90. [PMID: 25867139 DOI: 10.1111/cas.12674] [Cited by in Crossref: 46] [Cited by in F6Publishing: 43] [Article Influence: 6.6] [Reference Citation Analysis]
336 Keating GM. Bevacizumab: a review of its use in advanced cancer. Drugs 2014;74:1891-925. [PMID: 25315029 DOI: 10.1007/s40265-014-0302-9] [Cited by in Crossref: 106] [Cited by in F6Publishing: 92] [Article Influence: 15.1] [Reference Citation Analysis]
337 Giakoustidis A, Neofytou K, Khan A, Mudan S. Addition of bevacizumab to preoperative chemotherapy for colorectal liver metastases does not increase perioperative morbidity and mortality. Hepat Oncol 2014;1:363-75. [PMID: 30190972 DOI: 10.2217/hep.14.17] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
338 Iwamoto S, Takahashi T, Tamagawa H, Nakamura M, Munemoto Y, Kato T, Hata T, Denda T, Morita Y, Inukai M, Kunieda K, Nagata N, Kurachi K, Ina K, Ooshiro M, Shimoyama T, Baba H, Oba K, Sakamoto J, Mishima H. FOLFIRI plus bevacizumab as second-line therapy in patients with metastatic colorectal cancer after first-line bevacizumab plus oxaliplatin-based therapy: the randomized phase III EAGLE study. Ann Oncol 2015;26:1427-33. [PMID: 25908603 DOI: 10.1093/annonc/mdv197] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 3.7] [Reference Citation Analysis]
339 Noda M, Inaji M, Karakama J, Arai Y, Kuroha M, Tamura K, Tanaka Y, Maehara T. Ischemic Stroke with Multiple Cerebral Artery Stenosis in a Patient with an Anaplastic Astrocytoma during Bevacizumab Treatment: A Case Report. NMC Case Report Journal 2022;9:13-7. [DOI: 10.2176/jns-nmc.2021-0297] [Reference Citation Analysis]
340 Hamming LC, Slotman BJ, Verheul HMW, Thijssen VL. The clinical application of angiostatic therapy in combination with radiotherapy: past, present, future. Angiogenesis 2017;20:217-32. [PMID: 28364160 DOI: 10.1007/s10456-017-9546-9] [Cited by in Crossref: 20] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
341 García-Carbonero R, Gómez España MA, Casado Sáenz E, Alonso Orduña V, Cervantes Ruipérez A, Gallego Plazas J, García Alfonso P, Juez Martel I, González Flores E, Lomas Garrido M, Isla Casado D; SEOM (Spanish Society for Medical Oncology). SEOM clinical guidelines for the treatment of advanced colorectal cancer. Clin Transl Oncol 2010;12:729-34. [PMID: 20974564 DOI: 10.1007/s12094-010-0587-4] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.6] [Reference Citation Analysis]
342 Girardi F, Franceschi E, Brandes AA. Cardiovascular safety of VEGF-targeting therapies: current evidence and handling strategies. Oncologist 2010;15:683-94. [PMID: 20547589 DOI: 10.1634/theoncologist.2009-0235] [Cited by in Crossref: 27] [Cited by in F6Publishing: 27] [Article Influence: 2.3] [Reference Citation Analysis]
343 McCormack PL, Keam SJ. Bevacizumab: a review of its use in metastatic colorectal cancer. Drugs. 2008;68:487-506. [PMID: 18318567 DOI: 10.2165/00003495-200868040-00009] [Cited by in Crossref: 54] [Cited by in F6Publishing: 53] [Article Influence: 3.9] [Reference Citation Analysis]
344 Paluri R, Madan A, Li P, Jones B, Saleh M, Jerome M, Miley D, Keef J, Robert F. Phase 1b trial of nintedanib in combination with bevacizumab in patients with advanced solid tumors. Cancer Chemother Pharmacol 2019;83:551-9. [PMID: 30603797 DOI: 10.1007/s00280-018-3761-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
345 Andrea C, Fausto P, Francesca BK, Mary C, Mara G, Veronica L, Sandro B. Which strategy after first-line therapy in advanced colorectal cancer? World J Gastroenterol 2014; 20(27): 8921-8927 [PMID: 25083064 DOI: 10.3748/wjg.v20.i27.8921] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
346 Zacharias AJ, Jayakrishnan TT, Rajeev R, Rilling WS, Thomas JP, George B, Johnston FM, Gamblin TC, Turaga KK. Comparative Effectiveness of Hepatic Artery Based Therapies for Unresectable Colorectal Liver Metastases: A Meta-Analysis. PLoS One. 2015;10:e0139940. [PMID: 26448327 DOI: 10.1371/journal.pone.0139940] [Cited by in Crossref: 26] [Cited by in F6Publishing: 20] [Article Influence: 3.7] [Reference Citation Analysis]
347 Yoshida M, Shimura T, Sato M, Ebi M, Nakazawa T, Takeyama H, Joh T. A novel predictive strategy by immunohistochemical analysis of four EGFR ligands in metastatic colorectal cancer treated with anti-EGFR antibodies. J Cancer Res Clin Oncol 2013;139:367-78. [PMID: 23099994 DOI: 10.1007/s00432-012-1340-x] [Cited by in Crossref: 24] [Cited by in F6Publishing: 22] [Article Influence: 2.4] [Reference Citation Analysis]
348 Huang GC, Chen LJ, Liu HC, Chen YJ. Development of vitreous haemorrhage during treatment with bevacizumab for metastatic rectal cancer. Clin Drug Investig 2008;28:523-6. [PMID: 18598098 DOI: 10.2165/00044011-200828080-00007] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
349 Lai E, Liscia N, Donisi C, Mariani S, Tolu S, Pretta A, Persano M, Pinna G, Balconi F, Pireddu A, Impera V, Dubois M, Migliari M, Spanu D, Saba G, Camera S, Musio F, Ziranu P, Puzzoni M, Demurtas L, Pusceddu V, Dettori M, Massa E, Atzori F, Dessì M, Astara G, Madeddu C, Scartozzi M. Molecular-Biology-Driven Treatment for Metastatic Colorectal Cancer. Cancers (Basel) 2020;12:E1214. [PMID: 32413973 DOI: 10.3390/cancers12051214] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 5.5] [Reference Citation Analysis]
350 Palmer AC, Sorger PK. Combination Cancer Therapy Can Confer Benefit via Patient-to-Patient Variability without Drug Additivity or Synergy. Cell. 2017;171:1678-1691.e13. [PMID: 29245013 DOI: 10.1016/j.cell.2017.11.009] [Cited by in Crossref: 233] [Cited by in F6Publishing: 200] [Article Influence: 46.6] [Reference Citation Analysis]
351 Passardi A, Scarpi E, Gelsomino F, Palladino MA, Casadei Gardini A, Turci D, Chiuri VE, Mucciarini C, Tassinari D, Ragazzini A, Frassineti GL, Valgiusti M, Ulivi P, Amadori D. Impact of second-line cetuximab-containing therapy in patients with KRAS wild-type metastatic colorectal cancer: results from the ITACa randomized clinical trial. Sci Rep 2017;7:10426. [PMID: 28874797 DOI: 10.1038/s41598-017-11048-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
352 Zoratto F, Rossi L, Giordani E, Strudel M, Papa A, Tomao S. From conventional chemotherapy to targeted therapy: use of monoclonal antibodies (moAbs) in gastrointestinal (GI) tumors. Tumour Biol 2014;35:8471-82. [PMID: 25062724 DOI: 10.1007/s13277-014-2367-1] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
353 Goel S, Duda DG, Xu L, Munn LL, Boucher Y, Fukumura D, Jain RK. Normalization of the vasculature for treatment of cancer and other diseases. Physiol Rev. 2011;91:1071-1121. [PMID: 21742796 DOI: 10.1152/physrev.00038.2010] [Cited by in Crossref: 887] [Cited by in F6Publishing: 851] [Article Influence: 80.6] [Reference Citation Analysis]
354 Ciardiello F, Ciardiello D, Martini G, Napolitano S, Tabernero J, Cervantes A. Clinical management of metastatic colorectal cancer in the era of precision medicine. CA Cancer J Clin 2022. [PMID: 35472088 DOI: 10.3322/caac.21728] [Reference Citation Analysis]
355 Chibaudel B, Tournigand C, Bonnetain F, Richa H, Benetkiewicz M, André T, de Gramont A. Therapeutic strategy in unresectable metastatic colorectal cancer: an updated review. Ther Adv Med Oncol 2015;7:153-69. [PMID: 26673925 DOI: 10.1177/1758834015572343] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.4] [Reference Citation Analysis]
356 Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346-354. [PMID: 24048067 DOI: 10.1038/nature12626] [Cited by in Crossref: 1335] [Cited by in F6Publishing: 1314] [Article Influence: 148.3] [Reference Citation Analysis]
357 Ravoori MK, Nishimura M, Singh SP, Lu C, Han L, Hobbs BP, Pradeep S, Choi HJ, Bankson JA, Sood AK, Kundra V. Tumor T1 Relaxation Time for Assessing Response to Bevacizumab Anti-Angiogenic Therapy in a Mouse Ovarian Cancer Model. PLoS One 2015;10:e0131095. [PMID: 26098849 DOI: 10.1371/journal.pone.0131095] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
358 Grothey A. Medical treatment of advanced colorectal cancer in 2009. Ther Adv Med Oncol 2009;1:55-68. [PMID: 21789113 DOI: 10.1177/1758834009343302] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
359 Mina LA, Sledge GW Jr. Rethinking the metastatic cascade as a therapeutic target. Nat Rev Clin Oncol 2011;8:325-32. [PMID: 21502993 DOI: 10.1038/nrclinonc.2011.59] [Cited by in Crossref: 78] [Cited by in F6Publishing: 70] [Article Influence: 7.1] [Reference Citation Analysis]
360 Rudek MA, Dasari A, Laheru D, He P, Jin R, Walker R, Taylor GE, Jimeno A, Donehower RC, Hidalgo M, Messersmith WA, Purcell WT. Phase 1 Study of ABT-751 in Combination With CAPIRI (Capecitabine and Irinotecan) and Bevacizumab in Patients With Advanced Colorectal Cancer. J Clin Pharmacol 2016;56:966-73. [PMID: 26632033 DOI: 10.1002/jcph.681] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
361 Hanrahan EO, Lin HY, Kim ES, Yan S, Du DZ, McKee KS, Tran HT, Lee JJ, Ryan AJ, Langmuir P. Distinct patterns of cytokine and angiogenic factor modulation and markers of benefit for vandetanib and/or chemotherapy in patients with non-small-cell lung cancer. J Clin Oncol. 2010;28:193-201. [PMID: 19949019 DOI: 10.1200/jco.2009.22.4279] [Cited by in Crossref: 107] [Cited by in F6Publishing: 69] [Article Influence: 8.2] [Reference Citation Analysis]
362 Marmorino F, Salvatore L, Barbara C, Allegrini G, Antonuzzo L, Masi G, Loupakis F, Borelli B, Chiara S, Banzi MC, Miraglio E, Amoroso D, Dargenio F, Bonetti A, Martignetti A, Paris M, Tomcikova D, Boni L, Falcone A, Cremolini C. Serum LDH predicts benefit from bevacizumab beyond progression in metastatic colorectal cancer. Br J Cancer 2017;116:318-23. [PMID: 28081548 DOI: 10.1038/bjc.2016.413] [Cited by in Crossref: 12] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
363 Falchook GS, Naing A, Wheler JJ, Tsimberidou AM, Zinner R, Hong DS, Fu S, Piha-Paul SA, Janku F, Hess KR, Bastida C, Kurzrock R. Dual EGFR inhibition in combination with anti-VEGF treatment in colorectal cancer. Oncoscience 2014;1:540-9. [PMID: 25594061 DOI: 10.18632/oncoscience.73] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.6] [Reference Citation Analysis]
364 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF. [Therapy response of liver tumors after selective internal radiation therapy]. Radiologe. 2008;48:839-849. [PMID: 18766324 DOI: 10.1007/s00117-008-1730-x] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
365 Rice C, Huang LE. From antiangiogenesis to hypoxia: current research and future directions. Cancer Manag Res 2010;3:9-16. [PMID: 21407995 DOI: 10.2147/CMR.S14812] [Cited by in Crossref: 3] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
366 Cisterna BA, Kamaly N, Choi WI, Tavakkoli A, Farokhzad OC, Vilos C. Targeted nanoparticles for colorectal cancer. Nanomedicine (Lond) 2016;11:2443-56. [PMID: 27529192 DOI: 10.2217/nnm-2016-0194] [Cited by in Crossref: 66] [Cited by in F6Publishing: 54] [Article Influence: 11.0] [Reference Citation Analysis]
367 Trinh XB, Tjalma WA, Vermeulen PB, Van den Eynden G, Van der Auwera I, Van Laere SJ, Helleman J, Berns EM, Dirix LY, van Dam PA. The VEGF pathway and the AKT/mTOR/p70S6K1 signalling pathway in human epithelial ovarian cancer. Br J Cancer 2009;100:971-8. [PMID: 19240722 DOI: 10.1038/sj.bjc.6604921] [Cited by in Crossref: 77] [Cited by in F6Publishing: 68] [Article Influence: 5.9] [Reference Citation Analysis]
368 Grivas P, Monk BJ, Petrylak D, Reck M, Foley G, Guenther S, Hennessy D, Makris C, Moehler M. Immune Checkpoint Inhibitors as Switch or Continuation Maintenance Therapy in Solid Tumors: Rationale and Current State. Target Oncol 2019;14:505-25. [PMID: 31535338 DOI: 10.1007/s11523-019-00665-1] [Cited by in Crossref: 12] [Cited by in F6Publishing: 8] [Article Influence: 6.0] [Reference Citation Analysis]
369 Watanabe T, Itabashi M, Shimada Y, Tanaka S, Ito Y, Ajioka Y, Hamaguchi T, Hyodo I, Igarashi M, Ishida H, Ishihara S, Ishiguro M, Kanemitsu Y, Kokudo N, Muro K, Ochiai A, Oguchi M, Ohkura Y, Saito Y, Sakai Y, Ueno H, Yoshino T, Boku N, Fujimori T, Koinuma N, Morita T, Nishimura G, Sakata Y, Takahashi K, Tsuruta O, Yamaguchi T, Yoshida M, Yamaguchi N, Kotake K, Sugihara K; Japanese Society for Cancer of the Colon and Rectum. Japanese Society for Cancer of the Colon and Rectum (JSCCR) Guidelines 2014 for treatment of colorectal cancer. Int J Clin Oncol. 2015;20:207-239. [PMID: 25782566 DOI: 10.1007/s10147-015-0801-z] [Cited by in Crossref: 379] [Cited by in F6Publishing: 363] [Article Influence: 54.1] [Reference Citation Analysis]
370 Spratlin JL, Cohen RB, Eadens M, Gore L, Camidge DR, Diab S, Leong S, O'Bryant C, Chow LQ, Serkova NJ, Meropol NJ, Lewis NL, Chiorean EG, Fox F, Youssoufian H, Rowinsky EK, Eckhardt SG. Phase I pharmacologic and biologic study of ramucirumab (IMC-1121B), a fully human immunoglobulin G1 monoclonal antibody targeting the vascular endothelial growth factor receptor-2. J Clin Oncol. 2010;28:780-787. [PMID: 20048182 DOI: 10.1200/jco.2009.23.7537] [Cited by in Crossref: 364] [Cited by in F6Publishing: 188] [Article Influence: 30.3] [Reference Citation Analysis]
371 Lee J, Shin SJ, Chung IJ, Kim TW, Chun HG, Shin DB, Kim YH, Song HS, Han SW, Kim JG, Kim SY, Choi YJ, Chung HC. A phase II open-label randomized multicenter trial of TSU-68 in combination with S-1 and oxaliplatin versus S-1 in combination with oxaliplatin in patients with metastatic colorectal cancer. Invest New Drugs 2014;32:561-8. [PMID: 24573743 DOI: 10.1007/s10637-014-0075-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
372 Martin LK, Cucci A, Wei L, Rose J, Blazer M, Schmidt C, Khabiri H, Bloomston M, Bekaii-Saab T. Yttrium-90 radioembolization as salvage therapy for colorectal cancer with liver metastases. Clin Colorectal Cancer 2012;11:195-9. [PMID: 22277350 DOI: 10.1016/j.clcc.2011.12.002] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.8] [Reference Citation Analysis]
373 Wang F, Dai G, Deng Y, Tang Y, Wang W, Niu Z, Bi F, Zhu L, Guo Z, Yan J, Hu B, Tao M, Yang S, Zhang S, Wen L, Xu R. Efficacy and safety of chemotherapy combined with bevacizumab in Chinese patients with metastatic colorectal cancer: A prospective, multicenter, observational, non-interventional phase IV trial. Chin J Cancer Res 2021;33:490-9. [PMID: 34584374 DOI: 10.21147/j.issn.1000-9604.2021.04.06] [Reference Citation Analysis]
374 Fuloria J. Safety profiles of current antiangiogenic therapies for metastatic colorectal cancer. Onco Targets Ther 2012;5:133-42. [PMID: 22930641 DOI: 10.2147/OTT.S31412] [Cited by in Crossref: 9] [Cited by in F6Publishing: 1] [Article Influence: 0.9] [Reference Citation Analysis]
375 Zhao Z, Li J, Ye R, Wu X, Gao L, Niu B. A phase II clinical study of combining FOLFIRI and bevacizumab plus erlotinib in 2nd-line chemotherapy for patients with metastatic colorectal cancer. Medicine (Baltimore) 2017;96:e7182. [PMID: 28746175 DOI: 10.1097/MD.0000000000007182] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
376 Zhang Y, Wang J. MicroRNAs are important regulators of drug resistance in colorectal cancer. Biol Chem 2017;398:929-38. [PMID: 28095367 DOI: 10.1515/hsz-2016-0308] [Cited by in Crossref: 37] [Cited by in F6Publishing: 33] [Article Influence: 7.4] [Reference Citation Analysis]
377 Ciciola P, Cascetta P, Bianco C, Formisano L, Bianco R. Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents. J Clin Med 2020;9:E675. [PMID: 32138216 DOI: 10.3390/jcm9030675] [Cited by in Crossref: 25] [Cited by in F6Publishing: 25] [Article Influence: 12.5] [Reference Citation Analysis]
378 Vasudev NS, Reynolds AR. Anti-angiogenic therapy for cancer: current progress, unresolved questions and future directions. Angiogenesis. 2014;17:471-94. [PMID: 24482243 DOI: 10.1007/s10456-014-9420-y] [Cited by in Crossref: 415] [Cited by in F6Publishing: 389] [Article Influence: 51.9] [Reference Citation Analysis]
379 Hong YS, Cho HJ, Kim SY, Jung KH, Park JW, Choi HS, Oh JH, Kim BC, Sohn DK, Kim DY, Chang HJ. Carbonic anhydrase 9 is a predictive marker of survival benefit from lower dose of bevacizumab in patients with previously treated metastatic colorectal cancer. BMC Cancer 2009;9:246. [PMID: 19619339 DOI: 10.1186/1471-2407-9-246] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 1.8] [Reference Citation Analysis]
380 Aggarwal A, Fojo T, Chamberlain C, Davis C, Sullivan R. Do patient access schemes for high-cost cancer drugs deliver value to society?-lessons from the NHS Cancer Drugs Fund. Ann Oncol 2017;28:1738-50. [PMID: 28453615 DOI: 10.1093/annonc/mdx110] [Cited by in Crossref: 63] [Cited by in F6Publishing: 45] [Article Influence: 15.8] [Reference Citation Analysis]
381 Zhu Z, Yan L. Next generation of antibody therapy for cancer. Chin J Cancer 2011;30:293-302. [PMID: 21527062 DOI: 10.5732/cjc.011.10123] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 0.7] [Reference Citation Analysis]
382 Moriwaki T, Bando H, Takashima A, Yamazaki K, Esaki T, Yamashita K, Fukunaga M, Miyake Y, Katsumata K, Kato S, Satoh T, Ozeki M, Baba E, Yoshida S, Boku N, Hyodo I. Bevacizumab in combination with irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) in patients with metastatic colorectal cancer who were previously treated with oxaliplatin-containing regimens: a multicenter observational cohort study (TCTG 2nd-BV study). Med Oncol 2012;29:2842-8. [PMID: 22209842 DOI: 10.1007/s12032-011-0151-2] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 0.8] [Reference Citation Analysis]
383 Schiffer M, Zukovic L, Hall S, Merl MY. Assessment of extended urine protein monitoring frequency in patients receiving bevacizumab. J Oncol Pharm Pract 2021;27:902-6. [PMID: 32715917 DOI: 10.1177/1078155220943959] [Reference Citation Analysis]
384 Keefe D, Bowen J, Gibson R, Tan T, Okera M, Stringer A. Noncardiac vascular toxicities of vascular endothelial growth factor inhibitors in advanced cancer: a review. Oncologist 2011;16:432-44. [PMID: 21441297 DOI: 10.1634/theoncologist.2010-0271] [Cited by in Crossref: 62] [Cited by in F6Publishing: 43] [Article Influence: 5.6] [Reference Citation Analysis]
385 Zhong L, Wang R, Wang Y, Peng S, Ma Y, Ding S, Yang H, Chen S, Luo X, Wang W. Dual inhibition of VEGF and PARP suppresses KRAS-mutant colorectal cancer. Neoplasia 2020;22:365-75. [PMID: 32629177 DOI: 10.1016/j.neo.2020.06.001] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
386 Eng C. The evolving role of monoclonal antibodies in colorectal cancer: early presumptions and impact on clinical trial development. Oncologist 2010;15:73-84. [PMID: 20067946 DOI: 10.1634/theoncologist.2009-0167] [Cited by in Crossref: 36] [Cited by in F6Publishing: 23] [Article Influence: 3.0] [Reference Citation Analysis]
387 Bradshaw-Pierce EL, Pitts TM, Kulikowski G, Selby H, Merz AL, Gustafson DL, Serkova NJ, Eckhardt SG, Weekes CD. Utilization of quantitative in vivo pharmacology approaches to assess combination effects of everolimus and irinotecan in mouse xenograft models of colorectal cancer. PLoS One 2013;8:e58089. [PMID: 23520486 DOI: 10.1371/journal.pone.0058089] [Cited by in Crossref: 19] [Cited by in F6Publishing: 22] [Article Influence: 2.1] [Reference Citation Analysis]
388 Satake H, Ando K, Oki E, Shimokawa M, Makiyama A, Saeki H, Tsuji A, Mori M. Protocol of the EFFORT study: a prospective study of FOLFIRI plus aflibercept as second-line treatment after progression on FOLFOXIRI plus bevacizumab or during maintenance treatment in patients with unresectable/metastatic colorectal cancer. BMC Cancer 2020;20:1116. [PMID: 33203393 DOI: 10.1186/s12885-020-07576-9] [Reference Citation Analysis]
389 Cui HG, Cao XF. Surgery-predominant combined treatment for colorectal cancer. Shijie Huaren Xiaohua Zazhi 2008; 16(16): 1774-1780 [DOI: 10.11569/wcjd.v16.i16.1774] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
390 Cao S, Durrani FA, Toth K, Rustum YM, Seshadri M. Bevacizumab enhances the therapeutic efficacy of Irinotecan against human head and neck squamous cell carcinoma xenografts. Oral Oncol 2011;47:459-66. [PMID: 21530364 DOI: 10.1016/j.oraloncology.2011.04.001] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.5] [Reference Citation Analysis]
391 Riechelmann R, Grothey A. Antiangiogenic therapy for refractory colorectal cancer: current options and future strategies. Ther Adv Med Oncol 2017;9:106-26. [PMID: 28203302 DOI: 10.1177/1758834016676703] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
392 El Bali M, Bakkach J, Bennani Mechita M. Colorectal Cancer: From Genetic Landscape to Targeted Therapy. J Oncol 2021;2021:9918116. [PMID: 34326875 DOI: 10.1155/2021/9918116] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
393 Yang T, Xiao H, Liu X, Wang Z, Zhang Q, Wei N, Guo X. Vascular Normalization: A New Window Opened for Cancer Therapies. Front Oncol 2021;11:719836. [PMID: 34476218 DOI: 10.3389/fonc.2021.719836] [Reference Citation Analysis]
394 Chau CH, Figg WD. Angiogenesis inhibitors increase tumor stem cells. Cancer Biol Ther 2012;13:586-7. [PMID: 22441817 DOI: 10.4161/cbt.19852] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
395 Fenicia V, Abdolrahimzadeh S, Mannino G, Verrilli S, Balestrieri M, Recupero SM. Intravitreal bevacizumab in the successful management of choroidal metastases secondary to lung and breast cancer unresponsive to systemic therapy: a case series. Eye (Lond) 2014;28:888-91. [PMID: 24763241 DOI: 10.1038/eye.2014.96] [Cited by in Crossref: 19] [Cited by in F6Publishing: 18] [Article Influence: 2.4] [Reference Citation Analysis]
396 Willett CG, Duda DG, Ancukiewicz M, Shah M, Czito BG, Bentley R, Poleski M, Fujita H, Lauwers GY, Carroll M. A safety and survival analysis of neoadjuvant bevacizumab with standard chemoradiation in a phase I/II study compared with standard chemoradiation in locally advanced rectal cancer. Oncologist. 2010;15:845-851. [PMID: 20667969 DOI: 10.1634/theoncologist.2010-0030] [Cited by in Crossref: 40] [Cited by in F6Publishing: 40] [Article Influence: 3.3] [Reference Citation Analysis]
397 Rossi L, Vakiarou F, Zoratto F, Bianchi L, Papa A, Basso E, Verrico M, Lo Russo G, Evangelista S, Rinaldi G, Perrone-Congedi F, Spinelli GP, Stati V, Caruso D, Prete A, Tomao S. Factors influencing choice of chemotherapy in metastatic colorectal cancer (mCRC). Cancer Manag Res. 2013;5:377-385. [PMID: 24399885 DOI: 10.2147/cmar.s47986] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 0.9] [Reference Citation Analysis]
398 Jin Z, Hubbard JM. Optimizing biologic sequencing in metastatic colorectal cancer: first line and beyond. Curr Oncol 2019;26:S33-42. [PMID: 31819708 DOI: 10.3747/co.26.5589] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.7] [Reference Citation Analysis]
399 Xiangying M, Rugang Z, Lijuan D, Yaowei Z, Bing S, Junliang W, Dan L, Shikai W. Low-dose bevacizumab as an effective pre-treatment for peri-tumoral brain edema prior to CyberKnife radiosurgery: A case report. Cancer Biol Ther 2018;19:461-4. [PMID: 29420112 DOI: 10.1080/15384047.2018.1433499] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
400 Ciombor KK, Goldberg RM. Current evidence and controversies in the incorporation of biologics for metastatic colorectal cancer. Hepat Oncol 2014;1:331-45. [PMID: 30190967 DOI: 10.2217/hep.14.13] [Reference Citation Analysis]
401 Vera R, Gomez Dorronsoro M, Lopez-Ben S, Viudez A, Queralt B, Hernandez I, Ortiz-Duran MR, Zazpe C, Soriano J, Amat I, Herrera Cabezón J, Diaz E, Codina-Barreras A, Hernandez-Yagüe X, Quera A, Figueras J. Retrospective analysis of pathological response in colorectal cancer liver metastases following treatment with bevacizumab. Clin Transl Oncol 2014;16:739-45. [PMID: 24338508 DOI: 10.1007/s12094-013-1142-x] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.4] [Reference Citation Analysis]
402 He K, Cui B, Li G, Wang H, Jin K, Teng L. The effect of anti-VEGF drugs (bevacizumab and aflibercept) on the survival of patients with metastatic colorectal cancer (mCRC). Onco Targets Ther 2012;5:59-65. [PMID: 22570554 DOI: 10.2147/OTT.S29719] [Cited by in Crossref: 2] [Cited by in F6Publishing: 9] [Article Influence: 0.2] [Reference Citation Analysis]
403 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: A pilot study. World J Gastroenterol 2007; 13(46): 6231-6235 [PMID: 18069765 DOI: 10.3748/wjg.v13.i46.6231] [Cited by in CrossRef: 5] [Cited by in F6Publishing: 12] [Article Influence: 0.3] [Reference Citation Analysis]
404 Ikoma N, Raghav K, Chang G. An Update on Randomized Clinical Trials in Metastatic Colorectal Carcinoma. Surg Oncol Clin N Am. 2017;26:667-687. [PMID: 28923224 DOI: 10.1016/j.soc.2017.05.007] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 2.4] [Reference Citation Analysis]
405 Seo M, Choi JS, Rho CR, Joo CK, Lee SK. MicroRNA miR-466 inhibits Lymphangiogenesis by targeting prospero-related homeobox 1 in the alkali burn corneal injury model. J Biomed Sci 2015;22:3. [PMID: 25573115 DOI: 10.1186/s12929-014-0104-0] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
406 Petracci E, Scarpi E, Passardi A, Biggeri A, Milandri C, Vecchia S, Gelsomino F, Tassinari D, Tamberi S, Bernardini I, Accettura C, Frassineti GL, Amadori D, Nanni O. Effectiveness of bevacizumab in first- and second-line treatment for metastatic colorectal cancer: ITACa randomized trial. Ther Adv Med Oncol 2020;12:1758835920937427. [PMID: 32754229 DOI: 10.1177/1758835920937427] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
407 Königsberg R, Maierhofer J, Steininger T, Kienzer G, Dittrich C. Long-term remission of a Her2/neu positive primary breast cancer under double monoclonal antibody therapy with trastuzumab and bevacizumab. Radiol Oncol 2014;48:184-8. [PMID: 24991208 DOI: 10.2478/raon-2013-0083] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
408 Jiang C, Huang YH, Lu JB, Yang YZ, Rao HL, Zhang B, He WZ, Xia LP. Perivascular cell coverage of intratumoral vasculature is a predictor for bevacizumab efficacy in metastatic colorectal cancer. Cancer Manag Res 2018;10:3589-97. [PMID: 30271207 DOI: 10.2147/CMAR.S172261] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
409 Gray SW, Armstrong K, Demichele A, Schwartz JS, Hornik RC. Colon cancer patient information seeking and the adoption of targeted therapy for on-label and off-label indications. Cancer 2009;115:1424-34. [PMID: 19235785 DOI: 10.1002/cncr.24186] [Cited by in Crossref: 19] [Cited by in F6Publishing: 14] [Article Influence: 1.5] [Reference Citation Analysis]
410 Katsuta E, Qi Q, Peng X, Hochwald SN, Yan L, Takabe K. Pancreatic adenocarcinomas with mature blood vessels have better overall survival. Sci Rep 2019;9:1310. [PMID: 30718678 DOI: 10.1038/s41598-018-37909-5] [Cited by in Crossref: 36] [Cited by in F6Publishing: 38] [Article Influence: 12.0] [Reference Citation Analysis]
411 Arias Ron D, Labandeira CM, Cameselle García S, García Mata J, Salgado Fernández M. Sustained Stable Disease with Capecitabine plus Bevacizumab in Metastatic Appendiceal Adenocarcinoma: A Case Report. Case Rep Oncol 2020;13:69-75. [PMID: 32110222 DOI: 10.1159/000505237] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
412 Nogué M, Salud A, Vicente P, Arriví A, Roca JM, Losa F, Ponce J, Safont MJ, Guasch I, Moreno I. Addition of bevacizumab to XELOX induction therapy plus concomitant capecitabine-based chemoradiotherapy in magnetic resonance imaging-defined poor-prognosis locally advanced rectal cancer: the AVACROSS study. Oncologist. 2011;16:614-620. [PMID: 21467148 DOI: 10.1634/theoncologist.2010-0285] [Cited by in Crossref: 100] [Cited by in F6Publishing: 86] [Article Influence: 9.1] [Reference Citation Analysis]
413 Zhu X, Tian X, Yu C, Hong J, Fang J, Chen H. Increased risk of hemorrhage in metastatic colorectal cancer patients treated with bevacizumab: An updated meta-analysis of 12 randomized controlled trials. Medicine (Baltimore) 2016;95:e4232. [PMID: 27559943 DOI: 10.1097/MD.0000000000004232] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 1.8] [Reference Citation Analysis]
414 Lereclus E, Tout M, Girault A, Baroukh N, Caulet M, Borg C, Bouché O, Ternant D, Paintaud G, Lecomte T, Raoul W. A possible association of baseline serum IL-17A concentrations with progression-free survival of metastatic colorectal cancer patients treated with a bevacizumab-based regimen. BMC Cancer 2017;17:220. [PMID: 28347290 DOI: 10.1186/s12885-017-3210-z] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
415 Shah MA, Jhawer M, Ilson DH, Lefkowitz RA, Robinson E, Capanu M, Kelsen DP. Phase II study of modified docetaxel, cisplatin, and fluorouracil with bevacizumab in patients with metastatic gastroesophageal adenocarcinoma. J Clin Oncol. 2011;29:868-874. [PMID: 21189380 DOI: 10.1200/jco.2010.32.0770] [Cited by in Crossref: 129] [Cited by in F6Publishing: 72] [Article Influence: 10.8] [Reference Citation Analysis]
416 Brandes AA, Bartolotti M, Tosoni A, Poggi R, Franceschi E. Practical management of bevacizumab-related toxicities in glioblastoma. Oncologist 2015;20:166-75. [PMID: 25568148 DOI: 10.1634/theoncologist.2014-0330] [Cited by in Crossref: 34] [Cited by in F6Publishing: 32] [Article Influence: 4.9] [Reference Citation Analysis]
417 Cybulska-Stopa B, Ługowska I, Wiśniowski R, Domagała-Haduch M, Rajczykowski M, Piejko K, Bar-Letkiewicz I, Suwiński R, Regulski K, Mackiewicz J. Overweight is associated with better prognosis in metastatic colorectal cancer patients treated with bevacizumab plus FOLFOX chemotherapy. Contemp Oncol (Pozn) 2020;24:34-41. [PMID: 32514236 DOI: 10.5114/wo.2020.94728] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
418 Osterlund P, Peltonen R, Alanko T, Bono P, Isoniemi H. A single-institution experience with bevacizumab in the treatment of metastatic colorectal cancer and in conjunction with liver resection. Onco Targets Ther. 2014;7:1177-1184. [PMID: 25061319 DOI: 10.2147/ott.s63739] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
419 Li W, Quan YY, Li Y, Lu L, Cui M. Monitoring of tumor vascular normalization: the key points from basic research to clinical application. Cancer Manag Res 2018;10:4163-72. [PMID: 30323672 DOI: 10.2147/CMAR.S174712] [Cited by in Crossref: 25] [Cited by in F6Publishing: 17] [Article Influence: 6.3] [Reference Citation Analysis]
420 Moench R, Grimmig T, Kannen V, Tripathi S, Faber M, Moll EM, Chandraker A, Lissner R, Germer CT, Waaga-Gasser AM, Gasser M. Exclusive inhibition of PI3K/Akt/mTOR signaling is not sufficient to prevent PDGF-mediated effects on glycolysis and proliferation in colorectal cancer. Oncotarget 2016;7:68749-67. [PMID: 27626684 DOI: 10.18632/oncotarget.11899] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 5.3] [Reference Citation Analysis]
421 Garcia-Alfonso P, Chaves M, Muñoz A, Salud A, García-Gonzalez M, Grávalos C, Massuti B, González-Flores E, Queralt B, López-Ladrón A, Losa F, Gómez MJ, Oltra A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors (TTD). Capecitabine and irinotecan with bevacizumab 2-weekly for metastatic colorectal cancer: the phase II AVAXIRI study. BMC Cancer 2015;15:327. [PMID: 25925749 DOI: 10.1186/s12885-015-1293-y] [Cited by in Crossref: 7] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
422 Korpanty G, Smyth E, Sullivan LA, Brekken RA, Carney DN. Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway. Exp Biol Med (Maywood) 2010;235:3-9. [PMID: 20404013 DOI: 10.1258/ebm.2009.009191] [Cited by in Crossref: 31] [Cited by in F6Publishing: 28] [Article Influence: 2.6] [Reference Citation Analysis]
423 Peeters M, Strickland AH, Lichinitser M, Suresh AV, Manikhas G, Shapiro J, Rogowski W, Huang X, Wu B, Warner D, Jain R, Tebbutt NC. A randomised, double-blind, placebo-controlled phase 2 study of trebananib (AMG 386) in combination with FOLFIRI in patients with previously treated metastatic colorectal carcinoma. Br J Cancer 2013;108:503-11. [PMID: 23361051 DOI: 10.1038/bjc.2012.594] [Cited by in Crossref: 53] [Cited by in F6Publishing: 48] [Article Influence: 5.9] [Reference Citation Analysis]
424 Choi Y, Kwon CH, Lee SJ, Park J, Shin JY, Park DY. Integrative analysis of oncogenic fusion genes and their functional impact in colorectal cancer. Br J Cancer 2018;119:230-40. [PMID: 29955133 DOI: 10.1038/s41416-018-0153-3] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 4.0] [Reference Citation Analysis]
425 Velasco R, Alemany M, Villagrán M, Argyriou AA. Predictive Biomarkers of Oxaliplatin-Induced Peripheral Neurotoxicity. J Pers Med 2021;11:669. [PMID: 34357136 DOI: 10.3390/jpm11070669] [Reference Citation Analysis]
426 Castro-Carpeño Jd, Moyano MS, Sáenz EC, Belda-Iniesta C, Batlle JF, Barón MG. Bevacizumab: a safe and effective treatment in a patient with advanced colorectal cancer and repeated removal of metastases. Anticancer Drugs 2009;20 Spec No 1:S7-S10. [PMID: 19352110 DOI: 10.1097/01.cad.0000349778.09614.54] [Reference Citation Analysis]
427 Fakih M. Targeting angiogenesis beyond first-line bevacizumab progression: ziv-aflibercept or more bevacizumab? Colorectal Cancer 2013;2:9-12. [DOI: 10.2217/crc.12.69] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
428 Wang H, Ma B, Gao P, Song Y, Xu Q, Hu Y, Zhang C, Wang Z. Efficacy and safety of anti-epidermal growth factor receptor therapy compared with anti-vascular endothelial growth factor therapy for metastatic colorectal cancer in first-line and second-line therapies: a meta-analysis. Onco Targets Ther 2016;9:5405-16. [PMID: 27621654 DOI: 10.2147/OTT.S111240] [Cited by in Crossref: 1] [Article Influence: 0.2] [Reference Citation Analysis]
429 Chen J, Wang J, Ni T, He H, Zheng Q. Meta-analysis on the risk of fatal adverse events by bevacizumab, cetuximab, and panitumumab in 31 randomized trials including 25,000 patients with colorectal carcinoma. Medicine (Baltimore) 2020;99:e19908. [PMID: 32569154 DOI: 10.1097/MD.0000000000019908] [Reference Citation Analysis]
430 Lv C, Wu S, Zheng D, Wu Y, Yao D, Yu X. The Efficacy of Additional Bevacizumab to Cytotoxic Chemotherapy Regimens for the Treatment of Colorectal Cancer: An Updated Meta-Analysis for Randomized Trials. Cancer Biother Radiopharm. 2013;28:501-509. [PMID: 23768086 DOI: 10.1089/cbr.2012.1458] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 1.0] [Reference Citation Analysis]
431 Bendell JC, Bekaii-Saab TS, Cohn AL, Hurwitz HI, Kozloff M, Tezcan H, Roach N, Mun Y, Fish S, Flick ED, Dalal D, Grothey A. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study. Oncologist 2012;17:1486-95. [PMID: 23015662 DOI: 10.1634/theoncologist.2012-0190] [Cited by in Crossref: 65] [Cited by in F6Publishing: 63] [Article Influence: 6.5] [Reference Citation Analysis]
432 Kuderer NM, Poniewierski MS, Culakova E, Lyman GH, Khorana AA, Pabinger I, Agnelli G, Liebman HA, Vicaut E, Meyer G, Shepherd FA. Predictors of Venous Thromboembolism and Early Mortality in Lung Cancer: Results from a Global Prospective Study (CANTARISK). Oncologist 2018;23:247-55. [PMID: 28951500 DOI: 10.1634/theoncologist.2017-0205] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
433 Goel S, Wong AH, Jain RK. Vascular normalization as a therapeutic strategy for malignant and nonmalignant disease. Cold Spring Harb Perspect Med 2012;2:a006486. [PMID: 22393532 DOI: 10.1101/cshperspect.a006486] [Cited by in Crossref: 200] [Cited by in F6Publishing: 187] [Article Influence: 22.2] [Reference Citation Analysis]
434 Mohelnikova-Duchonova B, Melichar B, Soucek P. FOLFOX/FOLFIRI pharmacogenetics: The call for a personalized approach in colorectal cancer therapy. World J Gastroenterol 2014; 20(30): 10316-10330 [PMID: 25132748 DOI: 10.3748/wjg.v20.i30.10316] [Cited by in CrossRef: 40] [Cited by in F6Publishing: 41] [Article Influence: 5.0] [Reference Citation Analysis]
435 Hori N, Iwasa S, Hashimoto H, Yanai T, Kato K, Hamaguchi T, Yamada Y, Murakoshi K, Yokote N, Yamamoto H, Shimada Y. Reasons for avoidance of bevacizumab with first-line FOLFOX for advanced colorectal cancer. Int J Clin Oncol 2013;18:435-8. [PMID: 22415742 DOI: 10.1007/s10147-012-0398-4] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
436 Bruera G, Cannita K, Giordano AV, Vicentini R, Ficorella C, Ricevuto E. Differential prognosis of metastatic colorectal cancer patients post-progression to first-line triplet chemotherapy plus bevacizumab, FIr-B/FOx, according to second-line treatment and KRAS genotype. Int J Oncol 2014;44:17-26. [PMID: 24247407 DOI: 10.3892/ijo.2013.2179] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
437 Kuipers EJ, Grady WM, Lieberman D, Seufferlein T, Sung JJ, Boelens PG, van de Velde CJ, Watanabe T. Colorectal cancer. Nat Rev Dis Primers. 2015;1:15065. [PMID: 27189416 DOI: 10.1038/nrdp.2015.65] [Cited by in Crossref: 485] [Cited by in F6Publishing: 484] [Article Influence: 69.3] [Reference Citation Analysis]
438 Kwon HC, Oh SY, Lee S, Kim SH, Kim HJ. Bevacizumab plus infusional 5-fluorouracil, leucovorin and irinotecan for advanced colorectal cancer that progressed after oxaliplatin and irinotecan chemotherapy: a pilot study. World J Gastroenterol. 2007;13:6231-6235. [PMID: 18069765 DOI: 10.3748/wjg.13.6231] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
439 Di Bartolomeo M, Pietrantonio F, Martinetti A, Buzzoni R, Gevorgyan A, Bajetta E. Role of the antiangiogenic agent bevacizumab in the treatment of elderly patients with metastatic colorectal cancer. Drugs Aging 2011;28:83-91. [PMID: 21155618 DOI: 10.2165/11584710-000000000-00000] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
440 Fleming TR, Rothmann MD, Lu HL. Issues in using progression-free survival when evaluating oncology products. J Clin Oncol 2009;27:2874-80. [PMID: 19414672 DOI: 10.1200/JCO.2008.20.4107] [Cited by in Crossref: 117] [Cited by in F6Publishing: 36] [Article Influence: 9.0] [Reference Citation Analysis]
441 Wang TF, Lockhart AC. Aflibercept in the treatment of metastatic colorectal cancer. Clin Med Insights Oncol 2012;6:19-30. [PMID: 22253552 DOI: 10.4137/CMO.S7432] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 1.4] [Reference Citation Analysis]
442 Paiva TF Jr, de Jesus VH, Marques RA, da Costa AA, de Macedo MP, Peresi PM, Damascena A, Rossi BM, Begnami MD, de Lima VC. Angiogenesis-related protein expression in bevacizumab-treated metastatic colorectal cancer: NOTCH1 detrimental to overall survival. BMC Cancer 2015;15:643. [PMID: 26394830 DOI: 10.1186/s12885-015-1648-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
443 Strickler JH, Hurwitz HI. Bevacizumab-based therapies in the first-line treatment of metastatic colorectal cancer. Oncologist. 2012;17:513-524. [PMID: 22477726 DOI: 10.1634/theoncologist.2012-0003] [Cited by in Crossref: 48] [Cited by in F6Publishing: 39] [Article Influence: 4.8] [Reference Citation Analysis]
444 Cotte E, Villeneuve L, Passot G, Boschetti G, Bin-Dorel S, Francois Y, Glehen O; French Research Group of Rectal Cancer Surgery (GRECCAR). GRECCAR 8: impact on survival of the primary tumor resection in rectal cancer with unresectable synchronous metastasis: a randomized multicentre study. BMC Cancer 2015;15:47. [PMID: 25849254 DOI: 10.1186/s12885-015-1060-0] [Cited by in Crossref: 18] [Cited by in F6Publishing: 18] [Article Influence: 2.6] [Reference Citation Analysis]
445 Lu L, Zhuang T, Shao E, Liu Y, He H, Shu Z, Huang Y, Yao Y, Lin S, Lin S, Chen X, Chen X. Association of antibiotic exposure with the mortality in metastatic colorectal cancer patients treated with bevacizumab-containing chemotherapy: A hospital-based retrospective cohort study. PLoS One 2019;14:e0221964. [PMID: 31504043 DOI: 10.1371/journal.pone.0221964] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.7] [Reference Citation Analysis]
446 Salvatore L, Aprile G, Arnoldi E, Aschele C, Carnaghi C, Cosimelli M, Maiello E, Normanno N, Sciallero S, Valvo F, Beretta GD. Management of metastatic colorectal cancer patients: guidelines of the Italian Medical Oncology Association (AIOM). ESMO Open 2017;2:e000147. [PMID: 28761730 DOI: 10.1136/esmoopen-2016-000147] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 4.0] [Reference Citation Analysis]
447 Cheng K, Zhou YW, Chen Y, Li ZP, Qiu M, Liu JY. Biweekly Raltitrexed Combined With Irinotecan as Second-Line Therapy for Patients With Metastatic Colorectal Cancer: A Phase II Trial. Cancer Control 2022;29:10732748221080332. [PMID: 35343258 DOI: 10.1177/10732748221080332] [Reference Citation Analysis]
448 Snider KL, Maitland ML. Cardiovascular toxicities: clues to optimal administration of vascular endothelial growth factor signaling pathway inhibitors. Target Oncol 2009;4:67-76. [PMID: 19373440 DOI: 10.1007/s11523-009-0106-0] [Cited by in Crossref: 21] [Cited by in F6Publishing: 18] [Article Influence: 1.6] [Reference Citation Analysis]
449 Ciardiello D, Martini G, Famiglietti V, Napolitano S, De Falco V, Troiani T, Latiano TP, Ros J, Elez Fernandez E, Vitiello PP, Maiello E, Ciardiello F, Martinelli E. Biomarker-Guided Anti-Egfr Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers (Basel) 2021;13:1941. [PMID: 33920531 DOI: 10.3390/cancers13081941] [Reference Citation Analysis]
450 Velenik V, Ocvirk J, Music M, Bracko M, Anderluh F, Oblak I, Edhemovic I, Brecelj E, Kropivnik M, Omejc M. Neoadjuvant capecitabine, radiotherapy, and bevacizumab (CRAB) in locally advanced rectal cancer: results of an open-label phase II study. Radiat Oncol. 2011;6:105. [PMID: 21880132 DOI: 10.1186/1748-717x-6-105] [Cited by in Crossref: 61] [Cited by in F6Publishing: 26] [Article Influence: 5.5] [Reference Citation Analysis]
451 Cai J, Ma H, Huang F, Zhu D, Bi J, Ke Y, Zhang T. Correlation of bevacizumab-induced hypertension and outcomes of metastatic colorectal cancer patients treated with bevacizumab: a systematic review and meta-analysis. World J Surg Oncol 2013;11:306. [PMID: 24283603 DOI: 10.1186/1477-7819-11-306] [Cited by in Crossref: 42] [Cited by in F6Publishing: 42] [Article Influence: 4.7] [Reference Citation Analysis]
452 Ferrara N, Adamis AP. Ten years of anti-vascular endothelial growth factor therapy. Nat Rev Drug Discov. 2016;15:385-403. [PMID: 26775688 DOI: 10.1038/nrd.2015.17] [Cited by in Crossref: 406] [Cited by in F6Publishing: 394] [Article Influence: 67.7] [Reference Citation Analysis]
453 Hwang C, Heath EI. Angiogenesis inhibitors in the treatment of prostate cancer. J Hematol Oncol 2010;3:26. [PMID: 20678204 DOI: 10.1186/1756-8722-3-26] [Cited by in Crossref: 36] [Cited by in F6Publishing: 32] [Article Influence: 3.0] [Reference Citation Analysis]
454 Mulcahy MF, Mahvash A, Pracht M, Montazeri AH, Bandula S, Martin RCG 2nd, Herrmann K, Brown E, Zuckerman D, Wilson G, Kim TY, Weaver A, Ross P, Harris WP, Graham J, Mills J, Yubero Esteban A, Johnson MS, Sofocleous CT, Padia SA, Lewandowski RJ, Garin E, Sinclair P, Salem R; EPOCH Investigators. Radioembolization With Chemotherapy for Colorectal Liver Metastases: A Randomized, Open-Label, International, Multicenter, Phase III Trial. J Clin Oncol 2021;39:3897-907. [PMID: 34541864 DOI: 10.1200/JCO.21.01839] [Cited by in Crossref: 2] [Article Influence: 2.0] [Reference Citation Analysis]
455 Chua TC, Bester L, Saxena A, Morris DL. Radioembolization and systemic chemotherapy improves response and survival for unresectable colorectal liver metastases. J Cancer Res Clin Oncol 2011;137:865-73. [PMID: 20859640 DOI: 10.1007/s00432-010-0948-y] [Cited by in Crossref: 31] [Cited by in F6Publishing: 29] [Article Influence: 2.6] [Reference Citation Analysis]
456 Gherman A, Căinap C, Constantin AM, Cetean S, Căinap SS. Molecular targeted treatment of metastatic colorectal cancer: the cardiovascular adverse effects of Bevacizumab and Cetuximab. Clujul Med 2017;90:377-84. [PMID: 29151784 DOI: 10.15386/cjmed-745] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
457 Chamberlain MC. Bevacizumab for the treatment of recurrent glioblastoma. Clin Med Insights Oncol 2011;5:117-29. [PMID: 21603247 DOI: 10.4137/CMO.S7232] [Cited by in Crossref: 83] [Cited by in F6Publishing: 52] [Article Influence: 7.5] [Reference Citation Analysis]
458 Aprile G, Lutrino SE, Ferrari L, Casagrande M, Bonotto M, Ongaro E, Puglisi F. Evidence-based appraisal of the upfront treatment for unresectable metastatic colorectal cancer patients. World J Gastroenterol 2013; 19(46): 8474-8488 [PMID: 24379565 DOI: 10.3748/wjg.v19.i46.8474] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
459 Poultsides GA, Paty PB. Reassessing the need for primary tumor surgery in unresectable metastatic colorectal cancer: overview and perspective. Ther Adv Med Oncol. 2011;3:35-42. [PMID: 21789154 DOI: 10.1177/1758834010386283] [Cited by in Crossref: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.5] [Reference Citation Analysis]
460 Ulivi P, Marisi G, Passardi A. Relationship between hypoxia and response to antiangiogenic therapy in metastatic colorectal cancer. Oncotarget 2016;7:46678-91. [PMID: 27081084 DOI: 10.18632/oncotarget.8712] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 5.5] [Reference Citation Analysis]
461 Lin Z, Yang Y, Huang Y, Liang J, Lu F, Lao X. Vascular endothelial growth factor receptor tyrosine kinase inhibitors versus bevacizumab in metastatic colorectal cancer: A systematic review and meta-analysis. Mol Clin Oncol 2015;3:959-67. [PMID: 26171215 DOI: 10.3892/mco.2015.572] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.9] [Reference Citation Analysis]
462 Goel S, Negassa A, Acuna-Villaorduna A. Comparative Effectiveness of Biologic Agents Among Black and White Medicare Patients in the US With Metastatic Colorectal Cancer. JAMA Netw Open 2021;4:e2136378. [PMID: 34910154 DOI: 10.1001/jamanetworkopen.2021.36378] [Reference Citation Analysis]
463 Ait-Belkacem R, Berenguer C, Villard C, Ouafik L, Figarella-Branger D, Beck A, Chinot O, Lafitte D. Monitoring therapeutic monoclonal antibodies in brain tumor. MAbs 2014;6:1385-93. [PMID: 25484065 DOI: 10.4161/mabs.34405] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.3] [Reference Citation Analysis]
464 Suenaga M, Mizunuma N, Shouji D, Shinozaki E, Matsusaka S, Chin K, Oya M, Yamaguchi T, Muto T, Hatake K. Modified irinotecan plus bolus 5-fluorouracil/L-leucovorin for metastatic colorectal cancer at a single institution in Japan. J Gastroenterol 2008;43:842-8. [PMID: 19012037 DOI: 10.1007/s00535-008-2242-1] [Reference Citation Analysis]
465 Nandikolla AG, Rajdev L. Targeting angiogenesis in gastrointestinal tumors: current challenges. Transl Gastroenterol Hepatol 2016;1:67. [PMID: 28138633 DOI: 10.21037/tgh.2016.08.04] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
466 Ciombor KK, Bekaii-Saab T. A Comprehensive Review of Sequencing and Combination Strategies of Targeted Agents in Metastatic Colorectal Cancer. Oncologist 2018;23:25-34. [PMID: 29021377 DOI: 10.1634/theoncologist.2017-0203] [Cited by in Crossref: 34] [Cited by in F6Publishing: 30] [Article Influence: 6.8] [Reference Citation Analysis]
467 Martin LK, Li X, Kleiber B, Ellison EC, Bloomston M, Zalupski M, Bekaii-Saab TS. VEGF remains an interesting target in advanced pancreas cancer (APCA): results of a multi-institutional phase II study of bevacizumab, gemcitabine, and infusional 5-fluorouracil in patients with APCA. Ann Oncol. 2012;23:2812-2820. [PMID: 22767582 DOI: 10.1093/annonc/mds134] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.9] [Reference Citation Analysis]
468 Fan F, Samuel S, Gaur P, Lu J, Dallas NA, Xia L, Bose D, Ramachandran V, Ellis LM. Chronic exposure of colorectal cancer cells to bevacizumab promotes compensatory pathways that mediate tumour cell migration. Br J Cancer 2011;104:1270-7. [PMID: 21407219 DOI: 10.1038/bjc.2011.81] [Cited by in Crossref: 62] [Cited by in F6Publishing: 61] [Article Influence: 5.6] [Reference Citation Analysis]
469 Rossi L, Veltri E, Zullo A, Zoratto F, Colonna M, Longo F, Mottolese M, Giannarelli D, Ruco L, Marchetti P. Metastatic colorectal cancer first-line treatment with bevacizumab: the impact of K-ras mutation. Onco Targets Ther. 2013;6:1761-1769. [PMID: 24348051 DOI: 10.2147/ott.s43828] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
470 Buchler T, Pavlik T, Melichar B, Bortlicek Z, Usiakova Z, Dusek L, Kiss I, Kohoutek M, Benesova V, Vyzula R, Abrahamova J, Obermannova R. Bevacizumab with 5-fluorouracil, leucovorin, and oxaliplatin versus bevacizumab with capecitabine and oxaliplatin for metastatic colorectal carcinoma: results of a large registry-based cohort analysis. BMC Cancer 2014;14:323. [PMID: 24884897 DOI: 10.1186/1471-2407-14-323] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.0] [Reference Citation Analysis]
471 Chionh F, Lau D, Yeung Y, Price T, Tebbutt N. Oral versus intravenous fluoropyrimidines for colorectal cancer. Cochrane Database Syst Rev 2017;7:CD008398. [PMID: 28752564 DOI: 10.1002/14651858.CD008398.pub2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 10] [Article Influence: 1.2] [Reference Citation Analysis]
472 Xie H, Lafky JM, Morlan BW, Stella PJ, Dakhil SR, Gross GG, Loui WS, Hubbard JM, Alberts SR, Grothey A. Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol 2020;12:1758835920910913. [PMID: 32201506 DOI: 10.1177/1758835920910913] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
473 Kurkjian C, Kim ES. Risks and benefits with bevacizumab: evidence and clinical implications. Ther Adv Drug Saf 2012;3:59-69. [PMID: 25083226 DOI: 10.1177/2042098611430109] [Cited by in Crossref: 7] [Cited by in F6Publishing: 5] [Article Influence: 0.9] [Reference Citation Analysis]
474 Dahlberg SE, Sandler AB, Brahmer JR, Schiller JH, Johnson DH. Clinical course of advanced non-small-cell lung cancer patients experiencing hypertension during treatment with bevacizumab in combination with carboplatin and paclitaxel on ECOG 4599. J Clin Oncol 2010;28:949-54. [PMID: 20085937 DOI: 10.1200/JCO.2009.25.4482] [Cited by in Crossref: 174] [Cited by in F6Publishing: 71] [Article Influence: 14.5] [Reference Citation Analysis]
475 Yin C, Jiang C, Liao F, Rong Y, Cai X, Guo G, Qiu H, Chen X, Zhang B, He W, Xia L. Initial LDH level can predict the survival benefit from bevacizumab in the first-line setting in Chinese patients with metastatic colorectal cancer. Onco Targets Ther 2014;7:1415-22. [PMID: 25143746 DOI: 10.2147/OTT.S64559] [Cited by in Crossref: 11] [Cited by in F6Publishing: 16] [Article Influence: 1.4] [Reference Citation Analysis]
476 Vaklavas C, Lenihan D, Kurzrock R, Tsimberidou AM. Anti-vascular endothelial growth factor therapies and cardiovascular toxicity: what are the important clinical markers to target? Oncologist 2010;15:130-41. [PMID: 20139170 DOI: 10.1634/theoncologist.2009-0252] [Cited by in Crossref: 81] [Cited by in F6Publishing: 59] [Article Influence: 6.8] [Reference Citation Analysis]
477 Laskey RA, Richard SD, Smith AL, Lin JF, Beck TL, Lesnock JL, Kelley JL 3rd, Olawaiye AB, Sukumvanich P, Krivak TC. Retreatment with bevacizumab in patients with gynecologic malignancy is associated with clinical response and does not increase morbidity. Onco Targets Ther 2014;7:469-76. [PMID: 24711703 DOI: 10.2147/OTT.S57425] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
478 Zygoń J, Szajewski M, Kruszewski WJ, Rzepko R. VEGF, Flt-1, and microvessel density in primary tumors as predictive factors of colorectal cancer prognosis. Mol Clin Oncol 2017;6:243-8. [PMID: 28357103 DOI: 10.3892/mco.2016.1121] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
479 Mashiko S, Nagaoka I, Kitajima M, Watanabe T, Nishimura K, Futagawa S, Ochiai T. Evaluation of serum iron levels during FOLFOX4 and FOLFIRI therapies. Exp Ther Med 2010;1:507-11. [PMID: 22993568 DOI: 10.3892/etm_00000080] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
480 Tahover E, Uziely B, Salah A, Temper M, Peretz T, Hubert A. Hypertension as a predictive biomarker in bevacizumab treatment for colorectal cancer patients. Med Oncol 2013;30:327. [PMID: 23254964 DOI: 10.1007/s12032-012-0327-4] [Cited by in Crossref: 29] [Cited by in F6Publishing: 28] [Article Influence: 2.9] [Reference Citation Analysis]
481 Bullock KE, Petros WP, Younis I, Uronis HE, Morse MA, Blobe GC, Zafar SY, Gockerman JP, Lager JJ, Truax R, Meadows KL, Howard LA, O'Neill MM, Broadwater G, Hurwitz HI, Bendell JC. A phase I study of bevacizumab (B) in combination with everolimus (E) and erlotinib (E) in advanced cancer (BEE). Cancer Chemother Pharmacol 2011;67:465-74. [PMID: 21079958 DOI: 10.1007/s00280-010-1507-6] [Cited by in Crossref: 25] [Cited by in F6Publishing: 23] [Article Influence: 2.1] [Reference Citation Analysis]
482 Campos-Lobato LF, Alves-Ferreira PC, Lavery IC, Kiran RP. Abdominoperineal resection does not decrease quality of life in patients with low rectal cancer. Clinics (Sao Paulo). 2011;66:1035-1040. [PMID: 21808871 DOI: 10.1590/S1807-59322011000600019] [Cited by in Crossref: 20] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
483 Bennouna J, Hiret S, Bertaut A, Bouché O, Deplanque G, Borel C, François E, Conroy T, Ghiringhelli F, des Guetz G, Seitz JF, Artru P, Hebbar M, Stanbury T, Denis MG, Adenis A, Borg C. Continuation of Bevacizumab vs Cetuximab Plus Chemotherapy After First Progression in KRAS Wild-Type Metastatic Colorectal Cancer: The UNICANCER PRODIGE18 Randomized Clinical Trial. JAMA Oncol 2019;5:83-90. [PMID: 30422156 DOI: 10.1001/jamaoncol.2018.4465] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 9.0] [Reference Citation Analysis]
484 Zoratto F, Rossi L, Zullo A, Papa A, Zaccarelli E, Tomao L, Giordani E, Colonna M, Baiano G, Tomao S. Critical appraisal of bevacizumab in the treatment of metastatic colorectal cancer. Onco Targets Ther 2012;5:199-211. [PMID: 23055745 DOI: 10.2147/OTT.S30581] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
485 D'Adamo DR, Dickson MA, Keohan ML, Carvajal RD, Hensley ML, Hirst CM, Ezeoke MO, Ahn L, Qin LX, Antonescu CR, Lefkowitz RA, Maki RG, Schwartz GK, Tap WD. A Phase II Trial of Sorafenib and Dacarbazine for Leiomyosarcoma, Synovial Sarcoma, and Malignant Peripheral Nerve Sheath Tumors. Oncologist 2019;24:857-63. [PMID: 30126857 DOI: 10.1634/theoncologist.2018-0160] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 1.8] [Reference Citation Analysis]
486 Kristin E, Endarti D, Khoe LC, Taroeno-Hariadi KW, Trijayanti C, Armansyah A, Sastroasmoro S. Economic Evaluation of Adding Bevacizumab to Chemotherapy for Metastatic Colorectal Cancer (mCRC) Patients in Indonesia. Asian Pac J Cancer Prev 2021;22:1921-6. [PMID: 34181352 DOI: 10.31557/APJCP.2021.22.6.1921] [Reference Citation Analysis]
487 Prager G, Argilés G. Towards shedding some light on regorafenib treatment in refractory metastatic colorectal cancer. ESMO Open 2017;2:e000205. [PMID: 29303156 DOI: 10.1136/esmoopen-2017-000205] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
488 Amin M, Desai M, Trinkaus K, Brown A, Wang-Gillam A, Tan B, Picus J, Sorscher S, Highkin M, Lears K, Lockhart AC. Phase II trial of levocetirizine with capecitabine and bevacizumab to overcome the resistance of antiangiogenic therapies in refractory metastatic colorectal cancer. J Gastrointest Oncol 2019;10:412-20. [PMID: 31183190 DOI: 10.21037/jgo.2019.02.01] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
489 Ranieri G, Ferrari C, Di Palo A, Marech I, Porcelli M, Falagario G, Ritrovato F, Ramunni L, Fanelli M, Rubini G, Gadaleta CD. Bevacizumab-Based Chemotherapy Combined with Regional Deep Capacitive Hyperthermia in Metastatic Cancer Patients: A Pilot Study. Int J Mol Sci 2017;18:E1458. [PMID: 28684680 DOI: 10.3390/ijms18071458] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 2.0] [Reference Citation Analysis]
490 Tang PA, Moore MJ. Aflibercept in the treatment of patients with metastatic colorectal cancer: latest findings and interpretations. Therap Adv Gastroenterol. 2013;6:459-473. [PMID: 24179482 DOI: 10.1177/1756283x13502637] [Cited by in Crossref: 19] [Cited by in F6Publishing: 9] [Article Influence: 2.1] [Reference Citation Analysis]
491 Perkhofer L, Ettrich TJ, Seufferlein T. Pancreatic Cancer: Progress in Systemic Therapy. Gastrointest Tumors 2014;1:167-79. [PMID: 26672477 DOI: 10.1159/000380785] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
492 Chan DL, Pavlakis N, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Segelov E. Does the Chemotherapy Backbone Impact on the Efficacy of Targeted Agents in Metastatic Colorectal Cancer? A Systematic Review and Meta-Analysis of the Literature. PLoS One. 2015;10:e0135599. [PMID: 26275292 DOI: 10.1371/journal.pone.0135599] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 2.4] [Reference Citation Analysis]
493 Azzariti A, Porcelli L, Brunetti O, Del Re M, Longo V, Nardulli P, Signorile M, Xu JM, Calabrese A, Quatrale AE, Maiello E, Lorusso V, Silvestris N. Total and not bevacizumab-bound vascular endothelial growth factor as potential predictive factors to bevacizumab-based chemotherapy in colorectal cancer. World J Gastroenterol 2016; 22(27): 6287-6295 [PMID: 27468218 DOI: 10.3748/wjg.v22.i27.6287] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.2] [Reference Citation Analysis]
494 Suenaga M, Mizunuma N, Kobayashi K, Shinozaki E, Matsusaka S, Chin K, Kuboki Y, Ichimura T, Ozaka M, Ogura M. Management of venous thromboembolism in colorectal cancer patients treated with bevacizumab. Med Oncol. 2010;27:807-814. [PMID: 19697164 DOI: 10.1007/s12032-009-9289-6] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 0.3] [Reference Citation Analysis]
495 Glynne-Jones R, Hadaki M, Harrison M. The status of targeted agents in the setting of neoadjuvant radiation therapy in locally advanced rectal cancers. J Gastrointest Oncol 2013;4:264-84. [PMID: 23997939 DOI: 10.3978/j.issn.2078-6891.2013.037] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
496 Alidzanovic L, Starlinger P, Schauer D, Maier T, Feldman A, Buchberger E, Stift J, Koeck U, Pop L, Gruenberger B, Gruenberger T, Brostjan C. The VEGF rise in blood of bevacizumab patients is not based on tumor escape but a host-blockade of VEGF clearance. Oncotarget 2016;7:57197-212. [PMID: 27527865 DOI: 10.18632/oncotarget.11084] [Cited by in Crossref: 24] [Cited by in F6Publishing: 23] [Article Influence: 6.0] [Reference Citation Analysis]
497 Giordano G, Parcesepe P, Bruno G, Piscazzi A, Lizzi V, Remo A, Pancione M, D'Andrea MR, De Santis E, Coppola L, Pietrafesa M, Fersini A, Ambrosi A, Landriscina M. Evidence-Based Second-Line Treatment in RAS Wild-Type/Mutated Metastatic Colorectal Cancer in the Precision Medicine Era. Int J Mol Sci 2021;22:7717. [PMID: 34299337 DOI: 10.3390/ijms22147717] [Reference Citation Analysis]
498 Taghizadeh E, Tazik K, Taheri F, Shayankia G, Gheibihayat SM, Saberi A. Abnormal angiogenesis associated with HIF-1α/VEGF signaling pathway in recurrent miscarriage along with therapeutic goals. Gene Reports 2022;26:101483. [DOI: 10.1016/j.genrep.2021.101483] [Reference Citation Analysis]
499 Moorcraft SY, Smyth EC, Cunningham D. The role of personalized medicine in metastatic colorectal cancer: an evolving landscape. Therap Adv Gastroenterol 2013;6:381-95. [PMID: 24003339 DOI: 10.1177/1756283X13491797] [Cited by in Crossref: 27] [Cited by in F6Publishing: 16] [Article Influence: 3.0] [Reference Citation Analysis]
500 Iorio J, Lastraioli E, Tofani L, Petroni G, Antonuzzo L, Messerini L, Perrone G, Caputo D, Francesconi M, Amato MM, Cadei M, Arcangeli G, Villanacci V, Boni L, Coppola R, Di Costanzo F, Arcangeli A. hERG1 and HIF-2α Behave as Biomarkers of Positive Response to Bevacizumab in Metastatic Colorectal Cancer Patients. Transl Oncol 2020;13:100740. [PMID: 32105990 DOI: 10.1016/j.tranon.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
501 Hohla F, Winder T, Greil R, Rick FG, Block NL, Schally AV. Targeted therapy in advanced metastatic colorectal cancer: Current concepts and perspectives. World J Gastroenterol 2014; 20(20): 6102-6112 [PMID: 24876732 DOI: 10.3748/wjg.v20.i20.6102] [Cited by in CrossRef: 35] [Cited by in F6Publishing: 34] [Article Influence: 4.4] [Reference Citation Analysis]
502 Feo L, Polcino M, Nash GM. Resection of the Primary Tumor in Stage IV Colorectal Cancer: When Is It Necessary? Surg Clin North Am. 2017;97:657-669. [PMID: 28501253 DOI: 10.1016/j.suc.2017.01.012] [Cited by in Crossref: 23] [Cited by in F6Publishing: 20] [Article Influence: 4.6] [Reference Citation Analysis]
503 Choi Y, Won YJ, Lee S, Kim A, Kim Y, Park WY, Jo HJ, Song GA, Kwon CH, Park DY. Cytoplasmic TrkA Expression as a Screen for Detecting NTRK1 Fusions in Colorectal Cancer. Transl Oncol 2018;11:764-70. [PMID: 29689458 DOI: 10.1016/j.tranon.2018.03.011] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
504 Chan DLH, Segelov E, Wong RS, Smith A, Herbertson RA, Li BT, Tebbutt N, Price T, Pavlakis N. Epidermal growth factor receptor (EGFR) inhibitors for metastatic colorectal cancer. Cochrane Database Syst Rev. 2017;6:CD007047. [PMID: 28654140 DOI: 10.1002/14651858.cd007047] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
505 Komorowski AS, MacKay HJ, Pezo RC. Quality of adverse event reporting in phase III randomized controlled trials of breast and colorectal cancer: A systematic review. Cancer Med 2020;9:5035-50. [PMID: 32452660 DOI: 10.1002/cam4.3095] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
506 Borzomati D, Nappo G, Valeri S, Vincenzi B, Ripetti V, Coppola R. Infusion of Bevacizumab increases the risk of intestinal perforation: results on a series of 143 patients consecutively treated. Updates Surg 2013;65:121-4. [DOI: 10.1007/s13304-013-0207-2] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 1.1] [Reference Citation Analysis]
507 Wein A, Siebler J, Goertz R, Wolff K, Ostermeier N, Busse D, Kremer AE, Koch F, Hagel A, Farnbacher M, Kammerer FJ, Neurath MF, Gruetzmann R. Successful Multidisciplinary Treatment with Secondary Metastatic Liver Resection after Downsizing by Palliative Second-Line Treatment of Colorectal Cancer: A Curative Option. Case Rep Oncol 2016;9:379-86. [PMID: 27489542 DOI: 10.1159/000445677] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
508 Recondo GJ, Díaz-Cantón E, de la Vega M, Greco M, Recondo GS, Valsecchi ME. Advances and new perspectives in the treatment of metastatic colon cancer. World J Gastrointest Oncol 2014; 6(7): 211-224 [PMID: 25024813 DOI: 10.4251/wjgo.v6.i7.211] [Cited by in CrossRef: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.3] [Reference Citation Analysis]
509 Chen HX, Cleck JN. Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol. 2009;6:465-477. [PMID: 19581909 DOI: 10.1038/nrclinonc.2009.94] [Cited by in Crossref: 340] [Cited by in F6Publishing: 301] [Article Influence: 26.2] [Reference Citation Analysis]
510 Lopes-Coelho F, Martins F, Pereira SA, Serpa J. Anti-Angiogenic Therapy: Current Challenges and Future Perspectives. Int J Mol Sci 2021;22:3765. [PMID: 33916438 DOI: 10.3390/ijms22073765] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
511 Zuo PY, Chen XL, Liu YW, Xiao CL, Liu CY. Increased risk of cerebrovascular events in patients with cancer treated with bevacizumab: a meta-analysis. PLoS One 2014;9:e102484. [PMID: 25025282 DOI: 10.1371/journal.pone.0102484] [Cited by in Crossref: 44] [Cited by in F6Publishing: 39] [Article Influence: 5.5] [Reference Citation Analysis]
512 Shiomi K, Naito M, Sato T, Nakamura T, Nakashima H, Naito M, Mikubo M, Matsui Y, Watanabe M, Satoh Y. Effect of adjuvant chemotherapy after pulmonary metastasectomy on the prognosis of colorectal cancer. Ann Med Surg (Lond) 2017;20:19-25. [PMID: 28702182 DOI: 10.1016/j.amsu.2017.06.026] [Cited by in Crossref: 9] [Cited by in F6Publishing: 7] [Article Influence: 1.8] [Reference Citation Analysis]
513 Bates DO, Catalano PJ, Symonds KE, Varey AH, Ramani P, O'Dwyer PJ, Giantonio BJ, Meropol NJ, Benson AB, Harper SJ. Association between VEGF splice isoforms and progression-free survival in metastatic colorectal cancer patients treated with bevacizumab. Clin Cancer Res 2012;18:6384-91. [PMID: 23104894 DOI: 10.1158/1078-0432.CCR-12-2223] [Cited by in Crossref: 47] [Cited by in F6Publishing: 28] [Article Influence: 4.7] [Reference Citation Analysis]
514 Zinser-Sierra JW, Rodríguez-Ramírez S, Villalobos-Valencia R, Ramírez-Márquez M. Use of bevacizumab in metastatic colorectal cancer: report from the Mexican opinion and analysis forum on colorectal cancer treatment with bevacizumab (September 2009). Drugs R D 2011;11:101-11. [PMID: 21679003 DOI: 10.2165/11590440-000000000-00000] [Cited by in Crossref: 8] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
515 Benazzi C, Al-Dissi A, Chau CH, Figg WD, Sarli G, de Oliveira JT, Gärtner F. Angiogenesis in spontaneous tumors and implications for comparative tumor biology. ScientificWorldJournal 2014;2014:919570. [PMID: 24563633 DOI: 10.1155/2014/919570] [Cited by in Crossref: 29] [Cited by in F6Publishing: 22] [Article Influence: 3.6] [Reference Citation Analysis]
516 Eskander RN, Tewari KS. Development of bevacizumab in advanced cervical cancer: pharmacodynamic modeling, survival impact and toxicology. Future Oncol 2015;11:909-22. [PMID: 25760973 DOI: 10.2217/fon.14.276] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.1] [Reference Citation Analysis]
517 D'Agay MG, Galland L, Tharin Z, Truntzer C, Ghiringhelli F. Utility of exome sequencing in routine care for metastatic colorectal cancer. Mol Clin Oncol 2021;15:229. [PMID: 34631054 DOI: 10.3892/mco.2021.2392] [Reference Citation Analysis]
518 González Astorga B, Salvà Ballabrera F, Aranda Aguilar E, Élez Fernández E, García-Alfonso P, González Flores E, Vera García R, Fernández Montes A, López Muñoz AM, Salud Salvia A. Patient profiles as an aim to optimize selection in the second line setting: the role of aflibercept. Clin Transl Oncol 2021;23:1520-8. [PMID: 33630242 DOI: 10.1007/s12094-021-02568-y] [Reference Citation Analysis]
519 Konda B, Shum H, Rajdev L. Anti-angiogenic agents in metastatic colorectal cancer. World J Gastrointest Oncol 2015; 7(7): 71-86 [PMID: 26191351 DOI: 10.4251/wjgo.v7.i7.71] [Cited by in CrossRef: 13] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
520 El-Rayes BF, Zalupski M, Bekai-Saab T, Heilbrun LK, Hammad N, Patel B, Urba S, Shields AF, Vaishampayan U, Dawson S. A phase II study of bevacizumab, oxaliplatin, and docetaxel in locally advanced and metastatic gastric and gastroesophageal junction cancers. Ann Oncol. 2010;21:1999-2004. [PMID: 20332133 DOI: 10.1093/annonc/mdq065] [Cited by in Crossref: 70] [Cited by in F6Publishing: 67] [Article Influence: 5.8] [Reference Citation Analysis]
521 Matsuoka A, Maeda O, Mizutani T, Nakano Y, Tsunoda N, Kikumori T, Goto H, Ando Y. Bevacizumab Exacerbates Paclitaxel-Induced Neuropathy: A Retrospective Cohort Study. PLoS One 2016;11:e0168707. [PMID: 27992556 DOI: 10.1371/journal.pone.0168707] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 2.2] [Reference Citation Analysis]
522 Ahmadizar F, Onland-Moret NC, de Boer A, Liu G, Maitland-van der Zee AH. Efficacy and Safety Assessment of the Addition of Bevacizumab to Adjuvant Therapy Agents in Cancer Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. PLoS One 2015;10:e0136324. [PMID: 26331473 DOI: 10.1371/journal.pone.0136324] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 2.3] [Reference Citation Analysis]
523 Narihiro S, Suwa K, Ushigome T, Ohtsu M, Ryu S, Shimoyama Y, Okamoto T, Yanaga K. Safety and Efficacy of Trifluridine-Tipiracil Hydrochloride Oral Combination (TAS-102) in Patients with Unresectable Colorectal Cancer. In Vivo 2018;32:1643-6. [PMID: 30348728 DOI: 10.21873/invivo.11426] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
524 Jakobs TF, Hoffmann RT, Tatsch K, Trumm C, Reiser MF, Helmberger TK. [Developments and perspectives in radioablative techniques]. Radiologe. 2007;47:1083-1088. [PMID: 17943265 DOI: 10.1007/s00117-007-1572-y] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 0.8] [Reference Citation Analysis]
525 Choi HJ, Shin JY. Colorectal cancer with multiple metastases: is palliative surgery needed? J Korean Soc Coloproctol 2011;27:226-30. [PMID: 22102971 DOI: 10.3393/jksc.2011.27.5.226] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
526 Aparo S, Goel S. Evolvement of the treatment paradigm for metastatic colon cancer. From chemotherapy to targeted therapy. Crit Rev Oncol Hematol 2012;83:47-58. [PMID: 21944740 DOI: 10.1016/j.critrevonc.2011.08.006] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.1] [Reference Citation Analysis]
527 Cosmai L, Gallieni M, Liguigli W, Porta C. Renal toxicity of anticancer agents targeting vascular endothelial growth factor (VEGF) and its receptors (VEGFRs). J Nephrol 2017;30:171-80. [PMID: 27154025 DOI: 10.1007/s40620-016-0311-8] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 3.0] [Reference Citation Analysis]
528 Liu Y, Starr MD, Bulusu A, Pang H, Wong NS, Honeycutt W, Amara A, Hurwitz HI, Nixon AB. Correlation of angiogenic biomarker signatures with clinical outcomes in metastatic colorectal cancer patients receiving capecitabine, oxaliplatin, and bevacizumab. Cancer Med 2013;2:234-42. [PMID: 23634291 DOI: 10.1002/cam4.71] [Cited by in Crossref: 48] [Cited by in F6Publishing: 41] [Article Influence: 5.3] [Reference Citation Analysis]
529 Wu Q, Shi Y, Chen L, Xiao X, Dai G. Effect and safety of bevacizumab-containing chemotherapy treatment in Chinese patients with metastatic colorectal cancer. Onco Targets Ther. 2013;6:485-490. [PMID: 23671391 DOI: 10.2147/OTT.S41449] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
530 Abajo A, Rodriguez J, Bitarte N, Zarate R, Boni V, Ponz M, Chopitea A, Bandres E, Garcia-Foncillas J. Dose-finding study and pharmacogenomic analysis of fixed-rate infusion of gemcitabine, irinotecan and bevacizumab in pretreated metastatic colorectal cancer patients. Br J Cancer 2010;103:1529-35. [PMID: 20940716 DOI: 10.1038/sj.bjc.6605908] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
531 Tian Y, Zhai X, Tian H, Jing W, Zhu H, Yu J. Bevacizumab in Combination with Pemetrexed and Platinum Significantly Improved the Clinical Outcome of Patients with Advanced Adenocarcinoma NSCLC and Brain Metastases. Cancer Manag Res 2019;11:10083-92. [PMID: 31819641 DOI: 10.2147/CMAR.S222910] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
532 Carden CP, Larkin JM, Rosenthal MA. What is the risk of intracranial bleeding during anti-VEGF therapy? Neuro Oncol. 2008;10:624-630. [PMID: 18539884 DOI: 10.1215/15228517-2008-010] [Cited by in Crossref: 63] [Cited by in F6Publishing: 49] [Article Influence: 4.5] [Reference Citation Analysis]
533 Yu X, Wang QX, Xiao WW, Chang H, Zeng ZF, Lu ZH, Wu XJ, Chen G, Pan ZZ, Wan DS, Ding PR, Gao YH. Neoadjuvant oxaliplatin and capecitabine combined with bevacizumab plus radiotherapy for locally advanced rectal cancer: results of a single-institute phase II study. Cancer Commun (Lond) 2018;38:24. [PMID: 29784042 DOI: 10.1186/s40880-018-0294-z] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 3.8] [Reference Citation Analysis]
534 Placer C, Markinez I, Rodríguez A, Elósegui JL, Navascués JM. [Delayed anastomotic dehiscence in advanced colorectal cancer treated with Bevacizumab™]. Cir Esp 2010;88:267-8. [PMID: 20149351 DOI: 10.1016/j.ciresp.2009.12.011] [Reference Citation Analysis]
535 Sánchez-Gundín J, Fernández-Carballido AM, Martínez-Valdivieso L, Barreda-Hernández D, Torres-Suárez AI. New Trends in the Therapeutic Approach to Metastatic Colorectal Cancer. Int J Med Sci 2018;15:659-65. [PMID: 29910669 DOI: 10.7150/ijms.24453] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 6.5] [Reference Citation Analysis]
536 Velasco R, Bruna J. Chemotherapy-induced peripheral neuropathy: An unresolved issue. Neurología (English Edition) 2010;25:116-31. [DOI: 10.1016/s2173-5808(10)70022-5] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
537 Chan E, Goff LW, Cardin DB, Ancell K, Smith SJ, Whisenant JG, Ye F, Berlin JD. Phase II study of the Multikinase inhibitor of angiogenesis, Linifanib, in patients with metastatic and refractory colorectal cancer expressing mutated KRAS. Invest New Drugs 2017;35:491-8. [PMID: 28353122 DOI: 10.1007/s10637-017-0458-8] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
538 Tang JC, Feng YL, Liang X, Cai XJ. Autophagy in 5-Fluorouracil Therapy in Gastrointestinal Cancer: Trends and Challenges. Chin Med J (Engl). 2016;129:456-463. [PMID: 26879020 DOI: 10.4103/0366-6999.176069] [Cited by in Crossref: 27] [Cited by in F6Publishing: 24] [Article Influence: 5.4] [Reference Citation Analysis]
539 Lieu CH, Tan AC, Leong S, Diamond JR, Eckhardt SG. From bench to bedside: lessons learned in translating preclinical studies in cancer drug development. J Natl Cancer Inst 2013;105:1441-56. [PMID: 24052618 DOI: 10.1093/jnci/djt209] [Cited by in Crossref: 39] [Cited by in F6Publishing: 29] [Article Influence: 4.3] [Reference Citation Analysis]
540 Liu X, Guo W, Zhang W, Yin J, Zhang J, Zhu X, Liu T, Chen Z, Wang B, Chang J, Lv F, Hong X, Wang H, Wang J, Zhao X, Wu X, Li J. A multi-center phase II study and biomarker analysis of combined cetuximab and modified FOLFIRI as second-line treatment in patients with metastatic gastric cancer. BMC Cancer 2017;17:188. [PMID: 28288572 DOI: 10.1186/s12885-017-3174-z] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.8] [Reference Citation Analysis]
541 Garrett CR, Siu LL, El-Khoueiry A, Buter J, Rocha-Lima CM, Marshall J, LoRusso P, Major P, Chemidlin J, Mokliatchouk O. Phase I dose-escalation study to determine the safety, pharmacokinetics and pharmacodynamics of brivanib alaninate in combination with full-dose cetuximab in patients with advanced gastrointestinal malignancies who have failed prior therapy. Br J Cancer. 2011;105:44-52. [PMID: 21629245 DOI: 10.1038/bjc.2011.182] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 2.0] [Reference Citation Analysis]
542 Baek SK, Lee KT, Bae SB, Lee SC. Evaluating the recent developments in palliative chemotherapy for metastatic colorectal cancer. Korean J Intern Med 2019;34:1188-96. [PMID: 31346151 DOI: 10.3904/kjim.2019.071] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
543 Yoon HH, Bendell JC, Braiteh FS, Firdaus I, Philip PA, Cohn AL, Lewis N, Anderson DM, Arrowsmith E, Schwartz JD, Gao L, Hsu Y, Xu Y, Ferry D, Alberts SR, Wainberg ZA. Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trial. Ann Oncol. 2016;27:2196-2203. [PMID: 27765757 DOI: 10.1093/annonc/mdw423] [Cited by in Crossref: 69] [Cited by in F6Publishing: 64] [Article Influence: 11.5] [Reference Citation Analysis]
544 Lorusso P, Shields AF, Gadgeel S, Vaishampayan U, Guthrie T, Puchalski T, Xu J, Liu Q. Cediranib in combination with various anticancer regimens: results of a phase I multi-cohort study. Invest New Drugs 2011;29:1395-405. [PMID: 20607586 DOI: 10.1007/s10637-010-9484-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 1.1] [Reference Citation Analysis]
545 Mulcahy MF. Bevacizumab in the therapy for refractory metastatic colorectal cancer. Biologics 2008;2:53-9. [PMID: 19707427 DOI: 10.2147/btt.s1519] [Cited by in Crossref: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.2] [Reference Citation Analysis]
546 Macedo LT, da Costa Lima AB, Sasse AD. Addition of bevacizumab to first-line chemotherapy in advanced colorectal cancer: a systematic review and meta-analysis, with emphasis on chemotherapy subgroups. BMC Cancer. 2012;12:89. [PMID: 22414244 DOI: 10.1186/1471-2407-12-89] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 7.9] [Reference Citation Analysis]
547 Shen H, Ye XY, Li XF, Pan WS, Yuan Y. Severe esophageal bleeding in colorectal cancer due to antitumor therapy: A case report. Oncol Lett 2015;10:3660-2. [PMID: 26788187 DOI: 10.3892/ol.2015.3742] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
548 Eng C. Toxic effects and their management: daily clinical challenges in the treatment of colorectal cancer. Nat Rev Clin Oncol. 2009;6:207-218. [PMID: 19333227 DOI: 10.1038/nrclinonc.2009.16] [Cited by in Crossref: 44] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
549 Li D, McCall LM, Hahn OM, Hudis CA, Cohen HJ, Muss HB, Jatoi A, Lafky JM, Ballman KV, Winer EP, Tripathy D, Schneider B, Barry W, Dickler MN, Hurria A. Identification of risk factors for toxicity in patients with hormone receptor-positive advanced breast cancer treated with bevacizumab plus letrozole: a CALGB 40503 (alliance) correlative study. Breast Cancer Res Treat 2018;171:325-34. [PMID: 29789969 DOI: 10.1007/s10549-018-4828-5] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
550 Gounaris E, Heiferman MJ, Heiferman JR, Shrivastav M, Vitello D, Blatner NR, Knab LM, Phillips JD, Cheon EC, Grippo PJ. Zileuton, 5-lipoxygenase inhibitor, acts as a chemopreventive agent in intestinal polyposis, by modulating polyp and systemic inflammation. PLoS One. 2015;10:e0121402. [PMID: 25747113 DOI: 10.1371/journal.pone.0121402] [Cited by in Crossref: 30] [Cited by in F6Publishing: 30] [Article Influence: 4.3] [Reference Citation Analysis]
551 Tapia Rico G, Townsend AR, Broadbridge V, Price TJ. Targeted Therapies in Elderly Patients with Metastatic Colorectal Cancer: A Review of the Evidence. Drugs Aging 2017;34:173-89. [PMID: 28197947 DOI: 10.1007/s40266-017-0439-9] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.6] [Reference Citation Analysis]
552 Loupakis F, Bria E, Vaccaro V, Cuppone F, Milella M, Carlini P, Cremolini C, Salvatore L, Falcone A, Muti P. Magnitude of benefit of the addition of bevacizumab to first-line chemotherapy for metastatic colorectal cancer: meta-analysis of randomized clinical trials. J Exp Clin Cancer Res. 2010;29:58. [PMID: 20504361 DOI: 10.1186/1756-9966-29-58] [Cited by in Crossref: 39] [Cited by in F6Publishing: 33] [Article Influence: 3.3] [Reference Citation Analysis]
553 Eichholz A, Merchant S, Gaya AM. Anti-angiogenesis therapies: their potential in cancer management. Onco Targets Ther 2010;3:69-82. [PMID: 20616958 DOI: 10.2147/ott.s5256] [Cited by in Crossref: 1] [Cited by in F6Publishing: 22] [Article Influence: 0.1] [Reference Citation Analysis]
554 Nakayama G, Uehara K, Ishigure K, Yokoyama H, Ishiyama A, Eguchi T, Tsuboi K, Ohashi N, Fujii T, Sugimoto H, Koike M, Fujiwara M, Ando Y, Kodera Y. The efficacy and safety of bevacizumab beyond first progression in patients treated with first-line mFOLFOX6 followed by second-line FOLFIRI in advanced colorectal cancer: a multicenter, single-arm, phase II trial (CCOG-0801). Cancer Chemother Pharmacol 2012;70:575-81. [PMID: 22886005 DOI: 10.1007/s00280-012-1948-1] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.9] [Reference Citation Analysis]
555 Yang J, Liu R, Ektare V, Stephens J, Shelbaya A. Does Biosimilar Bevacizumab Offer Affordable Treatment Options for Cancer Patients in the USA? A Budget Impact Analysis from US Commercial and Medicare Payer Perspectives. Appl Health Econ Health Policy 2021;19:605-18. [PMID: 33506318 DOI: 10.1007/s40258-021-00637-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
556 Angelis A, Montibeller G, Hochhauser D, Kanavos P. Multiple criteria decision analysis in the context of health technology assessment: a simulation exercise on metastatic colorectal cancer with multiple stakeholders in the English setting. BMC Med Inform Decis Mak 2017;17:149. [PMID: 29073892 DOI: 10.1186/s12911-017-0524-3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
557 Inanç M, Er O, Karaca H, Berk V, Ozkan M, Saraymen R, Elmalı F. Prognostic value of tumor growth factor levels during chemotherapy in patients with metastatic colorectal cancer. Med Oncol 2012;29:3119-24. [PMID: 22580817 DOI: 10.1007/s12032-012-0250-8] [Cited by in Crossref: 8] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
558 Zunder SM, van Pelt GW, Gelderblom HJ, Mancao C, Putter H, Tollenaar RA, Mesker WE. Predictive potential of tumour-stroma ratio on benefit from adjuvant bevacizumab in high-risk stage II and stage III colon cancer. Br J Cancer 2018;119:164-9. [PMID: 29755119 DOI: 10.1038/s41416-018-0083-0] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
559 Gómez-España MA, Gallego J, González-Flores E, Maurel J, Páez D, Sastre J, Aparicio J, Benavides M, Feliu J, Vera R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer (2018). Clin Transl Oncol 2019;21:46-54. [PMID: 30565083 DOI: 10.1007/s12094-018-02002-w] [Cited by in Crossref: 14] [Cited by in F6Publishing: 10] [Article Influence: 3.5] [Reference Citation Analysis]
560 Xiao B, Wang W, Zhang D. Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials. Onco Targets Ther 2018;11:5059-74. [PMID: 30174444 DOI: 10.2147/OTT.S166151] [Cited by in Crossref: 10] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
561 Schmoll HJ, Twelves C, Sun W, O'Connell MJ, Cartwright T, McKenna E, Saif M, Lee S, Yothers G, Haller D. Effect of adjuvant capecitabine or fluorouracil, with or without oxaliplatin, on survival outcomes in stage III colon cancer and the effect of oxaliplatin on post-relapse survival: a pooled analysis of individual patient data from four randomised controlled trials. Lancet Oncol 2014;15:1481-92. [PMID: 25456367 DOI: 10.1016/S1470-2045(14)70486-3] [Cited by in Crossref: 88] [Cited by in F6Publishing: 43] [Article Influence: 11.0] [Reference Citation Analysis]
562 Xu R, Xu C, Liu C, Cui C, Zhu J. Efficacy and safety of bevacizumab-based combination therapy for treatment of patients with metastatic colorectal cancer. Onco Targets Ther. 2018;11:8605-8621. [PMID: 30584320 DOI: 10.2147/ott.s171724] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 1.8] [Reference Citation Analysis]
563 Gruenberger B, Scheithauer W, Punzengruber R, Zielinski C, Tamandl D, Gruenberger T. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer 2008;8:120. [PMID: 18439246 DOI: 10.1186/1471-2407-8-120] [Cited by in Crossref: 83] [Cited by in F6Publishing: 71] [Article Influence: 5.9] [Reference Citation Analysis]
564 Russell JS, Brown JM. Circulating mouse Flk1+/c-Kit+/CD45- cells function as endothelial progenitors cells (EPCs) and stimulate the growth of human tumor xenografts. Mol Cancer 2014;13:177. [PMID: 25047738 DOI: 10.1186/1476-4598-13-177] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 2.4] [Reference Citation Analysis]
565 De Falco V, Napolitano S, Roselló S, Huerta M, Cervantes A, Ciardiello F, Troiani T. How we treat metastatic colorectal cancer. ESMO Open 2020;4:e000813. [PMID: 32817137 DOI: 10.1136/esmoopen-2020-000813] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 6.0] [Reference Citation Analysis]
566 Stein A, Hiemer S, Schmoll H. Adjuvant Therapy for Early Colon Cancer: Current Status. Drugs 2011;71:2257-75. [DOI: 10.2165/11594490-000000000-00000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 17] [Article Influence: 1.6] [Reference Citation Analysis]
567 Luo J, Zhong X, Peng Y, Hao C, Liang X, Yang Y, Shi X, Chen X, Yi X, Li X, Wu J, Li J, Xiao Q, Wu C, Lu R, Pan Y, Wang X, Fan J, Wang Y, Wang Y. Self-anti-angiogenesis nanoparticles enhance anti-metastatic-tumor efficacy of chemotherapeutics. Bioactive Materials 2022;13:179-90. [DOI: 10.1016/j.bioactmat.2021.10.037] [Reference Citation Analysis]
568 Homma T, Kurokawa M, Yamamoto Y, Matsukura S, Ieki K, Suzuki S, Odaka M, Watanabe S, Yamaguchi M, Adachi M. Oxaliplatin-induced lung injury with allergic reaction. Chin J Cancer Res 2011;23:232-5. [PMID: 23467619 DOI: 10.1007/s11670-011-0232-y] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.1] [Reference Citation Analysis]
569 Yang W, Li W, Pan F, Yang XY, Zhao X, Qin L, Pan Y. TSP-1 as a novel biological marker of tumor vasculature normalization in colon carcinoma induced by Endostar. Oncol Lett 2020;19:2107-14. [PMID: 32194708 DOI: 10.3892/ol.2020.11320] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
570 Krishnamurthi SS, Brell JM, Hoppel CL, Egorin MJ, Weaver KC, Li X, Ingalls ST, Zuhowski EG, Schluchter MD, Dowlati A, Cooney MM, Gibbons J, Overmoyer BA, Ivy SP, Remick SC. Phase I clinical and pharmacokinetic study of oxaliplatin, irinotecan and capecitabine. Cancer Chemother Pharmacol 2009;63:441-50. [PMID: 18414865 DOI: 10.1007/s00280-008-0754-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 0.4] [Reference Citation Analysis]
571 Xu S, Sak A, Erol YB. Network Meta-analysis of First-Line Systemic Treatment for Patients With Metastatic Colorectal Cancer. Cancer Control 2021;28:10732748211033497. [PMID: 34554888 DOI: 10.1177/10732748211033497] [Reference Citation Analysis]
572 Woodrum C, Nobil A, Dabora SL. Comparison of three rapamycin dosing schedules in A/J Tsc2+/- mice and improved survival with angiogenesis inhibitor or asparaginase treatment in mice with subcutaneous tuberous sclerosis related tumors. J Transl Med. 2010;8:14. [PMID: 20146790 DOI: 10.1186/1479-5876-8-14] [Cited by in Crossref: 24] [Cited by in F6Publishing: 28] [Article Influence: 2.0] [Reference Citation Analysis]
573 Barillari G. The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs. Front Oncol 2020;10:806. [PMID: 32528888 DOI: 10.3389/fonc.2020.00806] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
574 Wong NS, Fernando NH, Bendell JC, Morse MA, Blobe GC, Honeycutt W, Pang H, Hurwitz HI. A phase II study of oxaliplatin, dose-intense capecitabine, and high-dose bevacizumab in the treatment of metastatic colorectal cancer. Clin Colorectal Cancer 2011;10:210-6. [PMID: 21855046 DOI: 10.1016/j.clcc.2011.03.018] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 0.6] [Reference Citation Analysis]
575 Ivanova JI, Saverno KR, Sung J, Duh MS, Zhao C, Cai S, Vekeman F, Peevyhouse A, Dhawan R, Fuchs CS. Real-world treatment patterns and effectiveness among patients with metastatic colorectal cancer treated with ziv-aflibercept in community oncology practices in the USA. Med Oncol. 2017;34:193. [PMID: 29103187 DOI: 10.1007/s12032-017-1049-4] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 2.8] [Reference Citation Analysis]
576 Chongqing T, Sini L, Xiaohui Z, Liubao P, Ye P, Shuxia Q, Liting W, Meiyu W, Xiaomin W. Cost-Effectiveness of First-Line Versus Second-Line Pembrolizumab or Chemotherapy in Patients With Microsatellite-Instability-High/Mismatch Repair-Deficient Advanced Colorectal Cancer. Front Pharmacol 2021;12:802942. [PMID: 34970153 DOI: 10.3389/fphar.2021.802942] [Reference Citation Analysis]
577 Pollom EL, Deng L, Pai RK, Brown JM, Giaccia A, Loo BW Jr, Shultz DB, Le QT, Koong AC, Chang DT. Gastrointestinal Toxicities With Combined Antiangiogenic and Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys 2015;92:568-76. [PMID: 26068491 DOI: 10.1016/j.ijrobp.2015.02.016] [Cited by in Crossref: 40] [Cited by in F6Publishing: 39] [Article Influence: 5.7] [Reference Citation Analysis]
578 Mendivil AN, Rodriguez PM, Felip E. Angiogenesis, multitarget kinase inhibitors and non-small cell lung cancer: a lesson from MONET1 trial. Transl Lung Cancer Res 2013;2:E13-6. [PMID: 25806210 DOI: 10.3978/j.issn.2218-6751.2012.09.12] [Reference Citation Analysis]
579 Osumi H, Shinozaki E, Ooki A, Wakatsuki T, Kamiimabeppu D, Sato T, Nakayama I, Ogura M, Takahari D, Chin K, Yamaguchi K. Early hypertension and neutropenia are predictors of treatment efficacy in metastatic colorectal cancer patients administered FOLFIRI and vascular endothelial growth factor inhibitors as second-line chemotherapy. Cancer Med 2021;10:615-25. [PMID: 33347731 DOI: 10.1002/cam4.3638] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
580 King BH, Baumgartner JM, Kelly KJ, Marmor RA, Lowy AM, Veerapong J. Preoperative bevacizumab does not increase complications following cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. PLoS One 2020;15:e0243252. [PMID: 33270763 DOI: 10.1371/journal.pone.0243252] [Reference Citation Analysis]
581 Parisi A, Cortellini A, Cannita K, Venditti O, Camarda F, Calegari MA, Salvatore L, Tortora G, Rossini D, Germani MM, Boccaccino A, Dell'Aquila E, Fulgenzi C, Santini D, Tursi M, Tinari N, Marino PD, Lombardi P, Keränen SR, Álvaro MH, Zurlo IV, Corsi DC, Emiliani A, Zanaletti N, Troiani T, Vitale P, Giampieri R, Merloni F, Occhipinti MA, Marchetti P, Roberto M, Mazzuca F, Ghidini M, Indini A, Garajova I, Zoratto F, Monache SD, Porzio G, Ficorella C. Evaluation of Second-line Anti-VEGF after First-line Anti-EGFR Based Therapy in RAS Wild-Type Metastatic Colorectal Cancer: The Multicenter "SLAVE" Study. Cancers (Basel) 2020;12:E1259. [PMID: 32429380 DOI: 10.3390/cancers12051259] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
582 Ducreux M, Boige V, Bouarioua N, Leconte B, Frikha H, Boisserie T, Malka D. Nouveautés dans la chimiothérapie du cancer colorectal métastasé. Oncologie 2008;10:169-74. [DOI: 10.1007/s10269-008-0851-1] [Cited by in Crossref: 1] [Article Influence: 0.1] [Reference Citation Analysis]
583 Jouinot A, Coriat R, Huillard O, Goldwasser F. Les biothérapies des cancers colorectaux métastatiques en 2014. La Presse Médicale 2014;43:1056-66. [DOI: 10.1016/j.lpm.2014.03.028] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
584 Hansen TF, Qvortrup C, Pfeiffer P. Angiogenesis Inhibitors for Colorectal Cancer. A Review of the Clinical Data. Cancers (Basel) 2021;13:1031. [PMID: 33804554 DOI: 10.3390/cancers13051031] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
585 Johnston PG. Identification of clinically relevant molecular subtypes in colorectal cancer: the dawning of a new era. Oncologist 2014;19:568-73. [PMID: 24718513 DOI: 10.1634/theoncologist.2014-038] [Cited by in Crossref: 12] [Cited by in F6Publishing: 10] [Article Influence: 1.5] [Reference Citation Analysis]
586 Michael M, Gibbs P, Smith R, Godwood A, Oliver S, Tebbutt N. Open-label phase I trial of vandetanib in combination with mFOLFOX6 in patients with advanced colorectal cancer. Invest New Drugs. 2009;27:253-261. [PMID: 19002384 DOI: 10.1007/s10637-008-9182-8] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.4] [Reference Citation Analysis]
587 Sims JS, Ung TH, Neira JA, Canoll P, Bruce JN. Biomarkers for glioma immunotherapy: the next generation. J Neurooncol 2015;123:359-72. [PMID: 25724916 DOI: 10.1007/s11060-015-1746-9] [Cited by in Crossref: 18] [Cited by in F6Publishing: 19] [Article Influence: 2.6] [Reference Citation Analysis]
588 Al-Husein B, Abdalla M, Trepte M, Deremer DL, Somanath PR. Antiangiogenic therapy for cancer: an update. Pharmacotherapy 2012;32:1095-111. [PMID: 23208836 DOI: 10.1002/phar.1147] [Cited by in Crossref: 120] [Cited by in F6Publishing: 98] [Article Influence: 13.3] [Reference Citation Analysis]
589 Mulder K, Koski S, Scarfe A, Chu Q, King K, Spratlin J. Antiangiogenic agents in advanced gastrointestinal malignancies: past, present and a novel future. Oncotarget 2010;1:515-29. [PMID: 21317448 DOI: 10.18632/oncotarget.101006] [Cited by in F6Publishing: 7] [Reference Citation Analysis]
590 Sun DC, Shi Y, Wang YR, Lv Y, Yan H, Mao H, Wang ZK, Wu ZY, Shi WW, Dai GH. KRAS mutation and primary tumor location do not affect efficacy of bevacizumab-containing chemotherapy in stagae IV colorectal cancer patients. Sci Rep 2017;7:14368. [PMID: 29085005 DOI: 10.1038/s41598-017-14669-2] [Cited by in Crossref: 7] [Cited by in F6Publishing: 9] [Article Influence: 1.4] [Reference Citation Analysis]
591 Hickey R, Vouche M, Sze DY, Hohlastos E, Collins J, Schirmang T, Memon K, Ryu RK, Sato K, Chen R, Gupta R, Resnick S, Carr J, Chrisman HB, Nemcek AA Jr, Vogelzang RL, Lewandowski RJ, Salem R. Cancer concepts and principles: primer for the interventional oncologist-part II. J Vasc Interv Radiol 2013;24:1167-88. [PMID: 23810312 DOI: 10.1016/j.jvir.2013.04.023] [Cited by in Crossref: 14] [Cited by in F6Publishing: 15] [Article Influence: 1.6] [Reference Citation Analysis]
592 Suenaga M, Fujimoto Y, Matsusaka S, Shinozaki E, Akiyoshi T, Nagayama S, Fukunaga Y, Oya M, Ueno M, Mizunuma N, Yamaguchi T. Perioperative FOLFOX4 plus bevacizumab for initially unresectable advanced colorectal cancer (NAVIGATE-CRC-01). Onco Targets Ther 2015;8:1111-8. [PMID: 26056475 DOI: 10.2147/OTT.S83952] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
593 Clarke S, Burge M, Cordwell C, Gibbs P, Reece W, Tebbutt N. An Australian translational study to evaluate the prognostic role of inflammatory markers in patients with metastatic ColorEctal caNcer Treated with bevacizumab (Avastin™) [ASCENT]. BMC Cancer 2013;13:120. [PMID: 23497305 DOI: 10.1186/1471-2407-13-120] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.7] [Reference Citation Analysis]
594 Pohl M, Reinacher-schick A, Schmiegel W. Palliative endoscopic and chemotherapeutic treatment. Eur Surg 2010;42:287-98. [DOI: 10.1007/s10353-010-0571-9] [Reference Citation Analysis]
595 Shojaei F, Wu X, Qu X, Kowanetz M, Yu L, Tan M, Meng YG, Ferrara N. G-CSF-initiated myeloid cell mobilization and angiogenesis mediate tumor refractoriness to anti-VEGF therapy in mouse models. Proc Natl Acad Sci USA. 2009;106:6742-6747. [PMID: 19346489 DOI: 10.1073/pnas.0902280106] [Cited by in Crossref: 334] [Cited by in F6Publishing: 306] [Article Influence: 25.7] [Reference Citation Analysis]
596 Fisher CM, Schefter TE. Profile of bevacizumab and its potential in the treatment of cervical cancer. Onco Targets Ther 2015;8:3425-31. [PMID: 26640382 DOI: 10.2147/OTT.S73251] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
597 Astsaturov IA, Meropol NJ, Alpaugh RK, Burtness BA, Cheng JD, McLaughlin S, Rogatko A, Xu Z, Watson JC, Weiner LM. Phase II and coagulation cascade biomarker study of bevacizumab with or without docetaxel in patients with previously treated metastatic pancreatic adenocarcinoma. Am J Clin Oncol. 2011;34:70-75. [PMID: 20458210 DOI: 10.1097/coc.0b013e3181d2734a] [Cited by in Crossref: 22] [Cited by in F6Publishing: 18] [Article Influence: 2.0] [Reference Citation Analysis]
598 Tol J, Cats A, Mol L, Koopman M, Bos MM, van der Hoeven JJ, Antonini NF, van Krieken JH, Punt CJ. Gastrointestinal ulceration as a possible side effect of bevacizumab which may herald perforation. Invest New Drugs. 2008;26:393-397. [PMID: 18335169 DOI: 10.1007/s10637-008-9125-4] [Cited by in Crossref: 40] [Cited by in F6Publishing: 35] [Article Influence: 2.9] [Reference Citation Analysis]
599 Fakih M. The role of targeted therapy in the treatment of advanced colorectal cancer. Curr Treat Options Oncol 2008;9:357-74. [PMID: 19238551 DOI: 10.1007/s11864-009-0089-1] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
600 Xiong S, Xiao GW. Reverting doxorubicin resistance in colon cancer by targeting a key signaling protein, steroid receptor coactivator. Exp Ther Med. 2018;15:3751-3758. [PMID: 29581735 DOI: 10.3892/etm.2018.5912] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
601 Nguyen HL, Hwang J. Treatment of metastatic colorectal cancer in the elderly. Curr Treat Options Oncol 2009;10:287-95. [PMID: 19821033 DOI: 10.1007/s11864-009-0111-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
602 Merla A, Goel S. Novel drugs targeting the epidermal growth factor receptor and its downstream pathways in the treatment of colorectal cancer: a systematic review. Chemother Res Pract 2012;2012:387172. [PMID: 23097702 DOI: 10.1155/2012/387172] [Cited by in Crossref: 4] [Cited by in F6Publishing: 10] [Article Influence: 0.4] [Reference Citation Analysis]
603 Riedesser JE, Ebert MP, Betge J. Precision medicine for metastatic colorectal cancer in clinical practice. Ther Adv Med Oncol 2022;14:175883592110727. [DOI: 10.1177/17588359211072703] [Reference Citation Analysis]
604 Denda T, Sakai D, Hamaguchi T, Sugimoto N, Ura T, Yamazaki K, Fujii H, Kajiwara T, Nakajima TE, Takahashi S, Otsu S, Komatsu Y, Nagashima F, Moriwaki T, Esaki T, Sato T, Itabashi M, Oki E, Sasaki T, Sunaga Y, Ziti-Ljajic S, Brillac C, Yoshino T. Phase II trial of aflibercept with FOLFIRI as a second-line treatment for Japanese patients with metastatic colorectal cancer. Cancer Sci 2019;110:1032-43. [PMID: 30657223 DOI: 10.1111/cas.13943] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 4.3] [Reference Citation Analysis]
605 Rodriguez J, Zarate R, Bandres E, Viudez A, Chopitea A, García-Foncillas J, Gil-Bazo I. Combining chemotherapy and targeted therapies in metastatic colorectal cancer. World J Gastroenterol 2007; 13(44): 5867-5876 [PMID: 17990352 DOI: 10.3748/wjg.v13.i44.5867] [Cited by in CrossRef: 19] [Cited by in F6Publishing: 19] [Article Influence: 1.3] [Reference Citation Analysis]
606 Munemoto Y, Kanda M, Ishibashi K, Hata T, Kobayashi M, Hasegawa J, Fukunaga M, Takagane A, Otsuji T, Miyake Y, Nagase M, Sakamoto J, Matsuoka M, Oba K, Mishima H. Capecitabine and oxaliplatin combined with bevacizumab are feasible for treating selected Japanese patients at least 75 years of age with metastatic colorectal cancer. BMC Cancer. 2015;15:786. [PMID: 26497654 DOI: 10.1186/s12885-015-1712-0] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 1.3] [Reference Citation Analysis]
607 Shankaran V, Unger JM, Darke AK, Hershman DL, Ramsey SD. Design, data linkage, and implementation considerations in the first cooperative group led study assessing financial outcomes in cancer patients and their informal caregivers. Contemp Clin Trials 2020;95:106037. [PMID: 32485324 DOI: 10.1016/j.cct.2020.106037] [Reference Citation Analysis]
608 de Gramont A, Watson S, Ellis LM, Rodón J, Tabernero J, de Gramont A, Hamilton SR. Pragmatic issues in biomarker evaluation for targeted therapies in cancer. Nat Rev Clin Oncol 2015;12:197-212. [PMID: 25421275 DOI: 10.1038/nrclinonc.2014.202] [Cited by in Crossref: 126] [Cited by in F6Publishing: 98] [Article Influence: 15.8] [Reference Citation Analysis]
609 Bupathi M, Ahn DH, Bekaii-Saab T. Spotlight on bevacizumab in metastatic colorectal cancer: patient selection and perspectives. Gastrointest Cancer 2016;6:21-30. [PMID: 28190957 DOI: 10.2147/GICTT.S97740] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
610 Papachristos A, Karatza E, Kalofonos H, Sivolapenko G. Pharmacogenetics in Model-Based Optimization of Bevacizumab Therapy for Metastatic Colorectal Cancer. Int J Mol Sci 2020;21:E3753. [PMID: 32466535 DOI: 10.3390/ijms21113753] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
611 Stanel SC, Sjöberg J, Salmonson T, Foggi P, Caleno M, Melchiorri D, Gravanis I, Tzogani K, Pignatti F. European Medicines Agency approval summary: Zaltrap for the treatment of patients with oxaliplatin-resistant metastatic colorectal cancer. ESMO Open 2017;2:e000190. [PMID: 28761750 DOI: 10.1136/esmoopen-2017-000190] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.2] [Reference Citation Analysis]
612 Winther SB, Österlund P, Berglund Å, Glimelius B, Qvortrup C, Sorbye H, Pfeiffer P; - on behalf of the Academy of Geriatric Cancer Research (AgeCare). Randomized study comparing full dose monotherapy (S-1 followed by irinotecan) and reduced dose combination therapy (S-1/oxaliplatin followed by S-1/irinotecan) as initial therapy for older patients with metastatic colorectal cancer: NORDIC 9. BMC Cancer 2017;17:548. [PMID: 28814275 DOI: 10.1186/s12885-017-3526-8] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
613 Starlinger P, Alidzanovic L, Schauer D, Maier T, Nemeth C, Perisanidis B, Tamandl D, Gruenberger B, Gruenberger T, Brostjan C. Neoadjuvant bevacizumab persistently inactivates VEGF at the time of surgery despite preoperative cessation. Br J Cancer. 2012;107:961-966. [PMID: 22850548 DOI: 10.1038/bjc.2012.342] [Cited by in Crossref: 15] [Cited by in F6Publishing: 12] [Article Influence: 1.5] [Reference Citation Analysis]
614 Day D, Siu LL. Approaches to modernize the combination drug development paradigm. Genome Med 2016;8:115. [PMID: 27793177 DOI: 10.1186/s13073-016-0369-x] [Cited by in Crossref: 38] [Cited by in F6Publishing: 24] [Article Influence: 6.3] [Reference Citation Analysis]
615 Suenaga M, Mizunuma N, Shinozaki E, Matsusaka S, Ozaka M, Ogura M, Chin K, Yamaguchi T. Anticoagulant therapy for venous thromboembolism detected by Doppler ultrasound in patients with metastatic colorectal cancer receiving bevacizumab. Onco Targets Ther 2015;8:243-9. [PMID: 25670906 DOI: 10.2147/OTT.S75722] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
616 Fujii Y, Hirahara N, Kaji S, Taniura T, Hyakudomi R, Yamamoto T, Tajima Y. Bevacizumab-induced intestinal perforation in a patient with inoperable breast cancer: a case report and review of the literature. J Med Case Rep 2018;12:84. [PMID: 29580267 DOI: 10.1186/s13256-018-1619-x] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
617 Clarke SJ, Burge M, Feeney K, Gibbs P, Jones K, Marx G, Molloy MP, Price T, Reece WHH, Segelov E, Tebbutt NC. The prognostic role of inflammatory markers in patients with metastatic colorectal cancer treated with bevacizumab: A translational study [ASCENT]. PLoS One 2020;15:e0229900. [PMID: 32142532 DOI: 10.1371/journal.pone.0229900] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
618 Aranda E, Aparicio J, Alonso V, Garcia-Albeniz X, Garcia-Alfonso P, Salazar R, Valladares M, Vera R, Vieitez JM, Garcia-Carbonero R. SEOM clinical guidelines for diagnosis and treatment of metastatic colorectal cancer 2015. Clin Transl Oncol 2015;17:972-81. [PMID: 26669312 DOI: 10.1007/s12094-015-1434-4] [Cited by in Crossref: 19] [Cited by in F6Publishing: 17] [Article Influence: 2.7] [Reference Citation Analysis]
619 Scarpelli M, Rampurwala M, Eickhoff J, Carmichael L, Heideman J, Binger K, Kolesar J, Perlman S, Harrow K, Dukart G, Liang C, Jeraj R, Liu G, Bruce JY. Pharmacodynamic study using FLT PET/CT in advanced solid malignancies treated with a sequential combination of X-82 and docetaxel. Cancer Chemother Pharmacol 2018;82:211-9. [PMID: 29802443 DOI: 10.1007/s00280-018-3599-3] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.8] [Reference Citation Analysis]
620 Holch J, Stintzing S, Heinemann V. Treatment of Metastatic Colorectal Cancer: Standard of Care and Future Perspectives. Visc Med 2016;32:178-83. [PMID: 27493945 DOI: 10.1159/000446052] [Cited by in Crossref: 22] [Cited by in F6Publishing: 19] [Article Influence: 3.7] [Reference Citation Analysis]
621 Nace GW, Steel JL, Amesur N, Zajko A, Nastasi BE, Joyce J, Sheetz M, Gamblin TC. Yttrium-90 radioembolization for colorectal cancer liver metastases: a single institution experience. Int J Surg Oncol 2011;2011:571261. [PMID: 22312513 DOI: 10.1155/2011/571261] [Cited by in Crossref: 8] [Cited by in F6Publishing: 21] [Article Influence: 0.7] [Reference Citation Analysis]
622 Shin S, Noh Y. Increased risk of adverse drug events secondary to bevacizumab treatment in patients with advanced or metastatic breast cancer: a meta-analysis of randomized controlled trials. Ther Clin Risk Manag 2018;14:833-47. [PMID: 29765225 DOI: 10.2147/TCRM.S148840] [Cited by in Crossref: 4] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
623 Bi M, Yang J, Wang Y, Zhang H, Gao Z, Zhou H, Shi M. Successful treatment of metastatic colorectal cancer with apatinib: report of two cases and literature review. Onco Targets Ther 2018;11:883-90. [PMID: 29497319 DOI: 10.2147/OTT.S148412] [Cited by in Crossref: 3] [Article Influence: 0.8] [Reference Citation Analysis]
624 García-Foncillas J, Díaz-Rubio E. Progress in metastatic colorectal cancer: growing role of cetuximab to optimize clinical outcome. Clin Transl Oncol 2010;12:533-42. [PMID: 20709651 DOI: 10.1007/s12094-010-0551-3] [Cited by in Crossref: 41] [Cited by in F6Publishing: 36] [Article Influence: 3.7] [Reference Citation Analysis]
625 Holm M, Saraswat M, Joenväärä S, Ristimäki A, Haglund C, Renkonen R. Colorectal cancer patients with different C-reactive protein levels and 5-year survival times can be differentiated with quantitative serum proteomics. PLoS One 2018;13:e0195354. [PMID: 29630649 DOI: 10.1371/journal.pone.0195354] [Cited by in Crossref: 20] [Cited by in F6Publishing: 22] [Article Influence: 5.0] [Reference Citation Analysis]
626 Mattheolabakis G, Mikelis CM. Nanoparticle Delivery and Tumor Vascular Normalization: The Chicken or The Egg? Front Oncol 2019;9:1227. [PMID: 31799190 DOI: 10.3389/fonc.2019.01227] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 4.3] [Reference Citation Analysis]
627 Yanagisawa Y, Midgley RS. Medical oncology: A novel low-toxicity regimen for advanced colorectal cancer? Nat Rev Clin Oncol 2010;7:556-7. [PMID: 20877418 DOI: 10.1038/nrclinonc.2010.140] [Reference Citation Analysis]
628 Dueland S, Smedman TM, Røsok B, Grut H, Syversveen T, Jørgensen LH, Line PD. Treatment of relapse and survival outcomes after liver transplantation in patients with colorectal liver metastases. Transpl Int 2021;34:2205-13. [PMID: 34792825 DOI: 10.1111/tri.13995] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
629 Stragier E, Prenen H. Antiangiogenic therapies in colorectal cancer. memo 2017;10:213-7. [DOI: 10.1007/s12254-017-0359-8] [Cited by in Crossref: 2] [Article Influence: 0.4] [Reference Citation Analysis]
630 Jain RK, Duda DG, Willett CG, Sahani DV, Zhu AX, Loeffler JS, Batchelor TT, Sorensen AG. Biomarkers of response and resistance to antiangiogenic therapy. Nat Rev Clin Oncol. 2009;6:327-338. [PMID: 19483739 DOI: 10.1038/nrclinonc.2009.63] [Cited by in Crossref: 435] [Cited by in F6Publishing: 398] [Article Influence: 33.5] [Reference Citation Analysis]
631 Smaglo BG, Hwang J. Continuum of care with anti-angiogenic therapies in metastatic colorectal cancer. J Gastrointest Oncol 2013;4:299-307. [PMID: 23997941 DOI: 10.3978/j.issn.2078-6891.2013.030] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
632 Okines AF, Reynolds AR, Cunningham D. Targeting angiogenesis in esophagogastric adenocarcinoma. Oncologist. 2011;16:844-858. [PMID: 21632459 DOI: 10.1634/thenocoligist.2010-0387] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
633 Rosenberger WF. Sequential design and analysis in the randomized clinical trial: A historical perspective. Sequential Analysis 2020;39:295-306. [DOI: 10.1080/07474946.2020.1823190] [Reference Citation Analysis]
634 Nishi T, Hamamoto Y, Nagase M, Denda T, Yamaguchi K, Amagai K, Miyata Y, Yamanaka Y, Yanai K, Ishikawa T, Kuroki Y, Fujii H. Phase II trial of panitumumab with irinotecan as salvage therapy for patients with advanced or recurrent colorectal cancer (TOPIC study). Oncol Lett. 2016;11:4049-4054. [PMID: 27313739 DOI: 10.3892/ol.2016.4532] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
635 Wolpin BM, Mayer RJ. Systemic treatment of colorectal cancer. Gastroenterology. 2008;134:1296-1310. [PMID: 18471507 DOI: 10.1053/j.gastro.2008.02.098] [Cited by in Crossref: 307] [Cited by in F6Publishing: 271] [Article Influence: 21.9] [Reference Citation Analysis]
636 Fumet JD, Isambert N, Hervieu A, Zanetta S, Guion JF, Hennequin A, Rederstorff E, Bertaut A, Ghiringhelli F. Phase Ib/II trial evaluating the safety, tolerability and immunological activity of durvalumab (MEDI4736) (anti-PD-L1) plus tremelimumab (anti-CTLA-4) combined with FOLFOX in patients with metastatic colorectal cancer. ESMO Open 2018;3:e000375. [PMID: 29942666 DOI: 10.1136/esmoopen-2018-000375] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 6.8] [Reference Citation Analysis]
637 Hershman DL, Wright JD, Lim E, Buono DL, Tsai WY, Neugut AI. Contraindicated use of bevacizumab and toxicity in elderly patients with cancer. J Clin Oncol 2013;31:3592-9. [PMID: 24002522 DOI: 10.1200/JCO.2012.48.4857] [Cited by in Crossref: 39] [Cited by in F6Publishing: 17] [Article Influence: 4.3] [Reference Citation Analysis]
638 Antonuzzo L, Giommoni E, Pastorelli D, Latiano T, Pavese I, Azzarello D, Aieta M, Pastina I, Di Fabio F, Bertolini A, Corsi DC, Mogavero S, Angelini V, Pazzagli M, Di Costanzo F. Bevacizumab plus XELOX as first-line treatment of metastatic colorectal cancer: The OBELIX study. World J Gastroenterol 2015; 21(23): 7281-7288 [PMID: 26109816 DOI: 10.3748/wjg.v21.i23.7281] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
639 Kobayashi T, Masaki T, Kogawa K, Matsuoka H, Sugiyama M. Hemoptysis and acute respiratory syndrome (ARDS) as delayed-type hypersensitivity after FOLFOX4 plus bevacizumab treatment. Int Surg 2013;98:445-9. [PMID: 24229039 DOI: 10.9738/INTSURG-D-12-00020.1] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
640 Randall LM, Monk BJ. Bevacizumab toxicities and their management in ovarian cancer. Gynecol Oncol 2010;117:497-504. [PMID: 20363017 DOI: 10.1016/j.ygyno.2010.02.021] [Cited by in Crossref: 62] [Cited by in F6Publishing: 64] [Article Influence: 5.2] [Reference Citation Analysis]
641 Sato S, Nakano H, Ishida Y, Otsubo T. The aspartate aminotransferase to platelet ratio before chemotherapy predicts adverse events for FOLFOX and XELOX regimens including bevacizumab as the first-line therapy for stage IV, recurrent and metastatic colorectal cancer. J Gastrointest Oncol 2013;4:203-9. [PMID: 23730517 DOI: 10.3978/j.issn.2078-6891.2013.016] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
642 Segelov E, Chan D, Shapiro J, Price TJ, Karapetis CS, Tebbutt NC, Pavlakis N. The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. Br J Cancer. 2014;111:1122-1131. [PMID: 25072258 DOI: 10.1038/bjc.2014.404] [Cited by in Crossref: 24] [Cited by in F6Publishing: 19] [Article Influence: 3.0] [Reference Citation Analysis]
643 Chen D, Gu K, Wang H. Optimizing sequential treatment with anti-EGFR and VEGF mAb in metastatic colorectal cancer: current results and controversies. Cancer Manag Res 2019;11:1705-16. [PMID: 30863179 DOI: 10.2147/CMAR.S196170] [Cited by in Crossref: 10] [Cited by in F6Publishing: 7] [Article Influence: 3.3] [Reference Citation Analysis]
644 Alejandro LM, Behrendt CE, Chen K, Openshaw H, Shibata S. Predicting acute and persistent neuropathy associated with oxaliplatin. Am J Clin Oncol 2013;36:331-7. [PMID: 22547012 DOI: 10.1097/COC.0b013e318246b50d] [Cited by in Crossref: 39] [Cited by in F6Publishing: 23] [Article Influence: 4.3] [Reference Citation Analysis]
645 Geiger-Gritsch S, Stollenwerk B, Miksad R, Guba B, Wild C, Siebert U. Safety of bevacizumab in patients with advanced cancer: a meta-analysis of randomized controlled trials. Oncologist. 2010;15:1179-1191. [PMID: 21045188 DOI: 10.1634/theoncologist.2009-0155] [Cited by in Crossref: 46] [Cited by in F6Publishing: 46] [Article Influence: 3.8] [Reference Citation Analysis]
646 Yang SX. Bevacizumab and breast cancer: current therapeutic progress and future perspectives. Expert Rev Anticancer Ther 2009;9:1715-25. [PMID: 19954282 DOI: 10.1586/era.09.153] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.3] [Reference Citation Analysis]
647 Wang F, Molina J, Satele D, Yin J, Lim VS, Adjei AA. A phase I study of the vascular endothelial growth factor inhibitor Vatalanib in combination with Pemetrexed disodium in patients with advanced solid tumors. Invest New Drugs 2019;37:658-65. [PMID: 30382439 DOI: 10.1007/s10637-018-0690-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 1.3] [Reference Citation Analysis]
648 Díaz-Rubio E, Gómez-España A, Massutí B, Sastre J, Abad A, Valladares M, Rivera F, Safont MJ, Martínez de Prado P, Gallén M, González E, Marcuello E, Benavides M, Fernández-Martos C, Losa F, Escudero P, Arrivi A, Cervantes A, Dueñas R, López-Ladrón A, Lacasta A, Llanos M, Tabernero JM, Antón A, Aranda E; Spanish Cooperative Group for the Treatment of Digestive Tumors. First-line XELOX plus bevacizumab followed by XELOX plus bevacizumab or single-agent bevacizumab as maintenance therapy in patients with metastatic colorectal cancer: the phase III MACRO TTD study. Oncologist 2012;17:15-25. [PMID: 22234633 DOI: 10.1634/theoncologist.2011-0249] [Cited by in Crossref: 147] [Cited by in F6Publishing: 136] [Article Influence: 14.7] [Reference Citation Analysis]
649 Shuford RA, Cairns AL, Moaven O. Precision Approaches in the Management of Colorectal Cancer: Current Evidence and Latest Advancements Towards Individualizing the Treatment. Cancers (Basel) 2020;12:E3481. [PMID: 33238500 DOI: 10.3390/cancers12113481] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
650 Mishima H, Oba K, Sakamoto J, Muro K, Yoshino T, Hyodo I, Maehara Y. FOLFIRI plus bevacizumab 5 mg/kg versus 10 mg/kg as second-line therapy in patients with metastatic colorectal cancer who have failed first-line bevacizumab plus oxaliplatin-based therapy: a randomized phase III study (EAGLE Study). Jpn J Clin Oncol. 2012;42:134-138. [PMID: 22167662 DOI: 10.1093/jjco/hyr180] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
651 Matikas A, Asimakopoulou N, Georgoulias V, Souglakos J. The place of targeted agents in the treatment of elderly patients with metastatic colorectal cancer. Cancers (Basel) 2015;7:439-49. [PMID: 25782007 DOI: 10.3390/cancers7010439] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
652 Malki A, ElRuz RA, Gupta I, Allouch A, Vranic S, Al Moustafa AE. Molecular Mechanisms of Colon Cancer Progression and Metastasis: Recent Insights and Advancements. Int J Mol Sci 2020;22:E130. [PMID: 33374459 DOI: 10.3390/ijms22010130] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
653 Osumi H, Matsusaka S, Suenaga M, Shinozaki E, Mizunuma N. Associations between deepness of response and clinical outcomes among Japanese patients with metastatic colorectal cancer treated with second-line FOLFIRI plus cetuximab. Onco Targets Ther 2015;8:2005-13. [PMID: 26273206 DOI: 10.2147/OTT.S87101] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
654 Makondi PT, Lee CH, Huang CY, Chu CM, Chang YJ, Wei PL. Prediction of novel target genes and pathways involved in bevacizumab-resistant colorectal cancer. PLoS One 2018;13:e0189582. [PMID: 29342159 DOI: 10.1371/journal.pone.0189582] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.5] [Reference Citation Analysis]
655 Rawla P, Barsouk A, Hadjinicolaou AV, Barsouk A. Immunotherapies and Targeted Therapies in the Treatment of Metastatic Colorectal Cancer. Med Sci (Basel) 2019;7:E83. [PMID: 31366129 DOI: 10.3390/medsci7080083] [Cited by in Crossref: 11] [Cited by in F6Publishing: 14] [Article Influence: 3.7] [Reference Citation Analysis]
656 Kim DD, Eng C. The current state of targeted agents in rectal cancer. Int J Surg Oncol 2012;2012:406830. [PMID: 22675625 DOI: 10.1155/2012/406830] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.3] [Reference Citation Analysis]
657 Ohhara Y, Fukuda N, Takeuchi S, Honma R, Shimizu Y, Kinoshita I, Dosaka-Akita H. Role of targeted therapy in metastatic colorectal cancer. World J Gastrointest Oncol 2016; 8(9): 642-655 [PMID: 27672422 DOI: 10.4251/wjgo.v8.i9.642] [Cited by in CrossRef: 58] [Cited by in F6Publishing: 54] [Article Influence: 9.7] [Reference Citation Analysis]
658 Kreisl TN, Kotliarova S, Butman JA, Albert PS, Kim L, Musib L, Thornton D, Fine HA. A phase I/II trial of enzastaurin in patients with recurrent high-grade gliomas. Neuro Oncol 2010;12:181-9. [PMID: 20150385 DOI: 10.1093/neuonc/nop042] [Cited by in Crossref: 77] [Cited by in F6Publishing: 62] [Article Influence: 6.4] [Reference Citation Analysis]
659 Gangi A, Lu SC. Chemotherapy-associated liver injury in colorectal cancer. Therap Adv Gastroenterol 2020;13:1756284820924194. [PMID: 32547639 DOI: 10.1177/1756284820924194] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
660 Feng QY, Wei Y, Chen JW, Chang WJ, Ye LC, Zhu DX, Xu JM. Anti-EGFR and anti-VEGF agents: Important targeted therapies of colorectal liver metastases. World J Gastroenterol 2014; 20(15): 4263-4275 [PMID: 24764664 DOI: 10.3748/wjg.v20.i15.4263] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 14] [Article Influence: 2.5] [Reference Citation Analysis]
661 Ocean AJ, Polite B, Christos P, Horvath L, Hamilton A, Matulich D, Chen HX, Sparano JA, Kindler HL. Cetuximab is associated with excessive toxicity when combined with bevacizumab Plus mFOLFOX6 in metastatic colorectal carcinoma. Clin Colorectal Cancer 2010;9:290-6. [PMID: 21208843 DOI: 10.3816/CCC.2010.n.042] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
662 Burger RA. Role of vascular endothelial growth factor inhibitors in the treatment of gynecologic malignancies. J Gynecol Oncol 2010;21:3-11. [PMID: 20379441 DOI: 10.3802/jgo.2010.21.1.3] [Cited by in Crossref: 15] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
663 Yanmaz MT, Guner SI, Satılmıs B, Akyol H, Aydın MA. Thirty-minutes infusion rate is safe enough for bevacizumab; no need for initial prolong infusion. Med Oncol 2014;31:276. [PMID: 25294426 DOI: 10.1007/s12032-014-0276-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
664 Seymour JF, Pfreundschuh M, Trnĕný M, Sehn LH, Catalano J, Csinady E, Moore N, Coiffier B; MAIN Study Investigators. R-CHOP with or without bevacizumab in patients with previously untreated diffuse large B-cell lymphoma: final MAIN study outcomes. Haematologica 2014;99:1343-9. [PMID: 24895339 DOI: 10.3324/haematol.2013.100818] [Cited by in Crossref: 55] [Cited by in F6Publishing: 53] [Article Influence: 6.9] [Reference Citation Analysis]
665 Strickler JH, Hurwitz HI. Palliative treatment of metastatic colorectal cancer: what is the optimal approach? Curr Oncol Rep 2014;16:363. [PMID: 24293074 DOI: 10.1007/s11912-013-0363-z] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
666 Martini G, Troiani T, Cardone C, Vitiello P, Sforza V, Ciardiello D, Napolitano S, Della Corte CM, Morgillo F, Raucci A, Cuomo A, Selvaggi F, Ciardiello F, Martinelli E. Present and future of metastatic colorectal cancer treatment: A review of new candidate targets. World J Gastroenterol 2017; 23(26): 4675-4688 [PMID: 28765689 DOI: 10.3748/wjg.v23.i26.4675] [Cited by in CrossRef: 57] [Cited by in F6Publishing: 59] [Article Influence: 11.4] [Reference Citation Analysis]
667 Rodríguez-fraile M, Iñarrairaegui M. Radioembolization with 90Y-microspheres for liver tumors. Revista Española de Medicina Nuclear e Imagen Molecular (English Edition) 2015;34:244-57. [DOI: 10.1016/j.remnie.2015.05.001] [Reference Citation Analysis]
668 Arnold D, Stein A. New developments in the second-line treatment of metastatic colorectal cancer: potential place in therapy. Drugs. 2013;73:883-891. [PMID: 23743737 DOI: 10.1007/s40265-013-0076-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 14] [Article Influence: 1.6] [Reference Citation Analysis]
669 Lai Y, Wang C, Civan JM, Palazzo JP, Ye Z, Hyslop T, Lin J, Myers RE, Li B, Jiang B. Effects of Cancer Stage and Treatment Differences on Racial Disparities in Survival From Colon Cancer: A United States Population-Based Study. Gastroenterology. 2016;150:1135-1146. [PMID: 26836586 DOI: 10.1053/j.gastro.2016.01.030] [Cited by in Crossref: 48] [Cited by in F6Publishing: 50] [Article Influence: 8.0] [Reference Citation Analysis]
670 Avallone A, Piccirillo MC, Nasti G, Rosati G, Carlomagno C, Di Gennaro E, Romano C, Tatangelo F, Granata V, Cassata A, Silvestro L, De Stefano A, Aloj L, Vicario V, Nappi A, Leone A, Bilancia D, Arenare L, Petrillo A, Lastoria S, Gallo C, Botti G, Delrio P, Izzo F, Perrone F, Budillon A. Effect of Bevacizumab in Combination With Standard Oxaliplatin-Based Regimens in Patients With Metastatic Colorectal Cancer: A Randomized Clinical Trial. JAMA Netw Open 2021;4:e2118475. [PMID: 34309665 DOI: 10.1001/jamanetworkopen.2021.18475] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
671 Mercer RW, Tyler MA, Ulasov IV, Lesniak MS. Targeted therapies for malignant glioma: progress and potential. BioDrugs 2009;23:25-35. [PMID: 19344189 DOI: 10.2165/00063030-200923010-00003] [Cited by in Crossref: 32] [Cited by in F6Publishing: 32] [Article Influence: 2.5] [Reference Citation Analysis]
672 Österlund P, Hermann F. Bevacizumab beyond first disease progression in metastatic colorectal cancer: a review of recent clinical trial data. Colorectal Cancer 2015;4:13-25. [DOI: 10.2217/crc.15.1] [Reference Citation Analysis]
673 Garde-Noguera J, Gil-Raga M, Evgenyeva E, García JA, Llombart-Cussac A, Camps-Herrero C. High pKDR immunohistochemical expression is an unfavourable prognostic biomarker in patients with advanced colorectal cancer treated with chemotherapy plus bevacizumab. Clin Transl Oncol 2016;18:405-12. [PMID: 26307753 DOI: 10.1007/s12094-015-1378-8] [Reference Citation Analysis]
674 Cosimelli M, Golfieri R, Cagol PP, Carpanese L, Sciuto R, Maini CL, Mancini R, Sperduti I, Pizzi G, Diodoro MG, Perrone M, Giampalma E, Angelelli B, Fiore F, Lastoria S, Bacchetti S, Gasperini D, Geatti O, Izzo F; Italian Society of Locoregional Therapies in Oncology (SITILO). Multi-centre phase II clinical trial of yttrium-90 resin microspheres alone in unresectable, chemotherapy refractory colorectal liver metastases. Br J Cancer. 2010;103:324-331. [PMID: 20628388 DOI: 10.1038/sj.bjc.6605770] [Cited by in Crossref: 156] [Cited by in F6Publishing: 133] [Article Influence: 13.0] [Reference Citation Analysis]
675 Kanai M, Ishiguro H, Mori Y, Kitano T, Nishimura T, Matsumoto S, Yanagihara K, Chiba T, Toi M. Temporary blood pressure drop after bevacizumab administration is associated with clinical course of advanced colorectal cancer. Br J Cancer 2011;105:1693-6. [PMID: 22033274 DOI: 10.1038/bjc.2011.398] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
676 Ogata Y, Tokunaga S, Emi Y, Oki E, Saeki H, Shirabe K, Hasegawa H, Sadanaga N, Samura H, Fujita F, Tanaka T, Kitazono M, Yamamoto M, Morikita T, Inomata M, Kakeji Y, Shirouzu K, Maehara Y; Kyushu Study Group of Clinical Cancer. A multicenter phase II clinical study of oxaliplatin, folinic acid, and 5-fluorouracil combination chemotherapy as second-line treatment for advanced colorectal cancer: a Japanese experience. Surg Today 2011;41:84-90. [PMID: 21191696 DOI: 10.1007/s00595-010-4418-6] [Reference Citation Analysis]
677 Goldstein DA, Ahmad BB, Chen Q, Ayer T, Howard DH, Lipscomb J, El-Rayes BF, Flowers CR. Cost-Effectiveness Analysis of Regorafenib for Metastatic Colorectal Cancer. J Clin Oncol 2015;33:3727-32. [PMID: 26304904 DOI: 10.1200/JCO.2015.61.9569] [Cited by in Crossref: 61] [Cited by in F6Publishing: 35] [Article Influence: 8.7] [Reference Citation Analysis]
678 Chee CE, Sinicrope FA. Targeted therapeutic agents for colorectal cancer. Gastroenterol Clin North Am 2010;39:601-13. [PMID: 20951919 DOI: 10.1016/j.gtc.2010.08.017] [Cited by in Crossref: 19] [Cited by in F6Publishing: 16] [Article Influence: 1.7] [Reference Citation Analysis]
679 Ishida K, Uesugi N, Hasegawa Y, Sugimoto R, Takahara T, Otsuka K, Nitta H, Kawasaki T, Wakabayashi G, Sugai T. Proposal for novel histological findings of colorectal liver metastases with preoperative chemotherapy. Pathol Int 2015;65:367-73. [PMID: 25940915 DOI: 10.1111/pin.12300] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.7] [Reference Citation Analysis]
680 Neumann UP, Seehofer D, Neuhaus P. The surgical treatment of hepatic metastases in colorectal carcinoma. Dtsch Arztebl Int. 2010;107:335-342. [PMID: 20532128 DOI: 10.3238/arztebl.2010.0335] [Cited by in Crossref: 2] [Cited